

**Funding Opportunities Monthly Edition
June 2025 Due Dates**

Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in June 2025.

The opportunities are organized in the following order:

1. [National Institutes of Health \(NIH\)](#)
2. [National Science Foundation \(NSF\)](#)
3. [Other Federal](#)
4. [Non Federal](#)

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 below for assistance or questions.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
122289	Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-24-039	17-Jun-2025	275,000 USD
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Laritza M. Rodriguez, M.D., Ph.D.</div> <div>240-477-9376</div> <div>laritza.rodriguez@nih.gov</div> <div></div> <div>Link to program URL</div> <div>17-Jun-2025 , 18-Nov-2025 , 15-Jun-2026 , 17-Nov-2026</div> <div>This notice of funding opportunity (NOFO) is a continuation of an NCI program to enhance the diversity of the pool of the cancer research workforce by recruiting and supporting eligible New Investigators and Early Stage Investigators from diverse backgrounds, including from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical and social sciences. This NOFO will fund investigators to develop a larger research project grant application.</div>			
117092	RFA-CA-25-013 -- Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-25-013	14-May-2025 [Optional][LOI/Pre-App]	Not Specified
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Altaf Mohammed, PhD</div> <div>240-276-6082</div> <div>wynne.norton@nih.gov</div> <div></div> <div>Link to program URL</div> <div>14-May-2025 [Optional][LOI/Pre-App], 13-Jun-2025</div> <div>Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support the discovery and development of novel natural products that are safe, non-toxic, and efficacious for cancer interception and prevention. The UG3 phase will provide up to three years of support for milestone-driven initial target selection, verification of the target in clinical samples and preclinical in vivo studies, assay development, and/or assay validation for target activity, as well as on-target toxicity screening, and pilot screening of natural agents. If UG3 milestones are met, support may be provided for a full-scale screening, identification of active natural compounds, full-scale evaluation of screened individual agents, assessment of the natural product's effect in vitro and in vivo, and determining the optimal dose for subsequent studies and safety testing in the UH3 phase.</div>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
113074	The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-130	21-May-2025 [Optional][LOI/Pre-App]	2,500,000 USD
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Joanna M. Watson, Ph.D.</div> <div>240-276-6206</div> <div>watsonjo@mail.nih.gov</div> <div></div> <div>Link to program URL</div> <div>21-May-2025 [Optional][LOI/Pre-App], 20-Jun-2025</div> <div>The National Cancer Institute's (NCI) Metastasis Research Network (MetNet) is a collection of U54 Research Centers that support using systems-level approaches to understand pressing questions in metastasis. The overall goal of the MetNet is to advance our understanding of metastasis as a whole body, systems-level problem to develop a comprehensive and cohesive picture of the processes involved. Through this Funding Opportunity Announcement (FOA), the NCI invites applications for MetNet Research Projects. These Research Projects should be defined as discrete entities that use systems-level approaches to address gaps and opportunities in metastasis research to integrate into the MetNet and complement ongoing research across the Network.</div>			
110471	Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-131	05-Jun-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Sudhir Srivastava, Ph.D., MPH</div> <div>240-276-7028</div> <div>srivasts@mail.nih.gov</div> <div></div> <div>Link to program URL</div> <div>05-Jun-2025</div> <div>This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that include imaging, biomarkers, digital pathomic and other -omic integration strategies for improving current approaches for the earliest detection of premetastatic aggressive cancer as well as identifying precancerous lesions that will subsequently demonstrate an aggressive phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions in a technology agnostic manner by improving sensitivity and specificity of applied tests. N-dimensional co-</div>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>registered, cross-correlated imaging results integrated with multiplexed biomarker data and digital pathomics using analytic strategies such as artificial intelligence and virtual reality visualization for improving discovery are encouraged. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and (3) to reduce false positives and false negatives.</p>				
121246	Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-237	05-Jun-2025	Not Specified
	Contact Name	David Dean Jr., Ph.D., M.S.			
	Contact Telephone	240-276-8703			
	Contact Email	chipper.dean@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026			
	Synopsis	<p>Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) intends to support the rigorous assessment of barriers to quality cancer treatment and follow-up care for sexual and gender minority (SGM) cancer survivors. This funding opportunity is intended to address a critical need for improved care delivery and outcomes for SGM cancer survivors. The goal is to address the disease burden in an underserved and understudied population that is at higher risk of poorer health outcomes. The NCI solicits proposals for observational and/or interventional studies of SGM survivors designed to understand barriers and/or improve care and outcomes for SGM people with cancer, using interoperable sexual orientation and gender identity (SOGI) data collection in cancer care settings, where appropriate.</p>			
120973	Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-069	05-Jun-2025	Not Specified
	Contact Name	Edward R. Sauter, MD, PhD			
	Contact Telephone	240-276-7657			
	Contact Email	edward.sauter@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer. Investigators wishing to study incretin mimetics other than GLP-1 RAs or GLP-1/GIP-1 RAs, such as dipeptidyl peptidase (DPP)-4 inhibitors, must justify why the agent(s) they propose to study are more effective and/or have a more favorable side effect profile than GLP-1 or GLP-1/GIP-1 RAs. Route of agent administration (oral vs. other) is, by itself, not an adequate justification.</p>				
111847	Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-25-294	05-Jun-2025	2,500,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Kelly D. Blake, ScD</p> <p>240-281-5934</p> <p>kelly.blake@nih.gov</p> <p></p> <p>Link to program URL</p> <p>05-Jun-2025</p> <p>Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.</p>			
117334	Impacts of Climate Change Across the Cancer Control Continuum (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-094	05-Jun-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p>	<p>Curt DellaValle, Ph.D., MPH</p> <p>240-276-7225</p> <p>curt.dellavalle@nih.gov</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026</p> <p>Synopsis This notice of funding opportunity (NOFO) aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control and behaviors.</p>				
128629	Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-145	06-May-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Kelly Filipski PhD, MPH</p> <p>Contact Telephone 240-276-6841</p> <p>Contact Email Kelly.Filipski@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to promote research studies designed to address adverse sequelae of cancer therapies that persist and become chronic co-morbidities or develop as delayed posttreatment effects. This NOFO supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, and translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. The scope of research projects includes mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
128619	Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-24-311	06-May-2025 [Optional][LOI/Pre-App]	2,499,995 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Charles Lin , Ph.D.</p> <p>Contact Telephone 240-276-6108</p> <p>Contact Email linp3@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites research grant applications (R01) for the development and application of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo. The motivation for this initiative is the recognition that much of the current imaging research on inflammation in cancer relies heavily on in vitro and ex vivo methods. These approaches have limited potential to provide significant insights into the dynamic interactions between cancer and inflammation. Utilizing molecular imaging probes in pre-clinical and clinical investigations allows for precise temporal resolution at molecular and cellular levels. This information is valuable for identifying and characterizing in vivo inflammatory cellular physiology in cancer and for detecting molecular changes in response to treatment. This NOFO encourages applications focused on developing integrated imaging approaches to investigate the role of inflammation in cancer through strong cross-discipline collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance the science and understanding of cancer inflammation interactions.</p>				
128621	Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-175	06-May-2025 [Optional][LOI/Pre-App]	499,999 USD
	<p>Contact Name Shane Woodward</p> <p>Contact Telephone 240-276-6624</p> <p>Contact Email woodwars@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-May-2025 [Optional][LOI/Pre-App], 07-May-2025 , 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 07-Sep-2025 , 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 07-Jan-2026 , 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 07-May-2026 , 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 07-Sep-2026 , 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App],</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>07-Jan-2027 , 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 07-May-2027 , 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</p> <p>National Cancer Institute (NCI) invites applications for research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
111859	Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-198	05-Jun-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Michael Graham Espey, Ph.D.</p> <p>240-276-5609</p> <p>SP@nih.gov</p> <p></p> <p>Link to program URL</p> <p>05-Jun-2025</p> <p>Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R01 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.</p>			
123053	National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-25-081	07-May-2025	2,499,995 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Lori A. Henderson, Ph.D.</p> <p>240-276-5930</p> <p>hendersonlori@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) is soliciting research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of DCTD and OHAM. The proposed project must involve at least 1 clinical trial related to the scientific interests of one or more of the following research programs: Cancer Therapy Evaluation Program, Cancer Imaging Program, Cancer Diagnosis Program, Radiation Research Program, Complementary and Alternative Medicine Program and/or the HIV and AIDS Malignancies Research Programs. Applicants may propose to conduct an early phase trial by itself, or in combination with another research aim(s) as appropriate. This NOFO does not accept Phase III clinical trials.</p>				
123051	Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-25-167	07-May-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Jessica Faupel-Badger, Ph.D., M.P.H.</p> <p>240-276-7296</p> <p>badgerje@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 05-Jan-2027</p> <p>Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this NOFO must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this NOFO and the application instructions. This NOFO does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients.</p>			
114678	Co-infection and Cancer (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-082	05-Jun-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p>	<p>Tram Kim Lam, Ph.D., MPH</p> <p>240-276-6967</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email lamt@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025 , 05-Oct-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.</p>				
128497	Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-144	07-May-2025	Not Specified
	<p>Contact Name Gila Neta, Ph.D.</p> <p>Contact Telephone 240-276-6785</p> <p>Contact Email gila.neta@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as evidence-based interventions). Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amidst disasters (e.g., pandemics, climate change) remain relevant.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
127772	Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-043	06-May-2025 [Optional][LOI/Pre-App]	2,500,000 USD
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Edward R. Sauter, M.D., Ph.D.</div> <div>240-276-7657</div> <div>edward.sauter@nih.gov</div> <div></div> <div>Link to program URL</div> <div>06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027</div> <div>Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter term outcomes such as weight loss and diabetes.</div>			
129319	Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-325	04-Jun-2025	1,250,000 USD
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Abhi Rao, Ph.D.</div> <div>240-276-5715</div> <div>abhi.rao@nih.gov</div> <div>Link to sponsor website</div> <div>Link to program URL</div> <div>04-Jun-2025 , 10-Sep-2025 , 04-Feb-2026 , 04-Jun-2026 , 10-Sep-2026 , 04-Feb-2027 , 04-Jun-2027 , 10-Sep-2027</div> <div>Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support extramural research to investigate and mitigate challenges in clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as "liquid biopsies", or other biospecimens as described in this NOFO. Extramural research funded under this NOFO may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for "liquid biopsies", tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF,</div>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.</p>				
112619	Biology of Bladder Cancer (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-218	05-Jun-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Ron Johnson, Ph. D.</p> <p>240-276-6250</p> <p>rjohnso2@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>05-Jun-2025</p> <p>This Funding Opportunity Announcement (FOA) encourages applications that investigate the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression and malignancy of bladder cancer. Furthermore, our understanding of the biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and contribute to the future development of new interventions.</p>			
120755	Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-153	05-Jun-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Suzanne Forry, Ph.D.</p> <p>240-276-5922</p> <p>forryscs@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate research in discovery and development of novel, small molecules for cancer. Molecules discovered through this NOFO may be used to probe cancer biology, to validate cancer targets, or as the basis for optimized drugs. Stages of discovery research covered by this NOFO include: 1) development of the primary screen assay(s) and testing in an initial pilot screen; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.			
120756	Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-25-254	05-Jun-2025	Not Specified
	Contact Name	Rebecca Ferrer			
	Contact Telephone	240-276-6914			
	Contact Email	ferrerra@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026			
	Synopsis	This Notice of Funding Opportunity (NOFO) will solicit mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. Expectancies are defined in this context as beliefs about future outcomes, including one's response to cancer or cancer treatment. Expectancies can be evoked by social, psychological, environmental, and systemic factors. Expectancy effects are the cognitive, behavioral, and biological outcomes caused by expectancies. Expectancy effects can be generated by expectancies held by patients, clinicians, family members, caregivers, and/or dyadic/social networks. Program is particularly interested in applications that enroll individuals and groups from populations historically underrepresented or excluded from biomedical and behavioral research.			
120897	Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-24-306	05-Jun-2025	2,495,000 USD
	Contact Name	Joanna Watson, Ph.D.			
	Contact Telephone	240-276-6206			
	Contact Email	Joanna.Watson@nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. The NCI, through this NOFO, encourages submission of projects devoted to demonstrating that mammalian models, including organoids, tumoroids and cell models, used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patient benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this NOFO could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.</p>				
129029	NCI Continuing Umbrella of Research Experiences (CURE) Mentored Clinical Scientist Research Career Development Award (K08 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-24-319	12-Jun-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 240-276-7360</p> <p>Contact Email K08CareerProgramDirector@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027 , 12-Oct-2027</p> <p>Synopsis The goal of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree or a health professional doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This NCI-sponsored K08 award is specifically designed to support clinical scientists from diverse backgrounds who bring unique perspectives shaped by their life experiences, geographic location, socioeconomic status, academic training, professional experience, disability status, military service, career stage, institutional affiliation, cultural background, and other factors that contribute to a diverse and inclusive</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>research workforce (NOT-OD-20-031), and who are committed to a career in basic biomedical, clinical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding. This Funding Opportunity Announcement (NOFO) is designed specifically to support candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Candidates not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must work with their organizations to apply to companion NOFO PAR-24-320 NCI Mentored Research Scientist Development Award to Promote Diversity (K08 Independent Clinical Trial Not Allowed))</p>				
129028	NCI Continuing Umbrella of Research Experiences (CURE) Non-Mentored Research Scientist Career Development Award (K22 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-24-318	12-Jun-2025	Not Specified
	Contact Name	Program Director			
	Contact Telephone	240-276-7754			
	Contact Email	vahedis@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027 , 12-Oct-2027			
	Synopsis	<p>This Notice of Funding Opportunity Announcement (NOFO), NCI Transition Career Development Award to Promote Diversity (K22) supports senior postdoctoral fellows or individuals in similar mentored roles who have not yet gained independence, helping them transition into assistant professor or equivalent roles. The program's goal is to establish successful careers for these individuals as independent research scientists. This NOFO is specifically designed to support individuals from diverse backgrounds, including those whose life experiences, geographic location, socioeconomic status, academic training, professional experience, disability status, military service, career stage, institutional affiliation, cultural background, and other factors contribute to a diverse and inclusive research workforce (NOT-OD-20-031). It provides salary and research support for up to three years of 'protected time,' dedicated to intensive research and career development during their transition into independent research careers. This Notice of Funding Opportunity (NOFO) is designed specifically to support candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Candidates not planning to lead an independent clinical trial but intending to gain experience in a trial led by another investigator should apply to the companion NOFO (PAR-24-317).</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
129027	NCI Continuing Umbrella of Research Experiences (CURE) Non-Mentored Research Scientist Career Development Award (K22 Independent Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-24-317	12-Jun-2025	Not Specified
<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Program Director</div> <div>240-276-7754</div> <div>vahedis@nih.gov</div> <div></div> <div>Link to program URL</div> <div>12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027 , 12-Oct-2027</div> <div> <p>This Notice of Funding Opportunity Announcement (NOFO), NCI Transition Career Development Award to Promote Diversity (K22) supports senior postdoctoral fellows or individuals in similar mentored roles who have not yet gained independence, helping them transition into assistant professor or equivalent roles. The program's goal is to establish successful careers for these individuals as independent research scientists. This NOFO is specifically designed to support individuals from diverse backgrounds, including those whose life experiences, geographic location, socioeconomic status, academic training, professional experience, disability status, military service, career stage, institutional affiliation, cultural background, and other factors contribute to a diverse and inclusive research workforce (NOT-OD-20-031). It provides salary and research support for up to three years of 'protected time,' dedicated to intensive research and career development during their transition into independent research careers. This Notice of Funding Opportunity (NOFO) is specifically intended to support candidates conducting research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Instead, candidates may propose gaining research experience within a clinical trial led by a mentor or co-mentor. Candidates intending to lead a clinical trial, a clinical trial feasibility study, or an ancillary clinical trial should apply to the companion NOFO. (PAR-24-318).</p> </div> </div>					
129588	Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-337	05-Jun-2025	2,495,000 USD
<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> </div> <div> <div>Miguel Ossandon MS</div> <div>240-276-5714</div> <div>ossandom@mail.nih.gov</div> <div></div> <div>Link to program URL</div> </div>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>Deadline Dates (ALL) 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines "innovation" as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. This FOA is not intended to support straight clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA. This FOA does not propose to support commercial production or basic research projects.</p>					
128883	Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-248	10-Jun-2025	Not Specified
<p>Contact Name Claire Zhu, Ph.D.</p> <p>Contact Telephone 240-276-7013</p> <p>Contact Email zhucla@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Jun-2025 , 10-Oct-2025 , 10-Feb-2026 , 10-Jun-2026 , 09-Oct-2026 , 10-Feb-2027 , 10-Jun-2027 , 08-Oct-2027</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO</p>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>screened arm participants, and a onetime collection of buccal cells from both the screened and the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and other clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens and may include other resources; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research on non-cancer outcomes, especially those related to aging (e.g., Alzheimer's, depression, hip fracture, osteoporosis and rheumatoid arthritis) may also be supported. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.</p>				
129030	NCI Continuing Umbrella of Research Experiences (CURE) Mentored Clinical Scientist Research Career Development Award (K08 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-24-320	12-Jun-2025	Not Specified
	Contact Name				
	Contact Telephone	240-276-7360			
	Contact Email	K08CareerProgramDirector@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027 , 12-Oct-2027			
	Synopsis	<p>The goal of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree or a health professional doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This NCI-sponsored K08 award is specifically designed to support clinical scientists from diverse backgrounds who bring unique perspectives shaped by their life experiences, geographic location, socioeconomic status, academic training, professional experience, disability status, military service, career stage, institutional affiliation, cultural background, and other factors that contribute to a diverse and inclusive research workforce (NOT-OD-20-031), and who are committed to a career in basic biomedical, clinical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding. This Notice of Funding Opportunity (NOFO) is designed specifically to support candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Candidates seeking support through this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PAR-24-319).					
114360	Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-25-072	14-Jun-2025	Not Specified
Contact Name		Wynne E. Norton, PhD			
Contact Telephone		240-276-6875			
Contact Email		wynne.norton@nih.gov			
Sponsor Website					
Program URL		Link to program URL			
Deadline Dates (ALL)		14-Jun-2025 , 17-Oct-2025			
Synopsis		Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) intends to accelerate the development of evidence-based cancer-related interventions that reflect the diversity of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. This FOA will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.			
110931	Notice of Special Interest (NOSI): Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer	National Cancer Institute/NIH/DHHS	NOT-CA-22-085	07-May-2025	Not Specified
Contact Name		Ron Johnson, Ph.D.			
Contact Telephone		240-276-6250			
Contact Email		rjohnso2@mail.nih.gov			
Sponsor Website					
Program URL		Link to program URL			
Deadline Dates (ALL)		07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 12-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 12-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 12-Oct-2026 , 16-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 12-Feb-2027 , 16-Feb-2027 , 07-May-2027			
Synopsis		The purpose of this Notice of Special Interest (NOSI) is to promote research in understanding the mechanisms by which			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	cannabis and cannabinoids affect cancer biology, cancer interception, cancer treatment and resistance, and management of cancer symptoms.				
115306	Notice of Special Interest (NOSI): Research on the Etiology, Early Detection, Screening and Prevention of Early-Onset Colorectal Cancer	National Cancer Institute/NIH/DHHS	NOT-CA-23-018	07-May-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Gary Della'Zanna</div> <div>240-276-7042</div> <div>Gary.DellaZanna@nih.gov</div> <div></div> <div>Link to program URL</div> <div>07-May-2025 , 16-Jun-2025</div> <div>The purpose of this Notice of Special Interest (NOSI) is to solicit applications directed toward identifying, characterizing, and mitigating risk factors, identifying biomarkers for early detection, best screening modalities, and preventive interventions for early-onset colorectal cancer (EOCRC), defined as occurring before 50 years of age.</div>			
121014	Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-070	16-Jun-2025	275,000 USD
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Edward R. Sauter, MD, PhD</div> <div>240-276-7657</div> <div>edward.sauter@nih.gov</div> <div></div> <div>Link to program URL</div> <div>16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026</div> <div>Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose-dependent insulintropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer.</div>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
128547	Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-143	07-May-2025	275,000 USD
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Gila Neta, Ph.D.</div> <div>240-276-6785</div> <div>gila.neta@nih.gov</div> <div></div> <div>Link to program URL</div> <div>07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028</div> <div>The purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as evidence-based interventions). Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amidst disasters (e.g., pandemics, climate change) remain relevant. All applications must be within the scope of the mission of one of the Institutes/Centers listed above. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</div>			
128525	Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-233	07-May-2025	100,000 USD
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div>	<div>Gila Neta, Ph.D.</div> <div>240-276-6785</div> <div>gila.neta@nih.gov</div> <div></div> <div>Link to program URL</div> <div>07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028</div>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as evidence-based interventions). Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amidst disasters (e.g., pandemics, climate change) remain relevant. All applications must be within the scope of the mission of one of the Institutes/Centers listed above. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
128676	Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-25-253	07-May-2025	275,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Mukesh Verma, Ph.D.</p> <p>240-276-6889</p> <p>vermam@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028 , 16-Feb-2028 , 07-May-2028 , 16-Jun-2028 , 07-Sep-2028</p> <p>Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical).</p>			
128723	Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-241	16-Jun-2025	275,000 USD
	<p>Contact Name</p>	<p>Margaret Mayer, PhD, MPH</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 202-815-5515</p> <p>Contact Email margaret.mayer@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support policy research projects that examine new or adapted policies pertaining to tobacco, alcohol, and/or cannabis in the U.S., with a particular focus on how the policy or policies influence tobacco, alcohol, and cannabis use or secondhand exposure among populations experiencing disparities. Funded projects will involve authentic engagement with one or more community organizations with the aim of promoting equity in cancer prevention by addressing tobacco, alcohol, and cannabis use and exposure. The long-term goal is to support tobacco, alcohol, and cannabis policy research studies that will improve health equity and promote cancer prevention. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
128654	Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-25-172	05-Jun-2025	1,250,000 USD
	<p>Contact Name Scott Rogers, MPH</p> <p>Contact Telephone 240-276-6932</p> <p>Contact Email rogerssc@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027</p> <p>Synopsis This notice of funding opportunity (NOFO) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, digital health and data science, and implementation science.</p>				
128724	Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-240	05-Jun-2025	2,500,000 USD
	<p>Contact Name Margaret Mayer Sutherland, PhD, MPH</p> <p>Contact Telephone 202-815-5515</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email margaret.mayer@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support policy research projects that examine new or adapted policies pertaining to tobacco, alcohol, and/or cannabis in the U.S., with a particular focus on how the policy or policies influence tobacco, alcohol, and cannabis use or secondhand exposure among populations experiencing disparities. Funded projects will involve authentic engagement with one or more community organizations with the aim of promoting equity in cancer prevention by addressing tobacco, alcohol, and cannabis use and exposure. The long-term goal is to support tobacco, alcohol, and cannabis policy research studies that will improve health equity and promote cancer prevention. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
128809	Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-243	05-Jun-2025	Not Specified
	<p>Contact Name Anu Sharman, Ph.D.</p> <p>Contact Telephone 240-276-6250</p> <p>Contact Email sharmananu@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027</p> <p>Synopsis National Cancer Institute (NCI) invites applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
125423	Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical	National Cancer	PAR-	18-Jun-2025	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Trial Optional)	Institute/NIH/DHHS	24-153		Specified
	<div>Contact NameYansong Bian, MD, PhD</div> <div>Contact Telephone240-276-5630</div> <div>Contact Emailyansong.bian@nih.gov</div> <div>Sponsor Website</div> <div>Program URLLink to program URL</div> <div>Deadline Dates (ALL)18-Jun-2025 , 18-Feb-2026 , 18-Jun-2026 , 18-Feb-2027</div> <div>SynopsisThe purpose of the NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research (K12) is to support the training of clinical scientists in community cancer prevention, screening, intervention, control, and treatment research. Special emphasis is placed on training clinical scientists whose career goal is to improve the care and outcomes of minority health populations and populations with health disparities that are underrepresented in clinical research by increasing their access to and representation as human subjects in cancer clinical trials using an equity lens. This Notice of Funding Opportunity (NOFO) allows the appointment of Scholars proposing to serve as the lead investigator of an independent community-based clinical trial; proposing to increase the integration of cancer health disparities research questions into clinical trials; or proposing a separate ancillary study to an existing prevention, screening, intervention, control or treatment trial; or proposing to gain research experience in a community-based clinical trial led by another investigator; or proposing to serve as leader of innovative clinical trial approaches that expand engagement of minority health populations and populations with health disparities that are underrepresented as human subjects in cancer clinical trials, as part of their research and career development.</div>				
114550	NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-078	07-May-2025	100,000 USD
	<div>Contact NameCrystal Wolfrey</div> <div>Contact Telephone240-276-6277</div> <div>Contact Emailwolfreyc@mail.nih.gov</div> <div>Sponsor Website</div> <div>Program URLLink to program URL</div> <div>Deadline Dates (ALL)07-May-2025 , 20-Jun-2025 , 07-Sep-2025 , 17-Oct-2025 , 07-Jan-2026</div> <div>SynopsisThis funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and</div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.				
129809	NCI Pathway to Independence Award (K99/R00 – Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-25-313	17-Jun-2025	Not Specified
	<div><div>Contact Name</div><div>Contact Telephone</div><div>Contact Email</div><div>Sponsor Website</div><div>Program URL</div><div>Deadline Dates (ALL)</div><div>Synopsis</div></div> <div><div>Michael Schmidt, Ph.D.</div><div>240-276-5630</div><div>mschmidt@mail.nih.gov</div><div></div><div>Link to program URL</div><div>17-Jun-2025 , 15-Oct-2025 , 17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026 , 17-Feb-2027 , 15-Jun-2027 , 14-Oct-2027</div><div>The goal of the NCI Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of talented postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-25-135).</div></div>				
128595	Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)	National Cancer Institute/NIH/DHHS	PAR-25-103	25-Jun-2025	Not Specified
	<div><div>Contact Name</div><div>Contact Telephone</div><div>Contact Email</div><div>Sponsor Website</div><div>Program URL</div><div>Deadline Dates (ALL)</div><div>Synopsis</div></div> <div><div>Brandy Heckman-Stoddard, Ph.D., M.P.H.</div><div>240-276-7048</div><div>heckmanbm@mail.nih.gov</div><div></div><div>Link to program URL</div><div>25-Jun-2025 , 25-Oct-2025 , 25-Feb-2026 , 25-Jun-2026 , 25-Oct-2026 , 25-Feb-2027 , 25-Jun-2027 , 25-Oct-2027</div><div>Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related</div></div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns this can include a pilot/feasibility clinical trial if necessary, improving trial design and rigor. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
128597	Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)	National Cancer Institute/NIH/DHHS	PAR-25-104	25-Jun-2025	Not Specified
	Contact Name	Brandy Heckman-Stoddard, Ph.D., M.P.H.			
	Contact Telephone	240-276-7048			
	Contact Email	heckmanbm@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-Jun-2025 , 25-Oct-2025 , 25-Feb-2026 , 25-Jun-2026 , 25-Oct-2026 , 25-Feb-2027 , 25-Jun-2027 , 25-Oct-2027			
	Synopsis	<p>Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns this can include a pilot/feasibility clinical trial if necessary, improving trial design and rigor. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
129235	Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-321	16-Jun-2025	275,000 USD
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Miguel R. Ossandon, Ph.D.</div> <div>240-276-5714</div> <div>ossandom@mail.nih.gov</div> <div></div> <div>Link to program URL</div> <div>16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027</div> <div>The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA</div>			
128848	NCI Pathway to Independence Award (K99/R00 – Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-135	17-Jun-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Michael Schmidt, Ph.D.</div> <div>240-276-5630</div> <div>mschmidt@mail.nih.gov</div> <div></div> <div>Link to program URL</div> <div>17-Jun-2025 , 15-Oct-2025 , 17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026 , 17-Feb-2027 , 15-Jun-2027 , 14-Oct-2027</div> <div>The goal of the NCI Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of talented postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.</div>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
112622	Biology of Bladder Cancer (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-219	16-Jun-2025	275,000 USD
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Ron Johnson, Ph. D.</div> <div>240-276-6250</div> <div>rjohnso2@mail.nih.gov</div> <div></div> <div>Link to program URL</div> <div>16-Jun-2025</div> <div> <p>This Funding Opportunity Announcement (FOA) encourages applications that investigate the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression and malignancy of bladder cancer. Furthermore, our understanding of the biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and contribute to the future development of new interventions.</p> </div> </div>				
117338	Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-152	16-Jun-2025	275,000 USD
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Curt DellaValle, Ph.D., MPH</div> <div>240-276-7225</div> <div>curt.dellavalle@nih.gov</div> <div></div> <div>Link to program URL</div> <div>16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026</div> <div> <p>This Notice of Funding Opportunity (NOFO) aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control and behaviors.</p> </div> </div>				
128810	Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)	National Cancer	PAR-	16-Jun-2025	400,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Institute/NIH/DHHS	25-244		USD
	<p>Contact Name Anu Sharman, Ph.D.</p> <p>Contact Telephone 240-276-6250</p> <p>Contact Email sharmananu@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027</p> <p>Synopsis National Cancer Institute (NCI) invites applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.</p>				
113746	<p>Notice of Special Interest (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers</p>	National Cancer Institute/NIH/DHHS	NOT-CA-23-004	05-Apr-2025	Not Specified
	<p>Contact Name Matthew Young, Ph.D.</p> <p>Contact Telephone 240-276-5846</p> <p>Contact Email matthew.young@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 01-Jul-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to encourage research studies leveraging partnerships between biomarker technology developers with assays for early cancer detection, and population-based researchers, including cohort and biorepository researchers. Proposals that facilitate early cancer biomarker assay development, verification, qualification, and validation utilizing statistically powered retrospective cohorts and/or through prospective studies in the appropriate populations with a sound study design are responsive to this NOSI.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
112442	NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-25-139	12-Jun-2025	275,000 USD
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Morgan O'Hayre, Ph.D.</div> <div>240-276-7482</div> <div>ohayrem@mail.nih.gov</div> <div></div> <div>Link to program URL</div> <div>12-Jun-2025 , 01-Jul-2025</div> <div> <p>This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among underserved populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative correlative studies in cancer patients with age, gender, racial/ethnic, or health disparities are encouraged to explore mechanisms underlying their differential responses (efficacy and toxicity) and resistance to therapeutic interventions. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways, molecular mechanisms, or mechanisms of metastasis), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed (see below for a more detailed description of studies that are not responsive for this FOA). The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to breakthroughs in particular areas, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research (preclinical or clinical).</p> </div> </div>				
122437	NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)	National Cancer Institute/NIH/DHHS	PAR-23-288	16-Jun-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Sergey Radaev, PhD</p> <p>Contact Telephone 240-276-5630</p> <p>Contact Email sradaev@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2025 , 14-Oct-2025 , 17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026</p> <p>Synopsis The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-23-286). This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>				
122436	NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-23-287	16-Jun-2025	Not Specified
	<p>Contact Name Sergey Radaev, PhD</p> <p>Contact Telephone 240-276-5630</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email sradaev@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2025 , 14-Oct-2025 , 17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026</p> <p>Synopsis The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This notice of funding opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-23-286).</p>				
122435	NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-23-286	16-Jun-2025	Not Specified
	<p>Contact Name Sergey Radaev, PhD</p> <p>Contact Telephone 240-276-5630</p> <p>Contact Email sradaev@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2025 , 14-Oct-2025 , 17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026</p> <p>Synopsis The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFOs (PAR-23-287 or PAR-23-288).</p>				
122281	Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-074	11-Jun-2025	Not Specified
	Contact Name	Tracy G. Lively, Ph.D.			
	Contact Telephone	240-276-5944			
	Contact Email	livelyt@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Jun-2025 , 15-Oct-2025 , 13-Feb-2026 , 10-Jun-2026 , 14-Oct-2026			
	Synopsis	<p>Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this NOFO supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this NOFO supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays. Investigators responding to this NOFO must address both UH2 and UH3 phases. Milestones to be accomplished in the UH2 phase for transition to the UH3 phase must be proposed by the investigators.				
122288	Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-075	11-Jun-2025	750,000 USD
	Contact Name	Sumana Dey, Ph.D.			
	Contact Telephone	240-276-5748			
	Contact Email	sumana.dey@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Jun-2025 , 15-Oct-2025 , 13-Feb-2026 , 10-Jun-2026 , 14-Oct-2026			
	Synopsis	<p>Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multidisciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.</p>			
111848	Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-25-295	16-Jun-2025	275,000 USD
	Contact Name	Kelly D. Blake, ScD			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-281-5934</p> <p>Contact Email kelly.blake@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2025</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication pilot interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.</p>				
111860	Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-199	16-Jun-2025	275,000 USD
	<p>Contact Name Michael Graham Espey, Ph.D.</p> <p>Contact Telephone 240-276-5609</p> <p>Contact Email SP@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2025</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R21 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.</p>				
114679	Co-infection and Cancer (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-083	16-Jun-2025	275,000 USD
	Contact Name Tram Kim Lam, Ph.D., MPH				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-6967</p> <p>Contact Email lamt@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2025 , 16-Oct-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.</p>				
117714	Notice of Special Interest (NOSI): RNA Modifications in Cancer Biology	National Cancer Institute/NIH/DHHS	NOT-CA-23-060	07-May-2025	Not Specified
	<p>Contact Name Stefan Maas, Ph.D.</p> <p>Contact Telephone 240-276-6230</p> <p>Contact Email stefan.maas@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis Through this Notice of Scientific Interest (NOSI), the National Cancer Institute intends to stimulate research on the role of RNA modifications in the area of cancer biology. Despite the recognition that RNA modifications and editing exert a substantial impact on gene expression and function, there is a lack of mechanistic insights into the dynamic regulation of RNA modifications and their de-regulation as drivers of cancer formation. A better understanding of the extent, diversity, and crosstalk between different types of RNA modification, and the elucidation of the molecular players that read and interpret the modification code are needed to reveal the mechanisms of RNA modifications that underlie cancer formation and the cancer phenotype.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
127774	Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-044	16-Jun-2025	550,000 USD
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Edward R. Sauter, M.D., Ph.D.</div> <div>240-276-7657</div> <div>edward.sauter@nih.gov</div> <div></div> <div>Link to program URL</div> <div>16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027</div> <div>Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter term outcomes such as weight loss and diabetes.</div> </div>				
129261	Exploratory/Developmental Bioengineering Research Grants(EBRG) (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-25-346	16-Jun-2025	275,000 USD
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Miguel R. Ossandon, Ph.D.</div> <div>240-276-5714</div> <div>ossandom@mail.nih.gov</div> <div></div> <div>Link to program URL</div> <div>16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027</div> <div>The purpose of this engineering-oriented notice of funding opportunity announcement (NOFO) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.</div> </div>				
113232	Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22-242	07-May-2025	Not Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> </div> <div> <div>Rao Divi, Ph.D.</div> <div>240-276-6913</div> </div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email divir@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 05-Jul-2025 , 07-Sep-2025</p> <p>Synopsis The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) develop, integrate, optimize, validate, translate or accelerate adoption of promising tools, methods and techniques: a) that fulfill an unmet need and address specific research or clinical problem in basic, translational, and/or clinical science and practice, b) capable of enhancing our understanding of health and disease, and/or c) improve practice of medicine. Applications may propose design-directed, developmental, discovery-driven, or hypothesis-driven research, and this FOA is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.</p>				
113233	Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-243	07-May-2025	Not Specified
	<p>Contact Name Rao Divi, Ph.D.</p> <p>Contact Telephone 240-276-6913</p> <p>Contact Email divir@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 05-Jul-2025 , 07-Sep-2025</p> <p>Synopsis The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical, or translational science. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. This FOA is not intended to support conventional clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of research are not sought by and will not be supported through this FOA. This FOA does not propose to support commercial production.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
123791	NCCIH Natural Product Mid Phase Clinical Trial Cooperative Agreement (R01 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-25-271	23-Jun-2025	1,750,000 USD
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Sekai Chideya, M.D., MPH</div> <div>301-827-1916</div> <div>sekai.chideya@nih.gov</div> <div></div> <div>Link to program URL</div> <div>23-Jun-2025 , 17-Jul-2025 , 23-Feb-2026 , 17-Mar-2026 , 20-Oct-2026 , 13-Nov-2026</div> <div>This Funding Opportunity Announcement (FOA) invites cooperative agreement applications for investigator-initiated mid-phase clinical trials of natural products. All applications submitted under this FOA must be supported by sufficient preliminary data of bioavailability and documentation that the natural product produces a replicable and measurable impact on a biological signature (i.e., measure of the mechanism of action). Only in cases when it is not possible/practical to measure a biological signature in the patient population of interest or when there is a fundamental understanding of the product’s mechanism of action will this preliminary data requirement be waived. Applications submitted to this FOA should propose a mid-phase clinical trial to do the following: determine the optimal dose or formulation of a given natural product for use in a future multi-site clinical trial; or determine which patient phenotypes will be responders versus non-responders to the natural product to inform inclusion/exclusion criteria of a future efficacy study. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This FOA will not support single-site or multi-site efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.</div>			
126574	Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-25-211	02-Jun-2025	1,750,000 USD
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div>	<div>Hye-Sook Kim, Ph.D.</div> <div>301-827-6910</div> <div>hye-sook.kim@nih.gov</div> <div></div> <div>Link to program URL</div>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<div>Deadline Dates (ALL)02-Jun-2025 , 02-Feb-2026 , 01-Oct-2026 , 02-Jun-2027</div> <div>Synopsis<div>The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate the development of effective precision probiotic interventions using a milestone-driven, biphasic award mechanism. It aims to identify, understand, and develop strategies to address barriers in precision probiotic interventions to account for the heterogeneity in humans that often causes inconsistent probiotic therapeutic responses. Specifically, this NOFO solicits applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders, which may then help enhance probiotic clinical outcomes. The first phase, funded by the R61 mechanism, will provide 1 or 2 years of support to identify host biological patterns (e.g., native microbiome, immune system, sex and/or gender, diet, age, genetic background, lifestyle, or health history) that are correlated with differences in probiotic clinical effects using observational or secondary data analysis studies. The second phase, funded under the R33 mechanism, will support studies to assess the causality of the factors identified in the R61 phase that impact probiotic responsiveness through rigorous mechanistic study designs in animal models or human subjects. This NOFO will not support efficacy or effectiveness clinical trials. The combined R61/R33 should not exceed 5 years. Transition to the R33 phase requires administrative review by NIH staff and is not guaranteed. Approval of the transition to the R33 phase will be based on the original R61/R33 peer review recommendations, successful completion of transition milestones, any proposed changes to the R33 research based on R61 findings, program priorities, and availability of funds. It is not expected that all applications will continue to the R33 phase. Support for a single phased award that does not need the R61 Exploratory phase is available in the companion (R33) NOFO, PAR-25-210. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</div></div>				
126576	Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-25-210	02-Jun-2025	1,400,000 USD
	<div>Contact NameHye-Sook Kim, Ph.D.</div> <div>Contact Telephone301-827-6910</div> <div>Contact Emailhye-sook.kim@nih.gov</div> <div>Sponsor Website</div> <div>Program URLLink to program URL</div> <div>Deadline Dates (ALL)02-Jun-2025 , 02-Feb-2026 , 01-Oct-2026 , 02-Jun-2027</div> <div>Synopsis<div>The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate the development of effective precision probiotic interventions. The NOFO aims to identify, understand, and develop strategies to address barriers in precision probiotic interventions' development to account for human heterogeneity resulting in inconsistent responses to probiotic treatments. Specifically, this NOFO solicits R33 applications that will assess the</div></div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>causality of person-specific features or patterns affecting probiotic responses and identify subgroups of probiotic responders in order to enhance therapeutic outcomes. This NOFO will support studies that assess whether host biological patterns (e.g., native microbiome, immune system, sex and/or gender, diet, age, genetic background, lifestyle, or health history) that are correlated with clinical probiotic effects can modulate responsiveness to probiotic interventions. Well-suited applications must offer rigorously designed mechanistic studies using relevant/innovative animal models or human subjects. This NOFO is intended to support projects where potential host biological patterns that are correlated with probiotic usage or interventions have been identified, as demonstrated with supportive preliminary data, which require further mechanistic studies to test for causality. This NOFO will not support efficacy or effectiveness clinical trials. Applicants pursuing early-stage research to identify host biological patterns that may affect probiotic health outcomes should consider the companion (R61/R33) PAR-25-211. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
123147	NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-25-267	20-Jun-2025	Not Specified
	Contact Name	Pete Murray, Ph.D.			
	Contact Telephone	301-496-4054			
	Contact Email	peter.murray@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	20-Jun-2025 , 15-Jul-2025 , 20-Oct-2025 , 18-Nov-2025 , 20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 14-Jul-2026 , 20-Oct-2026 , 17-Nov-2026			
	Synopsis	<p>This notice of funding opportunity (NOFO) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. Applications submitted under this NOFO are expected to propose a multisite feasibility clinical trial that will provide new information that is scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIH's mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R01) research is scientifically necessary to design or plan the subsequent fully powered, full-scale clinical trial. Under this R01, the data collected should be used to fill gaps in scientific knowledge, including, but not limited to the following: assessing whether the intervention can be delivered with fidelity across sites; demonstrating feasibility of recruitment, accrual, and randomization of participants across sites; demonstrating participant</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>adherence to the intervention, as well as retention of participants throughout the study across sites; refining and assessing the feasibility of protocolized multimodal interventions, and/or demonstrating feasibility of data collection across sites in preparation for a future fully powered, multisite efficacy or effectiveness trial. The need for multisite feasibility trials is expected to be justified by sufficient preliminary data from previous single site feasibility or acceptability trial(s) or the published literature. The data collected should be used to fill gaps in scientific knowledge and be necessary to develop a competitive fully powered multisite clinical trial that has the potential to make a significant impact on public health. Prior to submitting to this NOFO, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for the science area of the planned application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				
123153	Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-25-268	20-Jun-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Beda Jean-Francois, Ph.D.</p> <p>202-313-2144</p> <p>beda.jean-francois@nih.gov</p> <p></p> <p>Link to program URL</p> <p>20-Jun-2025 , 14-Jul-2025 , 20-Oct-2025 , 17-Nov-2025 , 20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 13-Jul-2026 , 20-Oct-2026 , 17-Nov-2026</p> <p>This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in NCCIH- designated areas of high research priority. Applications submitted under this NOFO are expected to propose a remotely delivered and conducted fully powered clinical trial with no in-person contact between research staff and study participants and may utilize mHealth tools or technologies. Applicants must provide justification for the remotely delivered approach and provide preliminary data on the feasibility and safety of the approach, along with evidence that the intervention has promise of clinical benefit. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.				
123152	Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-25-274	20-Jun-2025	450,000 USD
	Contact Name	Jennifer N. Baumgartner, Ph.D.			
	Contact Telephone	301-402-4084			
	Contact Email	jennifer.baumgartner@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	20-Jun-2025 , 14-Jul-2025 , 20-Oct-2025 , 17-Nov-2025 , 20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 13-Jul-2026 , 20-Oct-2026 , 17-Nov-2026			
	Synopsis	<p>The goal of this notice of funding opportunity (NOFO) is to support feasibility trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) for conditions that have been identified by NCCIH as high-priority research topics. This funding opportunity is intended to support feasibility clinical trials that provide new information that are scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIH's mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent competitive full-scale clinical trial. Under this R34, the data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: examining feasibility and acceptability of interventions lacking published data; tailoring or adapting the content or structure of an intervention to a specific population, modality, or setting; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention, and data collection procedures; refining and assessing the feasibility of protocolized multi-component interventions; or examining acceptability and adherence of control conditions. The subsequent full-scale clinical trial should have the potential to make a significant impact on public health. Prior to submitting to this NOFO, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for the science area of the planned application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
123155	Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24-276	20-Jun-2025	500,000 USD
	<div>Contact NameElizabeth Ginexi, Ph.D.</div> <div>Contact Telephone301-827-0160</div> <div>Contact Emailelizabeth.ginexi@nih.gov</div> <div>Sponsor Website</div> <div>Program URLLink to program URL</div> <div>Deadline Dates (ALL)20-Jun-2025 , 14-Jul-2025 , 20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 14-Jul-2026</div> <div>Synopsis<p>This notice of funding opportunity (NOFO), utilizing the U24 grant funding mechanism, encourages applications for a collaborating data coordinating center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under companion PAR-24-275. The DCC application must be specific to the companion clinical coordinating center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this NOFO applies must be relevant to the research mission of NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult the NCCIH website (https://www.nccih.nih.gov). Applicants are encouraged to contact the appropriate Scientific/Research Contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p></div>				
123858	Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24-313	23-Jun-2025	Not Specified
	<div>Contact NameWendy Weber, N.D., Ph.D, M.P.H.</div> <div>Contact Telephone301-402-1272</div> <div>Contact Emailweberwj@mail.nih.gov</div> <div>Sponsor Website</div> <div>Program URLLink to program URL</div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<div> <div>Deadline Dates (ALL)</div> <div>23-Jun-2025 , 15-Jul-2025 , 20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 14-Jul-2026</div> </div>					
<div> <div>Synopsis</div> <div> <p>This Notice of Funding Opportunity (NOFO), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under PAR-24-312. The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this NOFO applies must be relevant to the research mission of NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult the NCCIH website: (https://www.nccih.nih.gov). Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p> </div> </div>					
128271	Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24-275	21-May-2025 [Optional][LOI/Pre-App]	Not Specified
<div> <div>Contact Name</div> <div>Elizabeth Ginexi, Ph.D.</div> </div>					
<div> <div>Contact Telephone</div> <div>301-827-0160</div> </div>					
<div> <div>Contact Email</div> <div>elizabeth.ginexi@nih.gov</div> </div>					
<div> <div>Sponsor Website</div> <div></div> </div>					
<div> <div>Program URL</div> <div>Link to program URL</div> </div>					
<div> <div>Deadline Dates (ALL)</div> <div>21-May-2025 [Optional][LOI/Pre-App], 20-Jun-2025 , 14-Jul-2025 , 21-Jan-2026 [Optional][LOI/Pre-App], 20-Feb-2026 , 17-Mar-2026 , 23-May-2026 [Optional][LOI/Pre-App], 22-Jun-2026 , 14-Jul-2026</div> </div>					
<div> <div>Synopsis</div> <div> <p>This notice of funding opportunity (NOFO) encourages applications for investigator-initiated multisite clinical trials (e.g., efficacy, effectiveness, or pragmatic trials) to study the effects of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions), and/or multicomponent interventions that include physical, psychological, and/or nutritional approaches in NCCIH-designated areas of high research priority. Clinical coordinating centers (CCC) should develop and implement the proposed fully powered multisite clinical trial (Phase III and beyond). The objective of a CCC application is to present the scientific rationale and a comprehensive scientific and operational plan for the clinical trial. CCC applications are expected to describe plans for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results.</p> </div> </div>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>CCC applications submitted under this NOFO will utilize a two-phase, milestone-driven cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying data coordinating center (DCC) application (U24), submitted under PAR-24-087 and proposing a data analysis and data management plan for the clinical project, is required. Both a CCC application and a corresponding DCC application need to be submitted simultaneously for consideration by NCCIH. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult the NCCIH website (https://nccih.nih.gov/about/plans). Applicants are encouraged to contact the appropriate Scientific/Research Contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
124534	Notice of Special Interest (NOSI): National Center for Complementary and Integrative Health (NCCIH) T32 Supplement Program to Promote Diversity in Health Research	National Center for Complementary and Integrative Health/NIH/DHHS	NOT-AT-24-034	02-Jun-2025	Not Specified
	<p>Contact Name Jennifer N. Baumgartner, Ph.D.</p> <p>Contact Telephone 301-402-4084</p> <p>Contact Email jennifer.baumgartner@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Jun-2025 , 03-Nov-2025 , 02-Mar-2026 , 01-Jun-2026 , 02-Nov-2026</p> <p>Synopsis NCCIH announces an opportunity to allow institutions with existing NCCIH-funded Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (T32) programs to apply for an administrative supplement to promote diversity in health research. A very limited number of supplementary slots will be available in each fiscal year and the number awarded will depend on the number and merit of applications received and the availability of funds.</p>				
123835	Notice of Special Interest (NOSI): National Center for Complementary and Integrative Health (NCCIH) T32 Complementary and Integrative Health Practitioner Supplement Program for Pre- and Postdoctoral Candidates	National Center for Complementary and Integrative Health/NIH/DHHS	NOT-AT-24-033	02-Jun-2025	Not Specified
	<p>Contact Name Jennifer N. Baumgartner, Ph.D.</p> <p>Contact Telephone 301-402-4084</p> <p>Contact Email jennifer.baumgartner@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
123623	Deadline Dates (ALL)	02-Jun-2025 , 03-Nov-2025 , 02-Mar-2026 , 01-Jun-2026 , 02-Nov-2026			
	Synopsis	NCCIH announces an opportunity to allow existing NCCIH-funded Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (T32) programs to apply for an administrative supplement to support an additional training slot for predoctoral and postdoctoral candidates with professional clinical complementary and integrative health degrees.			
123623	Notice of Special Interest (NOSI): Administrative Supplements for Complementary Health Practitioner Research Experience (Admin Supplements)	National Center for Complementary and Integrative Health/NIH/DHHS	NOT-AT-24-032	02-Jun-2025	200,000 USD
	Contact Name	Lanay M. Mudd, Ph.D., FACSM			
	Contact Telephone	301-594-9346			
	Contact Email	lanay.mudd@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	02-Jun-2025 , 03-Nov-2025 , 02-Mar-2026 , 01-Jun-2026 , 02-Nov-2026			
	Synopsis	The National Center for Complementary and Integrative Health (NCCIH) encourages applications for administrative supplements to NCCIH-supported awards to support complementary health practitioners in an intensive, supervised research experience that will lead to a better understanding of, and practical experience in, complementary and integrative health research.			
119247	NEI Institutional Mentored Physician Scientist Award (K12 Clinical Trial Optional)	National Eye Institute/NIH/DHHS	PAR-23-197	09-Jun-2025	Not Specified
	Contact Name	Neeraj Agarwal, Ph.D.			
	Contact Telephone	301-435-8155			
	Contact Email	agarwalnee@nei.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	09-Jun-2025 , 09-Jun-2026			
	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to encourage institutions to propose creative and innovative institutional research career development programs which will prepare clinically trained vision scientists for independent			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>research careers. This NOFO is intended to expand and strengthen the community of clinician investigators engaged in vision research. This Notice of Funding Opportunity (NOFO) allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development program. For this career development program scholars are limited to clinical trials that are minimal risk. The existing clinical trial must be a NIH-defined clinical trial that fulfills the NIH requirement for minimal risk trial. A minimal risk trial is one in which the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity. For the purposes of this announcement, institutions are highly encouraged to recruit prospective PIs/PDs, mentors, and scholars from diverse backgrounds, including individuals from underrepresented racial and ethnic groups and individuals with disabilities as described in the NOT-OD-22-019 in all of its programs.</p>				
117409	Notice of Special Interest (NOSI): Development of Innovative Informatics and Data Science Technologies, Tools, and Methods for Vision Research	National Eye Institute/NIH/DHHS	NOT-EY-23-005	05-Apr-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>James Gao, Ph.D.</div> <div>301-594-6074</div> <div>james.gao@nih.gov</div> <div></div> <div>Link to program URL</div> <div>05-Apr-2025 , 07-May-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026 , 16-Feb-2026</div> <div>The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants that the National Eye Institute (NEI) is interested in supporting research to develop innovative informatics and data science methods, algorithms, and tools to improve data acquisition, analysis, visualization, annotation, integration, and interpretation. The emphasis will be on innovation and its potential impact on vision research, including discovery biology, population studies, as well as clinical and translational research.</div>			
129739	NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)	National Eye Institute/NIH/DHHS	PAR-25-358	07-May-2025	300,000 USD
	<div>Contact Name</div>	<div>Donald Everett, MA</div>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-435-8181</p> <p>Contact Email everettd@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The NEI supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies on eye/vision conditions. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This clinical research planning grant funding opportunity supports applicants in their planning efforts to conduct collaborative clinical research. The grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.</p>				
129611	NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)	National Eye Institute/NIH/DHHS	PAR-25-357	07-May-2025	275,000 USD
	<p>Contact Name Donald Everett, M.A.</p> <p>Contact Telephone 301-435-8181</p> <p>Contact Email everettd@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to conduct secondary data analyses using existing data collected from humans participating in vision-related clinical trials, epidemiologic, and other clinical research studies or represented in clinical and health care database resources (e.g., electronic health records). This NOFO may be used to develop new statistical methodologies or test hypotheses using existing data, but this NOFO must not be used to support the collection of new data. This NOFO encourages applications from institutions/organizations that propose to conduct vision-related secondary analyses of data collected from humans. Applications may be related to, but must be distinct from, the specific</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects wherein numerous data collection activities are required to meet each project's specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project's originally intended purpose. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest.</p>				
115585	Notice of Special Interest (NOSI): Development of Functional Assay Sites to Evaluate Candidate -Omics Variants Associated with Heart, Lung, Blood, or Sleep Disease (R01, R41, R42, R43, R44)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-23-066	05-Apr-2025	Not Specified
	<p>Contact Name: Charlene Schramm, Ph.D.</p> <p>Contact Telephone: 301-402-3793</p> <p>Contact Email: schrammc@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 05-Apr-2025 , 07-May-2025 , 07-May-2025 , 05-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 05-Jan-2026 , 07-Jan-2026 , 05-Feb-2026 , 05-Apr-2026 , 07-May-2026 , 05-Jun-2026 , 05-Sep-2026 , 07-Sep-2026</p> <p>Synopsis: The NHLBI is issuing this Notice of Special Interest (NOSI) to highlight interest in receiving grant applications focused on HLBS disorders in the following area(s): Development and/or application of moderate- or high-throughput functional assays to provide biological validation of candidate human variants associated with HLBS disorders Defining causal relationships between genotypes and phenotypes Development and validation of functionally informed risk predictions</p>				
116586	Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-23-067	07-May-2025	Not Specified
	<p>Contact Name: James Luo, Ph.D.</p> <p>Contact Telephone: 301-435-0533</p> <p>Contact Email: luoja@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in recent years, yet an understanding of the molecular mechanisms underlying many of these diseases has remained elusive. Furthermore, in most cases the impact of genetic variation on severity of disease and treatment outcomes remains unknown. Therefore, the NHLBI has created the Trans-omics for Precision Medicine (TOPMed) program, which aims to utilize genomics data to characterize a variety of HLBS diseases. TOPMed is well on its way to collecting whole genome sequence (WGS) from over 194,270 well-phenotyped individuals and is currently generating multi-omics data (e.g., over 31,852 RNA sequences, over 44,342 DNA methylation profiles, and 26,124 metabolomics profiles) from many of these individuals to complement whole genome sequence information. Having produced an unprecedented volume of high-throughput data, TOPMed now seeks to turn its attention to effectively leveraging this resource to uncover biological function and disease pathobiology through novel systems biology analyses and the power of artificial intelligence (AI) and Machine Learning (ML). Although lower costs and technological improvements in sequencing technology have vastly expanded our ability to generate large volumes of omics data, the ability to analyze such large datasets to extract biologically meaningful insights remains challenging. Systems level models incorporating trans-omics analyses will be an important step in uncovering the underlying biological networks and the gene-gene and gene-environment interactions influencing disease and treatment outcomes. Thus, advanced analyses that incorporate genotype and phenotype datasets from thousands to tens of thousands of individuals are essential to move TOPMed to the next phase of discovery.</p>				
125098	NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-25-026	05-May-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Sumita Khatri, MD</p> <p>301-402-9673</p> <p>sumita.khatri@nih.gov</p> <p></p> <p>Link to program URL</p> <p>05-May-2025 [Optional][LOI/Pre-App], 07-May-2025 , 04-Jun-2025 , 03-Sep-2025 [Optional][LOI/Pre-App], 07-Sep-2025 , 02-Oct-2025 , 04-Jan-2026 [Optional][LOI/Pre-App], 07-Jan-2026 , 03-Feb-2026 , 05-May-2026 [Optional][LOI/Pre-App], 07-May-2026 , 04-Jun-2026 , 03-Sep-2026 [Optional][LOI/Pre-App], 07-Sep-2026 , 02-Oct-2026 , 07-Jan-2027</p> <p>The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This FOA will utilize a</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.				
125065	NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-25-025	05-May-2025 [Optional][LOI/Pre-App]	4,545,000 USD
	Contact Name	Sumita Khatri, MD			
	Contact Telephone	301-402-9673			
	Contact Email	sumita.khatri@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-May-2025 [Optional][LOI/Pre-App], 07-May-2025 , 04-Jun-2025 , 02-Sep-2025 [Optional][LOI/Pre-App], 07-Sep-2025 , 02-Oct-2025 , 04-Jan-2026 [Optional][LOI/Pre-App], 07-Jan-2026 , 03-Feb-2026 , 05-May-2026 [Optional][LOI/Pre-App], 07-May-2026 , 04-Jun-2026 , 02-Sep-2026 [Optional][LOI/Pre-App], 07-Sep-2026 , 02-Oct-2026 , 07-Jan-2027			
	Synopsis	The objective of this Notice of Funding Opportunity (NOFO) is to support investigator-initiated, Phase 1 clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multi-site. Applicants applying for funding under this NOFO should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. If time and support for these and other pre-clinical and/or trial readiness activities are desired, applicants should consider the companion NOFO PAR-25-026, which utilizes an R61/R33 phased approach.			
112260	Notice of Special Interest (NOSI): Studies of Cellular/Molecular Pathobiological Mechanisms of Lung Diseases Using Human 3-Dimensional Cellular Systems (R01)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-030	07-May-2025	Not Specified
	Contact Name	Qing Lu, Ph.D.			
	Contact Telephone	301-480-9158			
	Contact Email	qing.lu@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-2025			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this NOSI is to promote research characterizing the pathobiological processes and mechanisms that drive the onset and progression of lung diseases at a molecular/cellular level, providing a systems-level understanding by studying experimental systems with cellular heterogeneity and 3-D architecture. It is expected that projects supported by this NOSI will utilize ex vivo preparations (e.g., thin human lung slices) or 3-D multi-cellular in vitro systems (e.g., organoids) of human lung cells and will employ state-of-art multi-omics measures (e.g., spatial or single cell/nucleus omics) to better understand specific pathobiological processes in systems of interacting cell types.			
108068	Notice of Special Interest (NOSI): Diagnostics and Disease Management Tools for Use in Underserved Populations	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-024	05-Jun-2025	Not Specified
	Contact Name	Bishow Adhikari, Ph.D.			
	Contact Telephone	301-594-2791			
	Contact Email	adhikarb@nhlbi.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2025			
	Synopsis	The purpose of this NOSI is to stimulate research focused on the development of transformative diagnostics and disease management tools for heart, lung, blood, or sleep (HLBS) disorders that are designed to meet the needs of the underserved populations. Underserved populations, for the purpose of this NOSI, can include racial and ethnic minorities, immigrants, the homeless, low-income individuals, the uninsured and people who live in communities that are socioeconomically disadvantaged, rural or have few health care resources. Please see NOT-OD-20-031 for NIH definitions. Special consideration will be given to technology solutions that are accessible and feasible in these communities. Working with community partners is required throughout the project to ensure successful development and implementation.			
114141	Notice of Special Interest (NOSI): Advancing Research in Lipoprotein(a) and Cardiovascular Disease (R01 Clinical Trials Allowed) and (R01 No Clinical Trials Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-052	07-May-2025	Not Specified
	Contact Name	Lijuan Liu, PhD			
	Contact Telephone	301-435-0582			
	Contact Email	lliu@nhlbi.nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106202	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026			
	Synopsis	The purpose of this NOSI is to stimulate research on lipoprotein(a) [Lp(a)] and its role in cardiovascular disease (CVD). We encourage multidisciplinary collaborations to conduct basic, preclinical, and mechanistic clinical studies on Lp(a) and CVD.			
106202	Notice of Special Interest (NOSI): Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre-adolescence Through Adolescence to Young Adulthood	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-21-015	07-May-2025	Not Specified
	Contact Name	Alison G.M. Brown, PhD, MS, RDN			
	Contact Telephone	301-435-0583			
	Contact Email	Alison.brown@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026			
	Synopsis	This Notice of Special Interest (NOSI) calls for research to understand and promote cardiovascular and cardiometabolic health during transitional phases across the lifecourse, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years). This initiative would support research to: 1) understand the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitional phases from pre-adolescence into adolescence and adolescence into young adulthood, and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitional phases.			
113286	Notice of Special Interest (NOSI): Basic and Translational Research on Circadian Regulation of Heart, Lung, Blood, and Sleep Disorders (R01)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-043	07-May-2025	Not Specified
	Contact Name	Ravi Balijepalli, Ph.D.			
	Contact Telephone	301-435-0504			
	Contact Email	ravi.balijepalli@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</p> <p>Synopsis This NOSI aims to stimulate research on understanding how circadian rhythms regulate cell function and metabolism of peripheral tissues, and to find new avenues for the investigation of heart, lung, and blood disease risk, pathogenesis, diagnosis, treatment, and prevention. Basic, translational, and clinical research applications to elucidate circadian-dependent mechanisms contributing to the pathophysiology of HLBS disorders are invited. This NOSI encourages multidisciplinary and multiple investigator teams of experts in heart, lung, and blood research fields to synergistically work with circadian biologists and sleep researchers to provide a comprehensive understanding of the circadian biology in relation to HLBS conditions. The purpose is to facilitate translational research to identify potential applications of circadian science to the diagnosis, prevention and treatment of HLBS conditions. Mechanism-based studies investigating the circadian rhythm dysregulation, clinical markers, and/or therapeutic targets of HLBS conditions are encouraged. Behavioral, physiological, pharmacological, molecular, and genomic studies aimed at elucidating the relationship between circadian-dependent mechanisms and disease are appropriate. Studies to delineate circadian-based mechanisms, therapeutic targets, epidemiological risk and clinical trials to assess therapeutic safety, efficacy, effectiveness, or implementation may be proposed.</p>				
128905	RFA-HL-26-019 -- Catalyze Product Definition – Medical Device Prototype Design/Testing and Disease Target Identification and Assay Development (R61/R33 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-26-019	21-Apr-2025	900,000 USD
	<p>Contact Name Mike Pieck, Ph.D.</p> <p>Contact Telephone 301-827-7986</p> <p>Contact Email nhlbi_catalyze@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Apr-2025 , 18-Jun-2025 , 21-Aug-2025 , 21-Oct-2025 , 22-Dec-2025 , 11-Feb-2026 , 21-Apr-2026 , 18-Jun-2026 , 21-Aug-2026 , 21-Oct-2026 , 23-Dec-2026 , 11-Feb-2027 , 23-Apr-2027 , 17-Jun-2027 , 23-Aug-2027 , 21-Oct-2027 , 23-Dec-2027</p> <p>Synopsis This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of heart, lung, blood and sleep (HLBS) diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
128906	RFA-HL-26-020 -- Catalyze: Product Definition – Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-26-020	21-Apr-2025	600,000 USD
	<div>Contact NameMike Pieck, Ph.D.</div> <div>Contact Telephone301-827-7986</div> <div>Contact Emailnhlbi_catalyze@nih.gov</div> <div>Sponsor Website</div> <div>Program URLLink to program URL</div> <div>Deadline Dates (ALL)21-Apr-2025 , 18-Jun-2025 , 21-Aug-2025 , 21-Oct-2025 , 22-Dec-2025 , 11-Feb-2026 , 21-Apr-2026 , 18-Jun-2026 , 21-Aug-2026 , 21-Oct-2026 , 23-Dec-2026 , 11-Feb-2027 , 23-Apr-2027 , 17-Jun-2027 , 23-Aug-2027 , 21-Oct-2027 , 23-Dec-2027</div> <div>SynopsisThis Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of heart, lung, blood, and sleep (HLBS) diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.</div>				
128904	RFA-HL-26-018 -- Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-26-018	21-Apr-2025	800,000 USD
	<div>Contact NameMike Pieck, Ph.D.</div> <div>Contact Telephone301-827-7986</div> <div>Contact Emailnhlbi_catalyze@nih.gov</div> <div>Sponsor Website</div> <div>Program URLLink to program URL</div> <div>Deadline Dates (ALL)21-Apr-2025 , 18-Jun-2025 , 21-Aug-2025 , 21-Oct-2025 , 22-Dec-2025 , 11-Feb-2026 , 21-Apr-2026 , 18-Jun-2026 , 21-Aug-2026 , 21-Oct-2026 , 23-Dec-2026 , 11-Feb-2027 , 23-Apr-2027 , 17-Jun-2027 , 23-Aug-2027 , 21-Oct-2027 , 23-Dec-2027</div> <div>SynopsisThis Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of heart, lung, blood and sleep (HLBS) diseases and disorders. This FOA is part</div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.				
112358	Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-193	12-May-2025	Not Specified
	Contact Name	Nancy DiFronzo, PhD			
	Contact Telephone	301-435-0065			
	Contact Email	difronzon@nhlbi.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-May-2025 , 11-Jun-2025 , 11-Sep-2025			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA PAR-22-192() that encourages applications for a collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial proposed in the collaborating CCC application. The application should also describe its approaches to collaborate with the CCC on implementation of the clinical trial community engagement and diversity plans. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.</p>			
112356	Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-25-028	11-May-2025	Not Specified
	Contact Name	Yves Rosenberg, MD, MPH			
	Contact Telephone	301-435-1292			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email rosenbey@nhlbi.nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-May-2025 , 11-Jun-2025 , 11-Sep-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. The application should also describe its approaches to increasing community engagement, reducing health inequities and disparities, and include a Plan for Increasing Diverse Perspectives (PDEP).</p>				
112357	Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-25-029	12-May-2025	Not Specified
	<p>Contact Name Nancy DiFronzo, PhD</p> <p>Contact Telephone 301-435-0065</p> <p>Contact Email difronzon@nhlbi.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-May-2025 , 11-Jun-2025 , 11-Sep-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-22-193). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The application should also describe its approaches to increasing community engagement and diversity as well as reducing health inequities and disparities. Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.</p>				
128901	RFA-HL-26-017 -- Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-26-017	21-Apr-2025	1,200,000 USD
	<p>Contact Name Mike Pieck, Ph.D.</p> <p>Contact Telephone 301-827-7986</p> <p>Contact Email nhlbi_catalyze@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Apr-2025 , 18-Jun-2025 , 21-Aug-2025 , 21-Oct-2025 , 22-Dec-2025 , 11-Feb-2026 , 21-Apr-2026 , 18-Jun-2026 , 21-Aug-2026 , 21-Oct-2026 , 23-Dec-2026 , 11-Feb-2027 , 23-Apr-2027 , 17-Jun-2027 , 23-Aug-2027 , 21-Oct-2027 , 23-Dec-2027</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and characterize potential therapeutic candidates (compound and lead series) to treat heart, lung, blood, and sleep (HLBS) diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic candidates.</p>				
128899	RFA-HL-26-016 -- Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-26-016	21-Apr-2025	700,000 USD
	<p>Contact Name Mike Pieck, Ph.D.</p> <p>Contact Telephone 301-827-7986</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email nhlbi_catalyze@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Apr-2025 , 18-Jun-2025 , 21-Aug-2025 , 21-Oct-2025 , 22-Dec-2025 , 11-Feb-2026 , 21-Apr-2026 , 18-Jun-2026 , 21-Aug-2026 , 21-Oct-2026 , 23-Dec-2026 , 11-Feb-2027 , 23-Apr-2027 , 17-Jun-2027 , 23-Aug-2027 , 21-Oct-2027 , 23-Dec-2027</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption. Well-suited applications must offer the potential to accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, prevention or epidemiology, while addressing issues associated with HLBS-related diseases and disorders. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation. Applications considered nonresponsive to the FOA will not be reviewed. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Product Definition or Preclinical FOAs.</p>				
127015	NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24-209	12-Jun-2025	Not Specified
	<p>Contact Name Kristen Z. Morgan, Ph.D.</p> <p>Contact Telephone 301-827-5163</p> <p>Contact Email direducation@nhlbi.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027</p> <p>Synopsis The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers currently in training in the NHLBI Division of Intramural Research with the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA, PAR-24-211 "NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22- Clinical Trial Required)".</p>				
127019	NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24-211	12-Jun-2025	Not Specified
	<p>Contact Name: Kristen Z. Morgan, Ph.D.</p> <p>Contact Telephone: 301-827-5163</p> <p>Contact Email: direducation@nhlbi.nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027</p> <p>Synopsis: The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers currently in training in the NHLBI Division of Intramural Research with the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Notice of Funding Opportunity Announcement (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not proposing to serve as lead investigator of an independent clinical trial must apply to the companion NOFO, PAR-24-209.</p>				
113729	RFA-HL-25-011 -- Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-25-011	07-May-2025	150,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Qing Lu, Ph.D.				
Contact Telephone	301-480-9158				
Contact Email	Qing.Lu@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 15-Oct-2025 , 07-Jan-2026				
Synopsis	<p>The purpose of this funding opportunity announcement (FOA) is to solicit current or recently completed NHLBI K01, K08, K23, and K25 recipients for small grant support to expand their current research objectives or to branch out to a new study that resulted from the research conducted under the K award. Active NHLBI K01, K08, K23, and K25 recipients may apply for R03 support after the notice of award (NoA) for their first type-5 K awards has been issued. Recently completed NHLBI K01, K08, K23, and K25 recipients are eligible to apply for the R03 if the earliest possible R03 start date falls within 2 years of their prior NHLBI K award Project Period end date. This FOA is intended to enhance the capability of NHLBI K01, K08, K23, and K25 recipients to conduct research as they complete their transition to fully independent investigator status. This R03 program is intended to support research projects that can be carried out and completed within a short period of time (no more than two years) with limited resources and that may generate preliminary data to support a subsequent R01-equivalent application. These studies include, but are not limited to, pilot or feasibility studies; proof of concept studies; secondary analysis of existing data; small, self-contained research projects; development of new research methodologies or technologies, or development of novel experimental models. A minimum of 40% protected overall research effort, not necessarily limited to the proposed R03 project, is required from applicants. For current and previous K23 recipients, research proposed in the R03 application may or may not include patient-oriented research.</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

122332 [NHLBI Clinical Trial Pilot Studies \(R34 Clinical Trial Optional\)](#)

National Heart, Lung, and Blood
Institute/NIH/DHHS

PAR-25-
032

07-May-2025

450,000
USD

Contact Name	Patrice Desvigne-Nickens, MD
Contact Telephone	301-435-0504
Contact Email	desvignp@mail.nih.gov
Sponsor Website	

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, or sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at Clinical Trial Development Continuum NHLBI, NIH), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application. Plan for Enhancing Diverse Perspectives The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: -Transdisciplinary research projects and collaborations among neuroscientists and researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. - Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). - Individual applications and partnerships that enhance geographic and regional heterogeneity. - Investigators and teams composed of researchers at different career stages. - Participation of individuals from diverse backgrounds, including groups historically underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. - Opportunities to enhance the research environment to benefit early- and mid-career investigators. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				
121563	Developing Novel Theory and Methods for Understanding the Genetic	National Human Genome Research	PAR-25-	05-Jun-2025	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Architecture of Complex Human Traits (R01 Clinical Trial Not Allowed)	Institute/NIH/DHHS	255		Specified
	<div>Contact NameAlexander Arguello, Ph.D.</div> <div>Contact Telephone240-731-3753</div> <div>Contact Emailalexander.arguello@nih.gov</div> <div>Sponsor Website</div> <div>Program URLLink to program URL</div> <div>Deadline Dates (ALL)05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</div> <div>Synopsis<p>The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should be interdisciplinary drawing from the natural and social sciences, account for interdependencies across scales of biological, social, and ecological organization, and make extensive use of theory, modeling, and validation with available large-scale datasets. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p></div>				
123681	Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-24-112	05-Jun-2025	Not Specified
	<div>Contact NameAri Joffe, Ph.D.</div> <div>Contact Telephone240-669-5084</div> <div>Contact Emailari.joffe@nih.gov</div> <div>Sponsor Website</div> <div>Program URLLink to program URL</div> <div>Deadline Dates (ALL)05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</div> <div>Synopsis<p>The purpose of this Notice of Funding Opportunity (NOFO) is to support research that improves understanding of basic mechanisms and biomarkers of trained immunity (i.e., innate immune memory), plus the functional implications of trained immunity, related to 1) immune system development and function, 2) immunity to vaccines or natural infections, or 3) allergic diseases, autoimmunity, or rejection of organ/tissue/cell transplantation.</p></div>				
113281	NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22-225	07-May-2025	Not Specified
	<div>Contact NameMr. Martin Gutierrez, B.S.</div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
129890	Contact Telephone	240-292-4844			
	Contact Email	mgutierrez@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 11-Jun-2025 , 07-Sep-2025			
	Synopsis	This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs should address scientific areas relevant to the NIAID mission including: biology and pathogenesis of infectious microbes, including HIV; host-microbe interactions; mechanisms regulating immune system development and function across the lifespan, and in response to infectious pathogens; immune dysfunction resulting in allergy, asthma, autoimmunity, immunodeficiency, or transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious and immune-mediated diseases. Each P01 application submitted to this FOA must include at least two related, synergistic research projects that share a common central theme, focus, and/or overall objective; and an administrative core. A P01 may include scientific cores, if needed for the proposed research.			
129890	RFA-AI-24-079 -- Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-24-079	14-May-2025 [Optional][LOI/Pre-App]	4,500,000 USD
	Contact Name	Gang Dong, M.D., Ph.D.			
	Contact Telephone	240-627-3508			
	Contact Email	gdong@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	14-May-2025 [Optional][LOI/Pre-App], 13-Jun-2025			
	Synopsis	The purpose of this notice of funding opportunity (NOFO) is to invite applications from single institutions or consortia of institutions to participate in the Asthma and Allergic Diseases Cooperative Research Centers (AADCRC) program. The program will support centers that integrate clinical and translational research to conduct studies on the mechanisms underlying the onset and progression of diseases of interest, including asthma, rhinitis (allergic and non-allergic), chronic rhinosinusitis, atopic dermatitis, food allergy, and drug allergy. The overarching goal of the program is to improve the understanding of the pathogenesis of these conditions and to provide a rational foundation for new, effective treatments and prevention strategies.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
115065	NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23-070	07-May-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone 301-594-5945</div> <div>Contact Email AITrainingHelpDesk@niaid.nih.gov</div> <div>Sponsor Website</div> <div>Program URL Link to program URL</div> <div>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026</div> <div>Synopsis <p>The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-23-071)</p> </div>				
115066	NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23-071	07-May-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone 301-594-5945</div> <div>Contact Email AITrainingHelpDesk@niaid.nih.gov</div> <div>Sponsor Website</div> <div>Program URL Link to program URL</div> <div>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026</div> <div>Synopsis <p>The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research</p> </div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-23-070).</p>				
129070	NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-25-251	07-May-2025	Not Specified
	<p>Contact Name Jyothi Arikath, PhD</p> <p>Contact Telephone 301-594-5945</p> <p>Contact Email AITrainingHelpDesk@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027 , 12-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of the NIAID Career Transition Award program is to assist postdoctoral fellows' transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.</p>				
129757	RFA-AI-25-006 -- Molecular Mechanisms of Combination Adjuvants (MMCA) (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-25-006	11-May-2025 [Optional][LOI/Pre-App]	2,499,995 USD
	<p>Contact Name Ari Joffe, Ph.D.</p> <p>Contact Telephone 240-669-5084</p> <p>Contact Email ari.joffe@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 11-May-2025 [Optional][LOI/Pre-App], 10-Jun-2025</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support research studies of two or more vaccine adjuvants (combination adjuvants) in order to understand the mechanisms by which they work in concert. All adjuvants considered must have previously demonstrated immune modulating activity. The long-term goal of this research program is to improve the rational design of vaccines by predicting the immune profile elicited by combination adjuvants.</p>				
113565	Notice of Special Interest (NOSI): argeting the Pathogen within the Arthropod Vector	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-074	07-May-2025	Not Specified
	<p>Contact Name Adriana Costero-Saint Denis, Ph.D.</p> <p>Contact Telephone 240-292-4184</p> <p>Contact Email acostero@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis This Notice of Special Interest (NOSI) invites applications to stimulate multidisciplinary research to better understand pathogen/vector interactions to identify approaches to prevent pathogen transmission to the vertebrate host.</p>				
114374	Notice of Special Interest (NOSI): Complement in Fundamental Immunology	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-23-012	07-May-2025	Not Specified
	<p>Contact Name Ari Joffe, PhD</p> <p>Contact Telephone 240-669-5084</p> <p>Contact Email ari.joffe@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The main objective of this program is to support studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses involved in pathogenic infections, vaccination, post-infection sequelae, autoimmunity, allergy, or transplantation. The results of such studies will inform the development of vaccines or therapeutics that target complement components.</p>				
109336	Notice of Special Interest (NOSI): Optimizing Vascularized Composite	National Institute of Allergy and	NOT-AI-	07-May-2025	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Allograft Survival	Infectious Diseases/NIH/DHHS	22-023		Specified
	<div>Contact Name Patricia Kehn, Ph.D.</div> <div>Contact Telephone 240-627-3547</div> <div>Contact Email pkehn@NIAID.nih.gov</div> <div>Sponsor Website</div> <div>Program URL Link to program URL</div> <div>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026</div> <div>Synopsis The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting preclinical studies utilizing animal models or human tissue specimens that focus on 1) optimizing treatment and graft monitoring to reduce incidence of acute rejection and maximize graft survival after vascularized composite allotransplantation (VCA) and 2) minimizing immunosuppression required for long-term VCA acceptance.</div>				
116360	Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Coccidioidomycosis (Valley fever) Vaccine	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-23-031	05-Apr-2025	Not Specified
	<div>Contact Name Dona C. Love, Ph.D.</div> <div>Contact Telephone 301-761-7788</div> <div>Contact Email Dona.Love@nih.gov</div> <div>Sponsor Website</div> <div>Program URL Link to program URL</div> <div>Deadline Dates (ALL) 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026</div> <div>Synopsis The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID’s interest in supporting research in the areas outlined in the NIAID Strategic Plan For Research To Develop A Valley Fever Vaccine. The proposed research should have clear relevance to the strategic priorities defined in the strategic plan, which encompasses three major research areas: 1) address gaps in Coccidioides basic research to support the development of a vaccine; 2) develop tools and resources to support vaccine development; 3) develop and advance vaccines to prevent coccidioidomycosis.</div>				
123682	Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-24-111	16-Jun-2025	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Ari Joffe, Ph.D.</p> <p>Contact Telephone 240-669-5084</p> <p>Contact Email ari.joffe@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to support research that improves understanding of basic mechanisms and biomarkers of trained immunity (i.e., innate immune memory), plus the functional implications of trained immunity, related to 1) immune system development and function, 2) immunity to vaccines or natural infections, or 3) allergic diseases, autoimmunity, or rejection of organ/tissue/cell transplantation.</p>				
113395	NIAID Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22-241	07-May-2025	Not Specified
	<p>Contact Name Diane Adger-Johnson, MPH</p> <p>Contact Telephone </p> <p>Contact Email AITrainingHelpDesk@niaid.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 05-Jul-2025 , 07-Sep-2025</p> <p>Synopsis The purpose of this funding opportunity announcement is to encourage applications for research projects within the NIAID mission. This FOA seeks to support either (a) a New Investigator (NI), an individual who has not previously competed successfully for substantial, independent funding from NIH, or (b) are an 'At-Risk' investigator, an individual who had prior support as a PD/PI on a substantial independent research award and unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year, from diverse backgrounds, including those from groups underrepresented in the health-related sciences.</p>				
114290	Notice of Special Interest (NOSI): Promoting Research Opportunities on HIV/AIDS in NIAMS	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-23-004	09-Apr-2025	Not Specified
	<p>Contact Name Heiyoung Park, Ph.D.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-594-5032</p> <p>Contact Email parkh1@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 06-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Dec-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 16-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 16-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of this announcement is to inform potential applicants to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of an area of special interest in HIV/AIDS-associated comorbidities that are within the NIAMS mission.</p>				
117716	Notice of Special Interest (NOSI): Supporting Exploratory/Developmental Research Focused on NIAMS Core Mission Areas	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-23-006	09-Apr-2025	Not Specified
	<p>Contact Name Jana Eisenstein</p> <p>Contact Telephone 301-594-5032</p> <p>Contact Email jana.eisenstein@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 06-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Dec-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Jan-2027</p> <p>Synopsis The purpose of this announcement is to notify the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is interested in receiving Exploratory/Developmental grant applications focused on NIAMS core mission areas. Awards will provide support for innovative projects that introduce novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential for significant impact, and to substantially advance research within the NIAMS mission. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs of high value to the NIAMS research community.</p>				
128167	Limited Competition: CCRP Initiative: Promoting a Basic Understanding	National Institute of Arthritis and	PA-25-	16-Jun-2025	450,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)	Musculoskeletal and Skin Diseases/NIH/DHHS	093		USD
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Peter J Koch, PhD</div> <div></div> <div>Peter.Koch@nih.gov</div> <div></div> <div>Link to program URL</div> <div>16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027</div> <div>This Notice of Funding Opportunity (NOFO) intends to support fundamental research that will contribute to basic understanding of skin injuries caused by chemicals that have been identified as public health threats, with an emphasis on investigating the commonalities of such injuries and identifying potential shared signaling pathways and therapeutic targets for medical countermeasure development.</div> </div>				
117677	Notice of Special Interest (NOSI): Synthetic Biology for Biomedical Applications	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	NOT-EB-23-002	05-May-2025	Not Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Hye-Sook Kim, Ph.D.</div> <div>301-827-6910</div> <div>hye-sook.kim@nih.gov</div> <div></div> <div>Link to program URL</div> <div>05-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 16-Oct-2025</div> <div>The purpose of this Notice is to announce that the National Center for Complementary and Integrative Health (NCCIH), the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), the National Institute on Aging (NIA), the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institute of General Medical Sciences (NIGMS) are encouraging new applications to advance research activities relevant to synthetic biology.</div> </div>				
115197	In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability	National Institute of Child Health and Human Development/NIH/DHHS	PAR-25-140	06-May-2025 [Optional][LOI/Pre-	2,499,995 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
(R01 Clinical Trial Not Allowed)					
	<p>Contact Name Mahua Mukhopadhyay, PhD</p> <p>Contact Telephone 301-435-6886</p> <p>Contact Email mukhopam@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation. The current (July 19, 2022) IMPC data release includes phenotypic data for 8260 knockout genes. Overall, the IMPC hopes to generate a null mutant and undertake broad-based phenotyping for every gene in the mouse genome. About 30% of these strains are expected to be either embryonic or perinatal lethal, or subviable. However, a large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in-depth phenotyping and research.</p>				
128527	Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-25-185	06-May-2025 [Optional][LOI/Pre-App]	2,499,995 USD
	<p>Contact Name Reiko Toyama, Ph.D.</p> <p>Contact Telephone 301-435-2723</p> <p>Contact Email ToyamaR@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including structural congenital anomalies (SCAs), intellectual developmental disabilities (IDDs) and inborn errors of metabolism (IEMs). Large quantities of genomic data collected from pediatric congenital anomalies cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening, functional validation and characterization of congenital anomaly-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest</p>				
112833	Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-25-146	05-Jun-2025	2,499,995 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Reiko Toyama, Ph.D.</p> <p>301-435-2723</p> <p>toyamar@nih.gov</p> <p></p> <p>Link to program URL</p> <p>05-Jun-2025</p> <p>The purpose of this funding opportunity announcement (FOA) is to support innovative research that will inform our understanding of the mechanisms underlying the formation of structural birth defects using animal models in conjunction with human translational/clinical approaches. Applicants are encouraged to take advantage of advances in genetics, 'omics methods (genomics, proteomics, metabolomics, etc.), and synthetic biology, biochemical and other approaches to developmental biology research to identify specific genetic, epigenetic, environmental, or gene/environment interactions associated with the formation of, susceptibility to, and variability of structural birth defects in human populations.</p>			
129048	Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-25-265	05-Jun-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p>	<p>Kathleen Huntzicker, Ph.D.</p> <p>301-451-2770</p> <p>kathleen.huntzicker@nih.gov</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027</p> <p>Synopsis This NOFO encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for conditions for which newborn screening has already been implemented, as well as for potentially fatal or disabling genetic conditions that could benefit in the near future from the early detection made possible by newborn screening. This research is especially critical given that accurate screening tests and demonstrable benefits of early intervention are often prerequisites for new conditions to be added to newborn screening panels.</p>				
113756	NCMRR Early Career Research Award (R03 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-23-029	16-Jun-2025	200,000 USD
	<p>Contact Name Maria Nurminskaya, PhD</p> <p>Contact Telephone 240-591-9986</p> <p>Contact Email Maria.nurminskaya@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026</p> <p>Synopsis The National Center for Medical Rehabilitation Research (NCMRR) Early Career Research (ECR) Award (R03) is intended to support both basic and clinical research from rehabilitation scientists who are establishing independent research careers. The research must be focused on one or more of the areas within the mission of NCMRR: Applicants are encouraged to refer to the NIH Research Plan on Rehabilitation for strategic priorities (https://www.nichd.nih.gov/newsroom/news/110121-NIH-rehab-plan). The NCMRR ECR Award R03 grant mechanism supports various types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new technology. Irrespective of the type of project, the intent of the NCMRR ECR Award R03 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.</p>				
128791	NICHD Small Research Grant Program (R03 Clinical Trial Required)	National Institute of Child Health and Human Development/NIH/DHHS	PA-25-125	07-May-2025	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email NICHDReferral@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The NICHD Small Research Grant Program (R03 Clinical Trial Required) supports clinical trials that fall within the NICHD mission. The R03 activity code supports small research projects that can be carried out in a short period of time with limited resources. The R03 program may be used for different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.</p>				
129049	Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-25-266	16-Jun-2025	275,000 USD
	<p>Contact Name Kathleen Huntzicker, Ph.D.</p> <p>Contact Telephone 301-451-2770</p> <p>Contact Email kathleen.huntzicker@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027</p> <p>Synopsis This NOFO encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for conditions for which newborn screening has already been implemented, as well as for potentially fatal or disabling genetic conditions that could benefit in the near future from the early detection made possible by newborn screening. This research is especially critical given that accurate screening tests and demonstrable benefits of early intervention are often prerequisites for new conditions to be added to newborn screening panels.</p>				
128792	NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required)	National Institute of Child Health and Human Development/NIH/DHHS	PA-25-126	07-May-2025	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email NICHDReferral@mail.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The NICHD Small Research Grant Program (Clinical Trial Required) supports clinical trials that fall within the NICHD mission. This funding opportunity announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ FOA.</p>				
126762	Advancement and Innovation in Measurement of Language Development and Predictors (R01 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-25-112	05-Jun-2025	Not Specified
	<p>Contact Name Virginia Salo</p> <p>Contact Telephone 301-402-3682</p> <p>Contact Email virginia.salo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025 , 05-Jul-2025 , 05-Oct-2025 , 05-Nov-2025 , 05-Feb-2026 , 05-Mar-2026 , 05-Jun-2026 , 05-Jul-2026 , 05-Oct-2026 , 05-Nov-2026 , 05-Feb-2027 , 05-Mar-2027 , 05-Jun-2027 , 05-Jul-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to encourage community-engaged research that broadens the conceptualization of qualities of the environment that can support language development in children and that focuses on the development of novel measures of children’s language development. The overall goal is to build the number of strengths-focused, culturally and linguistically responsive, and generalizable tools to further our understanding of children’s language development and/or impairment, and predictors thereof. This NOFO requires a Community Engagement (CE) Plan, which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a CE Plan will be considered incomplete and will be withdrawn. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
114857	Small Research Grants for Analyses of Gabriella Miller Kids First	National Institute of Child Health and	PAR-25-	16-Jun-2025	200,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Pediatric Research Data (R03 Clinical Trial Not Allowed)	Human Development/NIH/DHHS	109		USD
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Marcia Fournier, PhD</div> <div>240-328-8308</div> <div>marcia.fournier@nih.gov</div> <div></div> <div>Link to program URL</div> <div>16-Jun-2025 , 16-Oct-2025</div> <div> <p>The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. Kids First has established and continues to develop a Data Resource including a collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed.</p> </div> </div>				
126985	Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-25-092	16-Jun-2025	100,000 USD
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Susan M. Jekielek, PhD</div> <div></div> <div>susan.jekielek@nih.gov</div> <div></div> <div>Link to program URL</div> <div>16-Jun-2025 , 16-Oct-2025</div> <div> <p>The purpose of this funding opportunity announcement (FOA) is to support the archiving and documentation of existing data sets within the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive original data collected with NICHD funding.</p> </div> </div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
126760	Advancement and Innovation in Measurement of Language Development and Predictors (R21 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-25-113	16-Jun-2025	275,000 USD
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Virginia Salo</div> <div>301-402-3682</div> <div>virginia.salo@nih.gov</div> <div></div> <div>Link to program URL</div> <div>16-Jun-2025 , 16-Jul-2025 , 16-Oct-2025 , 16-Nov-2025 , 16-Feb-2026 , 16-Mar-2026 , 16-Jun-2026 , 16-Jul-2026 , 16-Oct-2026 , 16-Nov-2026 , 16-Feb-2027 , 16-Mar-2027 , 16-Jun-2027 , 16-Jul-2027</div> <div>The purpose of this notice of funding opportunity (NOFO) is to encourage community-engaged research that broadens the conceptualization of qualities of the environment that can support language development in children and that focuses on the development of novel measures of children's language development. The overall goal is to build the number of strengths-focused, culturally and linguistically responsive, and generalizable tools to further our understanding of children's language development and/or impairment, and predictors thereof. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</div>			
117230	NIDCR Research Grants for Analyses of Existing Genomics Data (R01) (Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-25-164	07-May-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Noffisat Oki</div> <div>301-402-6778</div> <div>noffisat.oki@nih.gov</div> <div></div> <div>Link to program URL</div> <div>07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</div> <div>The purpose of this NOFO is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) biology, and diseases and conditions, through analysis of existing and publicly available genomic data, with or without other types of complementary data, using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the proposed project(s), including methods for data and metadata mining, data integration, and Artificial Intelligence (AI)/Machine Learning (ML)/Deep Learning (DL) methods. In addition to analysis of existing data, experimental or in</div>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>silico work is required to validate the results of the proposed analysis, or to validate a newly developed analytic method. Projects aimed at understanding oral health disparities to inform strategies for improving health for all individuals are a priority. Projects focused on investigating and/or characterizing human biological pathways to inform identification of intervention targets or defining the pathogenicity of known genetic variants are encouraged.</p>				
117461	NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-23-162	07-May-2025	Not Specified
	<p>Contact Name Lorena Baccaglini, DDS, MS, PhD</p> <p>Contact Telephone 301-435-7908</p> <p>Contact Email lorena.baccaglini@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis This NOFO will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of data/biospecimens.</p>				
102596	NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-25-057	07-May-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Dena Fischer, DDS, MSD, MS</p> <p>Contact Telephone 301-594-4876</p> <p>Contact Email dena.fischer@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 [Optional][LOI/Pre-App], 08-May-2025 , 06-Jun-2025 , 04-Sep-2025 , 07-Sep-2025 [Optional][LOI/Pre-App], 07-Oct-2025 , 06-Jan-2026 , 10-Jan-2026 [Optional][LOI/Pre-App], 09-Feb-2026 , 08-May-2026 , 09-May-2026 [Optional][LOI/Pre-App], 08-Jun-2026 , 08-Sep-2026 [Optional][LOI/Pre-App], 09-Sep-2026 , 08-Oct-2026 , 08-Jan-2027 , 09-Jan-2027 [Optional][LOI/Pre-App], 08-Feb-2027 , 06-May-2027 , 08-May-2027 [Optional][LOI/Pre-App], 07-Jun-2027 , 07-Sep-2027 [Optional][LOI/Pre-App], 08-Sep-2027 , 07-Oct-2027 , 06-Jan-2028</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>This Notice of Funding Opportunity (NOFO) will support UG3/UH3 phased, cooperative agreement research applications to plan and implement clinical trials within the mission of the National Institute of Dental and Craniofacial Research (NIDCR). Studies appropriate for this NOFO are those testing a drug, biologic, device, or procedure to improve dental, oral, or craniofacial diseases or conditions, including trials for any phase of testing for a Food and Drug Administration (FDA)-regulated product. Awards made under this NOFO will initially support a one-year milestone-driven planning phase (UG3), with possible transition to a clinical trial implementation phase (UH3) of up to five years. Progression to the UH3 phase is based on an administrative review and is dependent on success in meeting UG3 milestones, NIDCR program priorities, and availability of funds. The UG3/UH3 application must be submitted as a single application with the final design of the UH3 clinical trial including detail about the study population, intervention(s), and outcome(s) described in the application, following the instructions described in this NOFO. The UG3 planning phase permits both scientific and operational planning activities, though the planning phase cannot be used to test for intervention safety or efficacy or assess the study's primary outcome. The UH3 phase of the award will support the conduct of one investigator-initiated clinical trial. Applications designed to test behavior change interventions or those used as tools to understand mechanisms of behavior change will not be supported by this NOFO.</p>			
129024	NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-25-188	08-May-2025	Not Specified
	Contact Name	Jill Mattia, Ph.D.			
	Contact Telephone	301-451-7770			
	Contact Email	jill.mattia@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-May-2025 , 06-Jun-2025 , 04-Sep-2025 , 07-Oct-2025 , 06-Jan-2026 , 09-Feb-2026 , 08-May-2026 , 08-Jun-2026 , 09-Sep-2026 , 08-Oct-2026 , 08-Jan-2027 , 08-Feb-2027 , 06-May-2027 , 08-Jun-2027 , 08-Sep-2027 , 08-Oct-2027 , 08-Jan-2028			
	Synopsis	<p>The purpose of this Notice of Funding Opportunity (NOFO) is to provide support for the planning and implementation of well-designed, rigorously conducted, behavioral/biopsychosocial intervention studies relevant to dental, oral, and craniofacial health as well as associated medical and mental health status or comorbidities. A broad range of intervention research projects that meet the NIH Definition of a Clinical Trial are appropriate for this opportunity. Awards made under this NOFO will initially support a milestone-driven planning phase (UG3) for 1 year, with possible transition to a clinical trial implementation phase (UH3) of up to five years. The UG3/UH3 application must be submitted as a single application. Applications that employ traditional methods as well as novel/advanced features (e.g., mobile health, artificial</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	intelligence, telehealth, responsive health system records, multiple assignment randomized trial designs (SMART) or sequential randomization designs), etc., are encouraged. This NOFO will not support the testing of drugs, devices, or biologics regulated by the FDA; the corresponding NOFO for clinical trials in these areas is PAR-25-057.				
128678	NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-25-027	07-May-2025	Not Specified
	Contact Name	Leslie A. Frieden, PhD			
	Contact Telephone	301-496-4263			
	Contact Email	leslie.frieden@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027 , 12-Oct-2027 , 07-Jan-2028			
	Synopsis	The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to facilitate transition of highly qualified dentist scientists from NIH Intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. The award will provide support for two years of mentored postdoctoral research training in the NIH Intramural Research Program, and three years of independent research funding at the extramural institution. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (FON).			
110754	Notice of Special Interest (NOSI): Achieving Tissue Robustness Through Harnessing Immune System Plasticity	National Institute of Dental and Craniofacial Research/NIH/DHHS	NOT-DE-22-005	07-May-2025	Not Specified
	Contact Name	Preethi Chander, PhD			
	Contact Telephone	301-827-4620			
	Contact Email	preethi.chander@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	NIDCR announces its interest in encouraging state-of-the-art, systematic research approaches to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations, and to examine immune mechanisms of protection against recurrence of chronic inflammation in response to infectious and autoimmune diseases of dental, oral, and craniofacial (DOC) tissues. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward protection against episodic recurrence and preventative disease management in a patient-specific manner across the lifespan.			
127032	NIDCR Mentored Career Development Award to Promote Broad Participation in Research (K01 Independent Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-25-022	07-May-2025	Not Specified
	Contact Name	Shoba Thirumangalathu, Ph.D.			
	Contact Telephone	301-594-0652			
	Contact Email	nidcrtraining@nidcr.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027 , 12-Oct-2027 , 07-Jan-2028			
	Synopsis	The purpose of the NIDCR Mentored Career Development Award to Promote Broad Participation in Research is to strengthen the dental, oral, and craniofacial research workforce by expanding the pool of well-trained postdoctoral fellows and early career faculty engaged in these areas of research This Notice of Funding Opportunity (NOFO) provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This NOFO is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.			
117231	NIDCR Small Research Grants for Analyses of Existing Genomics Data (R03 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-25-166	07-May-2025	200,000 USD
	Contact Name	Noffisat Oki			
	Contact Telephone	301-402-6778			
	Contact Email	noffisat.oki@nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026</p> <p>Synopsis The purpose of this NOFO is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) biology, and diseases and conditions, through analysis of existing and publicly available genomic data, with or without other types of complementary data, using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the proposed project(s), including methods for data and metadata mining, data integration, and Artificial Intelligence (AI)/Machine Learning (ML)/Deep Learning (DL) methods. Projects focused on investigating and/or characterizing human biological pathways to inform identification of intervention targets or defining the pathogenicity of known genetic variants are encouraged.</p>				
116699	Notice of Special Interest (NOSI): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (COVID-19)	National Institute of Dental and Craniofacial Research/NIH/DHHS	NOT-DE-23-004	07-May-2025	Not Specified
	<p>Contact Name Amanda Melillo, Ph.D.</p> <p>Contact Telephone 301-529-7217</p> <p>Contact Email amanda.melillo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026</p> <p>Synopsis The National Institute of Dental and Craniofacial Research (NIDCR) is reissuing this Notice of Special Interest (NOSI) to encourage research studies focused on the physiological involvement of oral cavity and oral manifestations related to SARS-CoV-2 and/or Coronavirus Disease 2019 (COVID-19).</p>				
128813	NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-25-105	07-May-2025	200,000 USD
	<p>Contact Name Preethi Chander, PhD</p> <p>Contact Telephone 301-827-4620</p> <p>Contact Email preethi.chander@nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>Synopsis This NIDCR Small Grant Program for New Investigators supports basic and clinical research, behavioral, and population science conducted by scientists who are establishing an independent research career in dental, oral and craniofacial research. This R03 program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator-initiated Research Project Grant (R01) or equivalent application.</p>				
125109	RFA-DK-25-009 -- Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-25-009	13-May-2025 [Optional][LOI/Pre-App]	650,000 USD
	<p>Contact Name Daniel Gossett, Ph.D.</p> <p>Contact Telephone 301-594-7723</p> <p>Contact Email daniel.gossett@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-May-2025 [Optional][LOI/Pre-App], 13-Jun-2025</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences This NOFO encourages applications from institutions that propose to establish research experiences in kidney technology development. Successful programs should include a collaborative capstone research or design project(s), innovative and/or ground-breaking technology development, multidisciplinary/interdisciplinary teamwork, education in entrepreneurship, product development and navigating regulatory pathways, and clinical immersion. Applications must include plans to recruit undergraduate students as participants and to engage students from engineering and other quantitative scientific and technical backgrounds, but applicants may also propose the inclusion of medical students, graduate students and/or dual-degree students (e.g., M.D./Ph.D.; Pharm.D./Ph.D.) prior to their qualifying exams and selection of Ph.D. mentor.</p>				
125933	RFA-DK-25-007 -- Nutrition Obesity Research Centers (P30 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-25-007	10-Jun-2025	3,750,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Mary E. Evans, Ph.D.</p> <p>Contact Telephone 301-594-4578</p> <p>Contact Email evansmary@niddk.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Jun-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications from institutions/organizations that propose to establish core centers that are part of an integrated and existing program of nutrition and/or obesity research. The Nutrition Obesity Research Centers (NORC) program is designed to support and enhance the national research effort in nutrition and obesity. NORCs support three primary research-related activities: Research Core services, a Pilot and Feasibility (P and F) program, and an Enrichment program. All activities pursued by Nutrition Obesity Research Centers are designed to enhance the efficiency, productivity, effectiveness and multidisciplinary nature of research in nutrition and obesity.</p>				
129207	RFA-DK-26-001 -- NIDDK Centers for Diabetes Translation Research (P30 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-26-001	12-May-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Shavon Artis Dickerson, DrPH, MPH</p> <p>Contact Telephone 301-435-3055</p> <p>Contact Email shavon.artisdickerson@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-May-2025 [Optional][LOI/Pre-App], 10-Jun-2025</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites applications that propose a Center for Diabetes Translation Research (CDTR) to support research across the translational science spectrum (i.e., bedside to clinical practice and community settings, dissemination and implementation research). The purpose of this Centers program is to accelerate innovation of diabetes translation to maximize positive impacts of research on population health through activities and core services that offer specialized expertise, tools, education, and support. An emphasis on novel methods and research to address health equity and reduce diabetes-related health disparities is encouraged. Novel research cores designed to improve other aspects of person-centered, community, and population health are also encouraged with justification of how such findings or strategies may be adapted to meaningfully inform on disparity-reduction approaches. A scientific base reflecting academic</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	institutions and diverse organizational collaborators (e.g., healthcare systems, community organizations, health departments, social services, etc.) is expected to foster a Center framework necessary for improving population health. CDRs are based on the core concept whereby shared resources aimed at fostering productivity, synergy, and novel research ideas among the funded investigators are supported in a cost-effective manner. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).				
130036	RFA-DK-26-009 -- New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-26-009	26-May-2025 [Optional][LOI/Pre-App]	200,000 USD
	Contact Name	Olivier Blondel, Ph.D. (for HIRN-related inquiries)			
	Contact Telephone	301-451-7344			
	Contact Email	blondelo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	26-May-2025 [Optional][LOI/Pre-App], 26-Jun-2025 , 06-Feb-2026 [Optional][LOI/Pre-App], 06-Mar-2026			
	Synopsis	<p>The New Investigator Gateway Award in T1D Research is designed to support a robust pipeline of innovative projects and talented new investigators in T1D research. In addition to providing support for preliminary research, the Gateway program provides an opportunity for new Program Directors/Principal Investigators (PD/PIs) to pursue their studies within the intellectual environment of a select number of large, ongoing collaborative research programs. Embedding awardees within an established scientific framework in each of these consortia will provide unique opportunities for New and Early Stage Investigators to increase their understanding of key questions in the field, to network, and to establish unique and potentially long-lasting collaborations that will propel their careers forward. Bringing New and Early Stage Investigators into existing collaborative research networks will also benefit the networks by providing new ideas and perspectives. This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.</p>			
116589	Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-25-102	07-May-2025	600,000 USD
	Contact Name	Aynur Unalp-Arida, M.D., M.Sc., Ph.D.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
128623	Contact Telephone	301-594-8879			
	Contact Email	aynur.unalp-arida@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026			
	Synopsis	This Funding Opportunity Announcement encourages the submission of pilot and feasibility clinical trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term proof-of-concept clinical trials in humans to acquire preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications for clinical trials submitted under this FOA should have clearly described aims and objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trials to improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. Preliminary data regarding intervention efficacy are not required.			
128623	Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-25-205	05-Jun-2025	Not Specified
	Contact Name	Shilpa Hattangadi, M.D.			
	Contact Telephone	301-594-7726			
	Contact Email	shilpam.hattangadi@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027			
	Synopsis	The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the leading edge of the field will change over time and will be updated regularly through the NIH Guide to Grants and Contracts and hyperlinked to this FOA. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
123312	NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-25-147	05-Jun-2025	Not Specified
	<p>Contact Name Tracy Rankin, Ph.D., M.P.H.</p> <p>Contact Telephone 301-594-4748</p> <p>Contact Email rankint@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis This NOFO invites applications for investigator-initiated, high-risk multi-center clinical trials involving more than one clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this NOFO. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-25-090). Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
123309	NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-25-089	05-Jun-2025	Not Specified
	<p>Contact Name Tracy Rankin, Ph.D., M.P.H.</p> <p>Contact Telephone 301-594-4748</p> <p>Contact Email rankint@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis This NOFO invites applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this NOFO. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-25-090). Consultation</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
with NIDDK Scientific/Research Staff strongly encouraged prior to the submission of either a U34 or U01 application. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).					
129390	RFA-DK-26-006 -- NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-26-006	18-Jun-2025 [Optional][LOI/Pre-App]	2,500,000 USD
Contact Name Carol Haft, Ph.D. Contact Telephone 301-594-7689 Contact Email haftc@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 18-Jun-2025 [Optional][LOI/Pre-App], 18-Jul-2025 Synopsis The NIDDK Catalyst Award is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and transformational studies in topic areas of interest to NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases, and to NIDDK's Division of Digestive Diseases and Nutrition. Applications should be focused on major scientific challenges and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of these two divisions within NIDDK. To be considered responsive to this initiative, the proposed research should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigator's research program or elsewhere.					
123308	NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-25-090	10-Jun-2025	450,000 USD
Contact Name Tracy Rankin, Ph.D., M.P.H. Contact Telephone 301-594-4748 Contact Email rankint@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 10-Jun-2025 , 11-Feb-2026 , 08-Oct-2026 , 10-Jun-2027 Synopsis NIDDK supports investigator-initiated, high-risk multi-center (more than one center) clinical studies through a two-part					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>process that may include an implementation planning cooperative agreement (U34). The U34 is designed to: 1) Permit early peer review of the rationale for the proposed clinical study; 2) Permit assessment of the design and protocol of the proposed study; 3) Provide support for the development of documents needed for the conduct of the study, including a manual of operations; and 4) Support the development of other essential elements required for the conduct of the clinical study. The proposed clinical study should be hypothesis-driven and focus on a disease in the mission of NIDDK. Consultation with NIDDK scientific staff is strongly encouraged prior to the submission of the U34 application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the FOA instructions carefully and view the available PEDP guidance material.</p>				
129262	High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-25-277	03-Jun-2025	Not Specified
	Contact Name	Norann Zaghloul, Ph.D.			
	Contact Telephone	301-435-6677			
	Contact Email	norann.zaghloul@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-Jun-2025 , 15-Oct-2025 , 03-Jun-2026 , 15-Oct-2026 , 03-Jun-2027 , 15-Oct-2027			
	Synopsis	<p>The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK. The interdisciplinary approach encouraged by this NOFO is envisioned to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This NOFO seeks novel approaches in areas that address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment, and prevention of diseases, including the promotion of health equity, within the mission of the NIDDK.</p>			
129839	RFA-DK-26-007 -- Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-26-007	26-May-2025 [Optional][LOI/Pre-App]	3,600,000 USD
	Contact Name	Beena Akolkar, Ph.D.			
	Contact Telephone	240-593-1733			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email beena.akolkar@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-May-2025 [Optional][LOI/Pre-App], 26-Jun-2025 , 06-Feb-2026 [Optional][LOI/Pre-App], 06-Mar-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites applications for studies of type 1 diabetes etiology and pathogenesis using data and samples from clinical trials and studies. This opportunity is intended to fund investigative teams collaborating to answer important questions about disease mechanisms leading to improved delay and durable prevention of type 1 diabetes. This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
129704	Small Grants for New Investigators to Broaden Participation in Health-Related Research (R21 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-25-097	07-May-2025	375,000 USD
	<p>Contact Name Katrina J. Serrano, Ph.D.</p> <p>Contact Telephone 301-480-7855</p> <p>Contact Email katrina.serrano@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical, clinical, behavioral and social sciences research, to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Human Genome Research Institute (NHGRI) or the National Institute of Biomedical Imaging and Bioengineering (NIBIB). New investigators at the time of award under this FOA will have had less than \$125,000 direct costs of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate transition to research independence. The R21 grant mechanism supports different types of projects including pilot and feasibility studies;</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.				
112160	NIDDK Central Repository Non-renewable Sample Access (X01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-22-171	25-Jun-2025	Not Specified
	Contact Name	Rebecca M. Rodriguez, Ph.D			
	Contact Telephone	301-451-0323			
	Contact Email	rebecca.rodriguez2@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-Jun-2025			
	Synopsis	The NIDDK Central Repository houses valuable biological samples and data from numerous major clinical studies. This initiative allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at the Repository's website. Applicants must include a volume and impact assessment report from the NIDDK Central Repository with the X01 Application to document sample availability.			
129740	Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-25-312	10-Apr-2025	Not Specified
	Contact Name	Mary Evans, Ph.D.			
	Contact Telephone	301-594-4578			
	Contact Email	evansmary@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	10-Apr-2025 , 09-May-2025 , 10-Jun-2025 , 09-Jul-2025 , 07-Aug-2025 , 09-Sep-2025 , 09-Oct-2025 , 07-Nov-2025 , 09-Dec-2025 , 09-Jan-2026 , 10-Feb-2026 , 10-Mar-2026 , 10-Apr-2026 , 08-May-2026 , 09-Jun-2026 , 09-Jul-2026 , 11-Aug-2026 , 09-Sep-2026 , 09-Oct-2026 , 10-Nov-2026 , 09-Dec-2026 , 08-Jan-2027 , 09-Feb-2027 , 09-Mar-2027 , 09-Apr-2027 , 11-May-2027 , 09-Jun-2027 , 09-Jul-2027 , 10-Aug-2027 , 09-Sep-2027 , 08-Oct-2027 , 09-Nov-2027 , 09-Dec-2027 , 11-Jan-2028			
	Synopsis	This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, sedentary behavior, and/or sleep) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity-related policy or program offers an uncommon and scientifically-compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date; however, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
129738	Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-25-091	07-May-2025	150,000 USD
	Contact Name	Lisa M. Spain, Ph.D.			
	Contact Telephone	301-451-9871			
	Contact Email	SpainL@niddk.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028			
	Synopsis	<p>The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces a program that provides NIDDK-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support during the latter years of the award period of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, K23, and K25 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>			
119809	RFA-ES-25-003 -- Time-Sensitive Research Opportunities in	National Institute of Environmental	RFA-ES-	01-Apr-2025	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Environmental Health Sciences (R21 Clinical Trial Not Allowed)	Health Sciences/NIH/DHHS	25-003		Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Toccare Chamberlain, M.A.</div> <div>984-287-4482</div> <div>toccare.chamberlain@nih.gov</div> <div></div> <div>Link to program URL</div> <div>02-Jun-2025 , 01-Aug-2025 , 01-Oct-2025 , 01-Dec-2025</div> <div> <p>This Notice of Funding Opportunity (NOFO) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the NOFO is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 4-6 months.</p> </div> </div>				
113566	Notice of Special Interest (NOSI): Understanding Exposure and Health Effects of Micro and/or Nanoplastics	National Institute of Environmental Health Sciences/NIH/DHHS	NOT-ES-23-002	07-May-2025	Not Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Lingamanaidu V. Ravichandran, Ph.D</div> <div>984-287-3309</div> <div>lingamanaidu.ravichandran@nih.gov</div> <div></div> <div>Link to program URL</div> <div>07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 16-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 16-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 16-Oct-2027</div> <div> <p>The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants that the National Institute of Environmental Health Sciences (NIEHS), has special interest in applications that investigate exposure to, and health effects of, microplastics (MPs) and nanoplastics (NPs).</p> </div> </div>				
128628	Research With Activities Related to Diversity (ReWARD) (R01 Clinical	National Institute of General Medical	PAR-25-	07-May-2025	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Trial Optional)	Sciences/NIH/DHHS	117		Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Laurie Stepanek, Ph.D.</div> <div></div> <div>laurie.stepanek@nih.gov</div> <div></div> <div>Link to program URL</div> <div>07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</div> <div>The NIH Research With Activities Related to Diversity (ReWARD) Program's overarching goal is to enhance the breadth and geographical location of research and research-related activities supported by NIH. The ReWARD program provides support for the health-related research of scientists who are making a significant contribution to Diversity, Equity, Inclusion, and Accessibility (DEIA) and who have no current NIH research project grant funding. The ReWARD program provides funding for both the scientific research and the DEIA activities of investigators. The grant will support scientific research in areas related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) and ongoing DEIA activities focused on enhancing diversity in the biomedical research enterprise within the United States and territories. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</div> </div>				
128746	Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-25-202	07-May-2025	275,000 USD
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Alvin T. Yeh</div> <div></div> <div>NIGMS_techdev@nigms.nih.gov</div> <div></div> <div>Link to program URL</div> <div>07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028</div> <div>This Funding Opportunity Announcement (FOA) supports exploratory research leading to the development of innovative technologies for biomedical research that is relevant to the NIGMS mission or that of other NIH Institutes or Centers (ICs) participating in this FOA. Projects should entail a high degree of risk and/or novelty, which will be offset by a high future potential impact in biomedical research. Outcomes or products of the proposed project, which should significantly advance</div> </div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>the current state of the art, may include, but are not limited to: laboratory instruments and other devices, algorithms and software, chemical reagents and processes, biological molecules or systems that have been modified by human intervention to become research tools. This NOFO does not support technology development that is narrowly focused on addressing specific biological questions or that re-purposes existing technologies for new uses. Rather, applications should propose development of new tools that can potentially benefit a broad spectrum of biomedical research. Moreover, feasibility of the proposed technology must not have already been established in the literature or with preliminary data. Applications that are focused on technology development to address specific biological questions and/or include unpublished or published data that provide proof of concept are not responsive to this NOFO and will be administratively withdrawn without review.</p>				
127138	Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-24-225	07-May-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Kenneth D. Gibbs, Jr., Ph.D.</p> <p>kenneth.gibbs@nih.gov</p> <p>Link to program URL</p> <p>07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027</p> <p>The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) program is to support a cohort of early career, independent investigators from diverse backgrounds (for example, individuals from underrepresented groups) conducting research in NIH mission areas. The program has two components: an individual career transition award for postdoctoral scholars (K99/R00) and a research education cooperative agreement (UE5) awarded to organizations to provide these scholars with additional mentoring, networking and professional development activities to support their transition to and success in independent, tenure-track or equivalent research-intensive faculty careers. The MOSAIC program supports NIH's efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The goal of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds from their mentored postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The program is designed to support postdoctoral researchers who have demonstrated meaningful contributions and proposed compelling future plans to promote broad participation in the biomedical research workforce, such as activities that promote inclusive, supportive, and accessible biomedical research</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	environments that support the success of trainees and scientists from all backgrounds, including individuals from underrepresented groups. This Notice of Funding Opportunity (NOFO) is designed specifically to support candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Candidates seeking support through this NOFO are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Candidates proposing a clinical trial or an ancillary clinical trial as lead investigator, should work with their institutions to apply to the companion NOFO PAR-24-226.				
128748	Focused Technology Research and Development (R01 Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-25-203	07-May-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Alvin T. Yeh</div> <div></div> <div>NIGMS_techdev@nigms.nih.gov</div> <div></div> <div>Link to program URL</div> <div>07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</div> <div>This Funding Opportunity Announcement (FOA) supports projects relevant to the NIGMS mission or those of other NIH institutes or Centers (ICs) participating in the FOA that focus solely on the development of technologies with the potential to enable acquisition of biomedical knowledge. Projects should be justified in terms of technical innovation and utility of such technical innovation for impacting future biomedical research. Outcomes or products of the proposed project should significantly advance the current state of the art and be sufficiently characterized for application in addressing a broad range of biomedical research questions. These outcomes may include, but are not limited to: laboratory instruments and other devices, algorithms and software, chemical reagents and processes, biological molecules or systems that have been modified by human intervention to become research tools. The goal of this FOA is to support the development of technologies with demonstrated proof-of-concept that have remaining significant technical challenges to full implementation and broad utility. As such, applications should not propose to test specific biological questions. Applications proposing to test specific biological questions are not responsive to this FOA and will be administratively withdrawn without review. Applications with a focus on optimization, hardening, or obvious extrapolations of established technology will be a lower priority for funding.</div>			
125765	Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-25-134	07-May-2025	375,000 USD
	<div>Contact Name</div>	<div>Charles Ansong, Ph.D.</div>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email charles.ansong@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 25-Jun-2025 , 07-Sep-2025 , 25-Oct-2025 , 07-Jan-2026 , 25-Feb-2026 , 07-May-2026 , 25-Jun-2026 , 07-Sep-2026 , 25-Oct-2026 , 07-Jan-2027 , 25-Feb-2027 , 07-May-2027 , 25-Jun-2027 , 07-Sep-2027 , 25-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate science degrees and have received no more than \$6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole. See Part II. Section 3.1 Eligible Organizations for more information.</p>				
125769	Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)	National Institute of General Medical Sciences/NIH/DHHS	PAR-25-148	07-May-2025	375,000 USD
	<p>Contact Name Mahua Mukhopadhyay, PhD</p> <p>Contact Telephone 301-435-6886</p> <p>Contact Email mukhopam@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 25-Jun-2025 , 07-Sep-2025 , 25-Oct-2025 , 07-Jan-2026 , 25-Feb-2026 , 07-May-2026 , 25-Jun-2026 , 07-Sep-2026 , 25-Oct-2026 , 07-Jan-2027 , 25-Feb-2027 , 07-May-2027 , 25-Jun-2027 , 07-Sep-2027 , 25-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate science degrees and have received no more than \$6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole. See Part II. Section 3.1 Eligible</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Organizations for more information. This Notice of Funding Opportunity (NOFO) supports investigator-initiated mechanistic and/or minimal risk clinical trials such as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm, and which address the mission and research interests of the participating NIH institutes.				
128806	Advancing Research Careers (ARC) Predoctoral to Postdoctoral Transition Award to Promote Diversity (F99/K00 - Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-25-084	07-May-2025	Not Specified
	Contact Name	Laurie Stepanek, Ph.D.			
	Contact Telephone				
	Contact Email	laurie.stepanek@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 10-Oct-2025 , 07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 15-Jun-2026 , 07-Sep-2026 , 14-Oct-2026 , 07-Jan-2027 , 11-Feb-2027 , 07-May-2027 , 11-Jun-2027 , 07-Sep-2027 , 08-Oct-2027 , 07-Jan-2028			
	Synopsis	<p>The purpose of the Advancing Research Careers (ARC) program is to support cohorts of promising, late-stage graduate students from diverse backgrounds pursuing research training in NIH mission areas. The program has two components: an individual predoctoral-to-postdoctoral transition award (F99/K00) and a research education cooperative agreement (UE5) awarded to organizations to provide F99/K00 fellows with additional mentoring, networking and professional development activities to support their transition to and success in mentored postdoctoral research positions. The ARC program supports NIH's efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The ARC Predoctoral to Postdoctoral Transition Award to Promote Diversity (F99/K00) is a two-phase award that will provide support for promising late-stage graduate students from diverse backgrounds pursuing research related to the mission areas of participating NIH Institutes, Centers and Offices (ICOs), to complete their doctoral research training (F99 phase) and transition into and succeed in postdoctoral biomedical research and career development opportunities (K00 phase). The program also is designed to support predoctoral researchers who have, appropriate to their career stage, demonstrated contributions and propose meaningful plans to promote broad participation in the biomedical research workforce. It is anticipated that completion of this phased award program will position ARC scholars to advance in impactful careers in the biomedical research workforce that typically require postdoctoral training (for example, academic research and teaching at a range of organization types, industry, or government research). This Notice of Funding Opportunity (NOFO) does not allow candidates to propose to lead an independent clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
111607	Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-22-155	10-May-2025 [Optional][LOI/Pre-App]	10,000,000 USD
<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Susan Koester, Ph.D.</div> <div>301-443-3563</div> <div>koesters@mail.nih.gov</div> <div></div> <div>Link to program URL</div> <div>10-May-2025 [Optional][LOI/Pre-App], 09-Jun-2025</div> <div> <p>This Funding Opportunity Announcement (FOA) encourages applications for Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research. The NIMH seeks teams of researchers working at different levels of analysis and employing integrative, novel, and creative experimental approaches to address high-risk, high-impact questions with the primary objectives of: (a) advancing the state of the science in basic brain and behavior research that will uncover and dissect the underlying mechanisms that will ultimately provide the foundation for understanding mental disorders; (b) supporting the integration and translation of basic and clinical neuroscience research on severe mental illnesses; and/or (c) advancing our understanding of the neurobehavioral developmental mechanisms and trajectories of psychopathology that begin in childhood and adolescence. The Conte Centers program is intended to support interdisciplinary basic neuroscience or translational research that demonstrates an extraordinary level of synergy, integration, and potential for advancing the state of the field. This program is intended only for projects that could not be achieved using other, more standard grant mechanisms.</p> </div> </div>					
112626	RFA-MH-22-185 -- NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-22-185	21-May-2025 [Optional][LOI/Pre-App]	2,500,000 USD
<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> </div> <div> <div>Eric R. Murphy, Ph.D.</div> <div>301-443-9230</div> <div>eric.murphy@nih.gov</div> <div></div> <div>Link to program URL</div> <div>21-May-2025 [Optional][LOI/Pre-App], 20-Jun-2025</div> </div>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The NIMH Biobehavioral Research Awards for Innovative New Scientists (BRAINS) award is intended to support the research and research career advancement of outstanding, exceptionally productive scientists who are in the early, formative stages of their careers and who plan to make a long-term career commitment to research in specific mission areas of the NIMH. This award seeks to assist these individuals in launching an innovative clinical, translational, basic, or services research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mental disorders. The NIMH BRAINS program will focus on the research priorities and gap areas identified in the NIMH Strategic Plan.			
124764	RFA-MH-25-110 -- BRAIN Initiative: Data Archives for the BRAIN Initiative (R24 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-25-110	25-May-2025 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Ming Zhan, Ph.D.			
	Contact Telephone	301-827-3678			
	Contact Email	ming.zhan@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-May-2025 [Optional][LOI/Pre-App], 24-Jun-2025 , 25-May-2026 [Optional][LOI/Pre-App], 24-Jun-2026			
	Synopsis	This Funding Opportunity Announcement (FOA) solicits applications to develop web-accessible data archives to capture, store, and curate data related to BRAIN Initiative activities. The data archives teams will work with the research community to incorporate software tools that allow users to analyze and visualize the data, and will use appropriate standards to describe the data, but an application with major focus on the creation of such software tools and data standards is not responsive to this NOFO. A goal of this program is to advance research by creating a data archive with appropriate standards and summary information that is broadly available and accessible to the research community for furthering research. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.			
126538	RFA-MH-25-136 -- Pilot Research Opportunities in Crisis Response Services for Suicide Prevention (R34 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-25-136	03-May-2025 [Optional][LOI/Pre-App]	675,000 USD
	Contact Name	Jennifer Humensky, Ph.D.			
	Contact Telephone	301-480-1265			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
126537	<p>Contact Email jennifer.humensky@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-May-2025 [Optional][LOI/Pre-App], 02-Jun-2025</p> <p>Synopsis This NOFO seeks to promote pilot exploratory/developmental research examining the effectiveness and implementation of crisis response services, approaches to improve the quality and outcomes of services, and the impact of state and local policy on implementation and outcomes. Research is sought that is conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related characteristics (e.g., youth; adult; older adult), geographic context (rural/remote settings), racial/ethnic and cultural considerations, and health disparities influence the types of care that are provided. Studies are encouraged that address the continuum of crisis service systems. Support for larger-scale or fully-powered studies is provided through a companion NOFO that utilizes the R01 mechanism (RFA-MH-25-135; Research Opportunities in Crisis Response Services for Suicide Prevention (R01 Clinical Trial Optional)).</p>				
	RFA-MH-25-135 -- Research Opportunities in Crisis Response Services for Suicide Prevention (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-25-135	03-May-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Jennifer Humensky, Ph.D.</p> <p>Contact Telephone 301-480-1265</p> <p>Contact Email jennifer.humensky@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-May-2025 [Optional][LOI/Pre-App], 02-Jun-2025</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) encourages research examining the effectiveness and implementation of crisis response services, approaches to improve the quality and outcomes of services, and the impact of state and local policy on implementation and outcomes. Research is sought that is conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related characteristics (e.g., youth; adult; older adult), geographic context (rural/remote settings), racial/ethnic and cultural considerations, and health disparities influence the types of care that are provided. Studies are encouraged that address the continuum of crisis service systems. Support for pilot studies is provided through a companion NOFO that utilizes the R34 mechanism (RFA-MH-25-136); Pilot Research Opportunities in Crisis Response Services for Suicide Prevention (R34 Clinical Trial Optional)).</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
126959	Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations II (U01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-24-240	13-Jun-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Miri Gitik, Ph.D.</div> <div>301-827-3523</div> <div>miri.gitik@nih.gov</div> <div></div> <div>Link to program URL</div> <div>13-Jun-2025 , 13-Feb-2026</div> <div>The following Notice of Funding Opportunity (NOFO) seeks cooperative agreements proposing coordinated efforts to accelerate gene discovery for psychiatric disorders in cohorts of non-European ancestry to advance our understanding of the genetic architecture of mental illnesses across ancestrally diverse global populations. Applicants should carefully read the NOFO instructions and review the accompanying U24 NOFO,PAR-24-241.</div>			
126862	Standardizing Data and Metadata from Wearable Devices (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-24-250	11-May-2025 [Optional][LOI/Pre-App]	Not Specified
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Christina Liu, Ph.D.</div> <div>301-827-9193</div> <div>christina.liu@nih.gov</div> <div></div> <div>Link to program URL</div> <div>11-May-2025 [Optional][LOI/Pre-App], 10-Jun-2025 , 11-May-2026 [Optional][LOI/Pre-App], 10-Jun-2026</div> <div>Wearable technology shows promise in providing information that can be used to create biomarkers of various diagnostic groups that have relevance to mental illness. However, there are barriers related to multiple and sometimes proprietary data standards that make data aggregation difficult from existing devices. The purpose of this Notice of Funding Opportunity (NOFO) is to support the creation of standards for data as well as metadata and related coordination activities that will allow researchers to easily access data from personal tracking devices and integrate those data for subsequent data analysis. The recipients will be expected to partner with device manufacturers, the researcher community, and other interested parties such as ethics experts if the effort is going to be successful. It is expected that the recipient will create standards for personal tracking device data that serve the same purpose as the Digital Imaging and Communications in Medicine (DICOM) or</div>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Neuroimaging Informatics Technology Initiative (NIFTI) formats and standards do for medical image files. Those medical image file standards have allowed secondary data analysis and have resulted in many software packages and workflows for secondary data analysis.				
128363	RFA-MH-26-140 -- BRAIN Initiative: Brain-Behavior Quantification and Synchronization – Next Generation Sensor Technology Development (U01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-26-140	14-May-2025 [Optional][LOI/Pre-App]	10,000,000 USD
	Contact Name	Yvonne Bennett, Ph.D.			
	Contact Telephone	301-222-7094			
	Contact Email	yvonne.bennett@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	14-May-2025 [Optional][LOI/Pre-App], 13-Jun-2025 , 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026 , 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-2027			
	Synopsis	<p>This Notice of Funding Opportunity (NOFO) from the NIH Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is intended to support the development of next generation sensor technologies and bioelectronic devices to further the goals of the Brain Behavior Quantification and Synchronization (BBQS) program of the NIH BRAIN Initiative. The BRAIN Initiative BBQS funding opportunities broadly support 1) development of tools for simultaneous, multimodal measurement of behavior within complex, dynamic physical and/or social environments and synchronize these data with simultaneously-recorded neural activity and 2) development of novel conceptual and computational models that capture dynamic behavior-environment relationships across multiple timescales and that can integrate correlated neural activity into the model. More information about the BRAIN Initiative including existing Notices of Funding Opportunities for the BBQS program can be found here. This NOFO focuses exclusively on the development of novel sensor technology and bioelectronic devices related to the BBQS program and follows a recent workshop BBQS Workshop May 2023. This NOFO will foster close interaction between engineers and behavioral scientists in a Research Consortium. Sensor developers in the Consortium will promote rigorous technology design, fabrication, testing, validation, and dissemination of information regarding sensors and bioelectronics toward improving our understanding of human and organismal behavior. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>			
125379	RFA-MH-25-130--Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	RFA-MH-25-130	14-May-2025 [Optional][LOI/Pre-App]	450,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
128553	Contact Name	Mary Rooney, Ph.D.			
	Contact Telephone	301-827-1325			
	Contact Email	mary.rooney@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	14-May-2025 [Optional][LOI/Pre-App], 13-Jun-2025			
	Synopsis	NIMH seeks applications for pilot research to adapt, optimize, and test empirically supported behavioral interventions that address common sleep problems in adolescents and young adults with or at risk for a mental health disorder. Pilot trials should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach in real world settings, and to conduct a preliminary test of the intervention's impact on target mechanisms and sleep and mental health outcomes, and to obtain preliminary data needed as a prerequisite a larger-scale effectiveness trial. An emphasis is placed on studies that address the needs of youth from understudied and underserved populations.			
128553	Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25-206	06-May-2025 [Optional][LOI/Pre-App]	750,000 USD
	Contact Name	Adam Haim, Ph.D.			
	Contact Telephone	301-435-3593			
	Contact Email	haima@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027			
	Synopsis	NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes. This notice of funding opportunity (NOFO) supports pilot research to evaluate the feasibility, tolerability, acceptability, safety, and preliminary indications of effectiveness of post-acute phase intervention approaches, to generate the preliminary data needed as a prerequisite to well powered effectiveness trials, and to inform the design of definitive effectiveness trials. Support for fully-powered, definitive effectiveness studies focused on post-acute phase interventions is provided via the R01 NOFO, PAR-25-207.</p>				
128559	Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25-207	06-May-2025 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Adam Haim, Ph.D.			
	Contact Telephone	301-435-3593			
	Contact Email	haima@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027			
	Synopsis	<p>NIMH seeks applications for research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. This notice of funding opportunity (NOFO) encourages clinical trials to establish the effectiveness and test hypotheses regarding mechanisms of action, mediators, and predictors and moderators of post-acute phase therapeutic and services interventions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden for promoting optimal longer-term outcomes. This NOFO is intended to support trials that are statistically powered to provide a definitive answer regarding the effectiveness of the post-acute phase intervention. Support for pilot effectiveness trials designed to evaluate the initial feasibility, tolerability, acceptability, safety and preliminary indications of post-acute phase intervention approaches is provided via the R01 NOFO, PAR-25-206 .</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
112309	Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-22-170	07-May-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Jamie Driscoll</div> <div>301-443-5288</div> <div>jdrisco1@mail.nih.gov</div> <div></div> <div>Link to program URL</div> <div>07-May-2025 , 05-Jun-2025 , 07-Sep-2025</div> <div>The goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. This FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as pharmacokinetic/pharmacodynamic (PK/PD) markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline in which treatment candidates and therapeutic targets can be evaluated for their ability to impact neurobiological mechanisms of potential clinical relevance to mental illnesses. The objectives of this FOA will be accomplished by supporting basic neuroscience aimed at improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivo physiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. The FOA may be considered a prequel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.</div>			
115030	Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-25-035	07-May-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div>	<div>Jamie Driscoll</div> <div>301-443-5288</div> <div>jdrisco1@mail.nih.gov</div> <div></div>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. This FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as pharmacokinetic/pharmacodynamic (PK/PD) markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline in which treatment candidates and therapeutic targets can be evaluated for their ability to impact neurobiological mechanisms of potential clinical relevance to mental illnesses. The objectives of this FOA will be accomplished by supporting basic neuroscience aimed at improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivo physiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. The FOA may be considered a prequel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.</p>				
117750	Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-25-063	07-May-2025	Not Specified
	<p>Contact Name Enrique Michelotti, PhD</p> <p>Contact Telephone 301-443-5415</p> <p>Contact Email michelottiel@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis The overarching goal of this Notice of Funding Opportunity (NOFO) is to support the development and validation of screening assays for the discovery of validated hits that can be used in future drug discovery/development efforts for identifying potential drug candidates for the treatment of mental illness. For purposes of this initiative, a “hit” is defined as a compound that has the desired activity in a compound screen and whose activity is confirmed upon retesting in orthogonal assays.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Stages of discovery research covered by this NOFO include 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); and 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.				
117550	Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-036	07-May-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Enrique Michelotti, Ph.D.</p> <p>301-443-5415</p> <p>michelottiel@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>This Notice of Funding Opportunity (NOFO) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) for molecular targets (e.g., receptors, intracellular messengers, disease-related proteins) that are implicated in brain disorders as tools to study disease pathophysiology and/or for assessing target engagement of potential therapeutic candidates. The objective of this NOFO is to stimulate research in the identification and development of PET and SPECT probes for disorders of primary interest to the NIMH or NIA.</p>			
128944	Navigator Emergency Department Diversion Models for Non-Urgent Mental Health Concerns (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25-289	06-May-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Mary Acri, Ph.D.</p> <p>301-910-8230</p> <p>mary.acri@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 ,</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to encourage research applications that test the effectiveness, implementation, and optimization of patient navigation Emergency Department (ED) diversion models for non-urgent youth mental health problems. A non-urgent ED visit is that in which a delay of several hours would not increase the potential for an adverse outcome to occur. For the purposes of this NOFO, NIMH defines a patient navigation model as an evidence-based intervention that is delivered by a mental health provider, an allied provider such as a nurse, or a lay provider (e.g., peer, community health worker) whose role is to (a) utilize triage tools to identify mental health acuity, (b) provide emotional support and build mental health knowledge among caregivers, (c) facilitate linkages to mental health services and additional resources as needed to support the family, and (d) address barriers to help-seeking. This NOFO is for projects for which there are preliminary data. Support for pilot studies is provided through a companion NOFO that utilizes the R34 mechanism: PAR-25-288 Planning Grant (R34 Clinical Trial Required).</p>				
129579	<p>Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed)</p> <p>Contact Name Jennifer Humensky, PhD</p> <p>Contact Telephone 301-480-1265</p> <p>Contact Email Jennifer.Humensky@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to encourage innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial R01-level projects that address NIMH strategic priorities that strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan. This NOFO solicits research projects including, but not limited to the following: (a) research identifying mutable factors that impact access, continuity, utilization, quality, value, and outcomes, including disparities in outcomes, or scalability of mental health services, which may serve as targets in future service delivery intervention development, (b) research that develops and tests new research tools, technologies, measures, or methods and statistical approaches to study these issues, and/or (c) research that integrates and analyzes large data sets to understand factors affecting mental health services outcomes using advanced computational and predictive analytic approaches. Wherever possible, projects should leverage existing infrastructure and partnerships to accomplish these goals.</p>	National Institute of Mental Health/NIH/DHHS	PAR-25-283	05-Jun-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
128912	Mood and Psychosis Symptoms During the Menopause Transition (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-281	05-Jun-2025	Not Specified
	<div>Contact NameLaura M. Rowland, Ph.D.</div> <div>Contact Telephone301-480-8335</div> <div>Contact Emaillaura.rowland@nih.gov</div> <div>Sponsor Website</div> <div>Program URLLink to program URL</div> <div>Deadline Dates (ALL)05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027</div> <div>Synopsis<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts This NOFO uses the R01 grant mechanism, while the companion NOFO PAR-25-282 uses the R21 mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism, while applicants with preliminary data who seek longer-term funding may wish to apply using the R01 mechanism.</p></div>				
128915	Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-290	06-May-2025 [Optional][LOI/Pre-App]	Not Specified
	<div>Contact NameJessica Tilghman, Ph.D.</div> <div>Contact Telephone301-827-0439</div> <div>Contact Emailjessica.tilghman@nih.gov</div> <div>Sponsor Website</div> <div>Program URLLink to program URL</div> <div>Deadline Dates (ALL)06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027</div> <div>Synopsis<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural</p></div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This FOA aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new therapies is outside the scope of this FOA, though development of novel tools/methods to enable relevant mental health studies is encouraged. This NOFO uses the R01 grant mechanism, encouraging longer-term projects, whereas its companion R21 NOFO, PAR-25-291, seeks grant applications encouraging shorter, higher-risk studies with little (or no) preliminary data.</p>				
117822	Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Required)	National Institute of Mental Health/NIH/DHHS	PA-23-150	12-Jun-2025	Not Specified
	Contact Name	Ashlee Van't Veer			
	Contact Telephone	301-443-3107			
	Contact Email	dnbbstrainingbranch@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026			
	Synopsis	<p>The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA, PAR-23-149.</p>			
117821	Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Not Allowed)	National Institute of Mental Health/NIH/DHHS	PA-23-149	12-Jun-2025	Not Specified
	Contact Name	Ashlee Van't Veer			
	Contact Telephone	301-443-3107			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email dnbbstrainingbranch@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026</p> <p>Synopsis The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator should apply to the companion FOA, PAR-23-150.</p>				
129181	NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22 No Independent Clinical Trials)	National Institute of Mental Health/NIH/DHHS	PAR-24-286	12-Jun-2025	Not Specified
	<p>Contact Name Ashlee Van't Veer, PhD</p> <p>Contact Telephone 301-443-3107</p> <p>Contact Email dnbbstrainingbranch@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027 , 12-Oct-2027</p> <p>Synopsis The primary goal of the NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22) Program (hereafter abbreviated as the NIMH Career Transition K22 Program) is to provide support for career intramural investigators at NIMH who aim to transition from the Division of Intramural Research Programs (IRP) to an independent research faculty position in the extramural community. Applicants should have a demonstrated record of meritorious research in mental health-related fields. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial.</p>				
128977	Full-Scale Hybrid Effectiveness-Implementation Trials for Mental Health	National Institute of Mental	PAR-25-	18-May-2025	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Interventions (R01 - Clinical Trial Required)	Health/NIH/DHHS	177	[Optional][LOI/Pre-App]	Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Joel Sherrill, Ph.D.</div> <div>301-443-2477</div> <div>jsherril@mail.nih.gov</div> <div></div> <div>Link to program URL</div> <div>18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025 , 15-Sep-2025 [Optional][LOI/Pre-App], 15-Oct-2025 , 14-Jan-2026 [Optional][LOI/Pre-App], 13-Feb-2026 , 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026 , 15-Sep-2026 [Optional][LOI/Pre-App], 15-Oct-2026 , 18-Jan-2027 [Optional][LOI/Pre-App], 17-Feb-2027 , 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-2027 , 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027</div> <div>IMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. This NOFO seeks to support well-powered clinical trials consistent with NIMH's priorities for: 1) optimizing preventive and therapeutic interventions with previously demonstrated efficacy for use with broader target populations or for delivery routine care, school, community, or online settings, and 2) research on implementation strategies that support the delivery and sustainability of optimized interventions in accessible settings. Applications responsive to this NOFO are hybrid effectiveness implementation trials that examine the effectiveness and clinical impact of interventions to prevent or treat mental illness, implementation challenges and strategies within the intervention setting, and at least one mechanism of action associated with an intervention and/or implementation strategy. The research covered under this announcement addresses practice-relevant questions and must be conducted within accessible intervention settings where the typical consumer can be identified as in need of care and be readily connected to an intervention. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion NOFOs listed above.</div> </div>				
119664	Schizophrenia and Related Disorders During mid- to Late-Life (R21 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-040	16-Jun-2025	275,000 USD
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> </div> <div> <div>Laura M. Rowland, Ph.D.</div> <div>301-480-8335</div> <div>laura.rowland@nih.gov</div> <div></div> <div>Link to program URL</div> </div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
119705	Deadline Dates (ALL)	16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026			
	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life, and to identify targets for future development of prevention and treatment interventions. This NOFO uses the R21 grant mechanism, while the companion NOFO (PAR-25-039) uses the R01 mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism, while applicants with preliminary data who seek longer-term funding should apply using the R01 mechanism.			
119705	Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-25-037	16-Jun-2025	275,000 USD
	Contact Name	David Panchision			
	Contact Telephone	301-402-3969			
	Contact Email	panchisiond@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026			
	Synopsis	This Notice of Funding Opportunity (NOFO) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this NOFO , the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to “model” disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present NOFO (R21 activity code) can be used for applications to develop early stage, high-risk, exploratory approaches or establish proof-of-concept where there is little or no preliminary data. Applicants proposing to develop lines of inquiry where feasibility or proof of concept has been established should apply			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	to the companion R01 NOFO PAR-25-038.				
119254	Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-065	05-Jun-2025	Not Specified
	Contact Name	Laura M. Rowland, Ph.D.			
	Contact Telephone	301-480-8335			
	Contact Email	laura.rowland@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026			
	Synopsis	The goal of this Notice of Funding Opportunity (NOFO) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both bio behavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This NOFO uses the R01 mechanism, while the companion announcement PAR-25-064 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism .			
119663	Schizophrenia and Related Disorders During mid- to Late-Life (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-039	05-Jun-2025	Not Specified
	Contact Name	Laura M. Rowland, Ph.D.			
	Contact Telephone	301-480-8335			
	Contact Email	laura.rowland@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026			
	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life, and to identify targets for future development of prevention and treatment interventions. This NOFO uses the R01 grant mechanism, while the companion NOFO (PAR-25-040), uses the R21 mechanism. Investigators proposing high			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism.					
119702	Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-25-038	05-Jun-2025	Not Specified
Contact Name		David Panchision			
Contact Telephone		301-402-3969			
Contact Email		panchisiond@mail.nih.gov			
Sponsor Website					
Program URL		Link to program URL			
Deadline Dates (ALL)		05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026			
Synopsis		<p>This Notice of Funding Opportunity (NOFO) encourages research on the biology of high-confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular, and circuit substrates of neural function. For the purposes of this NOFO, the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular, and circuit mechanisms, these are neither required nor expected. Studies should not attempt to “model” disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components, and processes. The resulting paradigms, component pathways, and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present NOFO (R01 activity code) can be used for applications to further develop lines of inquiry where feasibility or proof-of-concept has been established. Applicants proposing exploratory research at the early and conceptual stages of project development should apply to the companion R21 NOFO PAR-25-037.</p>			
118003	Notice of Special Interest (NOSI): NIMH Planning Grants for Natural History Studies of Rare Genetic Neurodevelopmental Disorders	National Institute of Mental Health/NIH/DHHS	NOT-MH-23-235	07-May-2025	Not Specified
Contact Name		Margaret Grabb, Ph.D.			
Contact Telephone		301-443-3563			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
118004	Contact Email	mgrabb@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026			
	Synopsis	The National Institute of Mental Health (NIMH) is issuing this Notice to highlight its interest in supporting planning grants to conduct retrospective natural history studies that explore the prevalence of disabling psychiatric symptoms and disruptions in function in patients (birth to 25 years of age) with rare genetic neurodevelopmental disorders (NDD). The principal goal of these studies is to assess the time of onset and severity of these symptoms, identify appropriate outcome measures, and establish potential timepoints for intervention. Additionally, the planning grants should focus on identifying potential quantitative clinical functional measures or biomarkers that could be used as prognostics and/or measures of change in future clinical trials. These retrospective natural history studies are expected to enable future prospective longitudinal studies (see Food and Drug Administration's (FDA's) guidance on natural history studies for rare disorders).			
118004	Notice of Special Interest (NOSI): Pre-Clinical Research on Gene Therapies for Rare Genetic Neurodevelopmental Disorders	National Institute of Mental Health/NIH/DHHS	NOT-MH-23-236	07-May-2025	Not Specified
128677	Contact Name				
	Contact Telephone	301-443-3563			
	Contact Email	NIMHgenetherapies@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
128677	Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026			
	Synopsis	The National Institute of Mental Health (NIMH) is issuing this Notice of Special Interest (NOSI) to highlight interest in pre-clinical research aimed at developing novel approaches for somatic cell gene therapies to treat neurodevelopmental disorders with prominent cognitive, social and/or affective impairment.			
128677	Integrating Mental Health Care into Health Care Systems in Low- and Middle-Income Countries (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-201	06-May-2025 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Vidya Vedham, Ph.D.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email vidya.vedham@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027</p> <p>Synopsis This notice of funding opportunity (NOFO) seeks implementation research projects focused on the integrating mental health services with chronic health care (for both communicable and non-communicable conditions) across various healthcare and non-healthcare settings (such as schools, places of worship, and community centers) in low and middle-income countries (LMICs). The objective is to develop, refine, and evaluate innovative strategies to facilitate the integration of mental health care with other services. This NOFO aims to support research geared towards implementing, scaling up, and ensuring the financial sustainability of integrated mental health care models, with the overarching goal of enhancing the availability, accessibility, utilization, and quality of mental health care services in both healthcare and non-healthcare settings. In addition, this NOFO seeks to strengthen sustainable mental health research capacity in LMICs.</p>				
128661	Laboratories to Optimize Digital Health (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25-136	06-May-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Adam Haim, Ph.D.</p> <p>Contact Telephone 301-435-3593</p> <p>Contact Email Haima@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027</p> <p>Synopsis NIMH seeks applications for innovative research projects to test strategies to increase the reach, efficiency, effectiveness, and quality of digital mental health interventions which may impact mental health outcomes, including suicide behaviors and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>serious mental illness. This Funding Opportunity Announcement (FOA) is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations.</p>				
128886	Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-25-287	05-Jun-2025	Not Specified
	Contact Name	Jessica Tilghman, PhD			
	Contact Telephone	301-827-0439			
	Contact Email	jessica.tilghman@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027			
	Synopsis	<p>The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitting in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animal and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches.</p>			
128985	Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25-182	18-May-2025 [Optional][LOI/Pre-App]	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Alexander Talkovsky, Ph.D.</p> <p>Contact Telephone 301-827-7614</p> <p>Contact Email alexander.talkovsky@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025 , 17-Sep-2025 [Optional][LOI/Pre-App], 17-Oct-2025 , 20-Jan-2026 [Optional][LOI/Pre-App], 19-Feb-2026 , 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026 , 15-Sep-2026 [Optional][LOI/Pre-App], 15-Oct-2026 , 18-Jan-2027 [Optional][LOI/Pre-App], 17-Feb-2027 , 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-2027 , 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027</p> <p>Synopsis NIMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-inhuman, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials The purpose of this NOFO is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH's experimental therapeutics approach, this NOFO is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective, and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial interventions may be standalone interventions or novel augmentations to efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of a novel intervention's impact on a target process or mechanism associated with mental disorder risk, causation, or maintenance (target engagement). Up to 3 years of additional support (R33 phase) will be provided for studies with findings that meet the "go/no-go" milestones embedded in the R61 phase. The R33 phase is intended to support the replication of target engagement and to test whether engaging the intervention target/mechanism mediates changes in clinical outcomes. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development and/or testing of the intervention. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion NOFOs listed above.</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
128983	Development of Psychosocial Therapeutic and Preventive Interventions for	National Institute of Mental	PAR-25-	18-May-2025	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Mental Disorders (R33 Clinical Trial Required)	Health/NIH/DHHS	181	[Optional][LOI/Pre-App]	Specified
	<div>Contact NameAlexander Talkovsky, Ph.D. Contact Telephone301-827-7614 Contact Emailalexander.talkovsky@nih.gov Sponsor Website Program URLLink to program URL Deadline Dates (ALL)18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025 , 17-Sep-2025 [Optional][LOI/Pre-App], 17-Oct-2025 , 20-Jan-2026 [Optional][LOI/Pre-App], 19-Feb-2026 , 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026 , 15-Sep-2026 [Optional][LOI/Pre-App], 15-Oct-2026 , 18-Jan-2027 [Optional][LOI/Pre-App], 17-Feb-2027 , 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-2027 , 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027 SynopsisNIMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this NOFO is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH’s experimental therapeutics approach, this NOFO is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial interventions may be standalone interventions or novel augmentations to efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. The R33 is intended to support the replication of target engagement and to test whether engaging the intervention target/mechanism mediates changes in clinical outcomes. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development and/or testing of the intervention. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion NOFOs listed above.</div>				
129578	Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-25-284	16-Jun-2025	450,000 USD
	<div>Contact NameVictor Lushin, M.D., Ph.D., M.S.W. Contact Telephone301-827-6280</div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email victor.lushin@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial pilot projects that address NIMH strategic priorities to strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan. Proposed research should seek to: Identify mutable factors that impact access, continuity, utilization, quality, value, and outcomes, including disparities in outcomes, or scalability of mental health services, which may serve as targets in future service delivery intervention development; Develop and test new research tools, technologies, measures, or methods and statistical approaches to study these issues; Test the feasibility of integrating and analyzing large data sets to understand factors affecting mental health services outcomes using advanced computational and predictive analytic approaches; Wherever possible, leverage existing infrastructure and partnerships to accomplish these goals.</p>				
129095	Accelerating Solutions to Improve Access and Quality of Empirically-Supported Practices for Youth Mental Health (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-310	06-May-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Marcy Burstein, Ph.D.</p> <p>Contact Telephone 301-443-9699</p> <p>Contact Email marcy.burstein@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026</p> <p>Synopsis This notice of funding opportunity (NOFO) is a call to action in response to the youth mental health crisis in the United States. NIMH seeks applications that will study methods to increase access to, and quality of, empirically-supported practices for youth mental health. Applications may address research related to: optimizing assessment, intervention and service strategies; overcoming challenges related to workforce shortages and waitlists for treatment; integration of treatment and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	preventive interventions into settings where youth are most likely to be identified as needing care (e.g., schools, pediatric medicine, community organizations, social services, and juvenile justice), and service interventions that address systemic barriers to access and quality of mental health care (e.g., structural, policy, organizational, value in terms of cost/financing, management).				
129833	National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-352	25-Jun-2025	Not Specified
	Contact Name	Yael Mandelblat-Cerf, Ph.D.			
	Contact Telephone	301-793-7563			
	Contact Email	yael.mandelblat-cerf@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-Jun-2025 , 25-Oct-2025 , 25-Feb-2026 , 25-Jun-2026 , 25-Oct-2026 , 25-Feb-2027 , 25-Jun-2027 , 25-Oct-2027			
	Synopsis	<p>The purpose of this notice of funding opportunity (NOFO) is to accelerate innovative drug and device therapies translation from discovery to early human studies. Studies appropriate for this NOFO will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative candidates for mental disorders; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders. This NOFO encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This NOFO will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral vector-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). This NOFO supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme, or program goal, requiring a broadly based, multidisciplinary, and often long-term approach should consider the companion NOFO PAR-25-353.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
123916	Advancing Learning Health Care Research in Outpatient Mental Health Treatment Settings (R34 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-278	17-May-2025 [Optional][LOI/Pre-App]	450,000 USD
Contact Name Michael Freed, Ph.D. Contact Telephone 301-443-3747 Contact Email michael.freed@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 17-May-2025 [Optional][LOI/Pre-App], 16-Jun-2025 , 17-Sep-2025 [Optional][LOI/Pre-App], 16-Oct-2025 Synopsis This Notice of Funding Announcement (NOFO) solicits exploratory/developmental research applications within the learning health care framework to support adoption, implementation, sustainability, and continuous improvement of evidence-based practices in outpatient mental health and substance use treatment systems. These settings could include, but are not limited to, Certified Community Behavioral Health Clinics (CCBHCs) funded through the Substance Abuse and Mental Health Services Administration (SAMHSA) expansion grant program and CCBHCs participating in their states' Section 223 CCBHC Medicaid demonstration program, or as a part of independent state programs where the CCBHCs are meeting the federal CCBHC certification criteria. This NOFO requires active collaboration between behavioral health researchers and community behavioral health partners across all phases of the research process. Studies that are co-designed between community clinic staff/service users and health services researchers may focus on (1) identifying subgroups within the population of individuals served by CCBHCs with unique needs, including health disparities experienced by people from racial and ethnic minority groups or underserved communities; (2) workforce development strategies, including new approaches to train providers who vary in terms of prior experience, expertise and skills; (3) developing and testing tools to promote measurement-based treatment; (4) hybrid effectiveness-implementation trials aimed at implementing and improving evidence-based prevention, treatment, or services delivery approaches in real-world settings; and (5) research to establish and/or expand 988 crisis response services within CCBHC settings.					
128885	Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-25-286	16-Jun-2025	275,000 USD
Contact Name Jessica Tilghman, PhD Contact Telephone 301-827-0439 Contact Email jessica.tilghman@nih.gov Sponsor Website					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Although the application should focus on the engineering development and bench top testing of the tool, animals and limited, non-clinical trial human testing necessary to demonstrate initial proof of concept is allowable. This NOFO uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity PAR-25-287 seeks R01 grant applications.</p>				
128945	Navigator Emergency Department Diversion Models for Non-Urgent Mental Health Concerns (R34 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25-288	17-May-2025 [Optional][LOI/Pre-App]	675,000 USD
	<p>Contact Name Mary Acri, Ph.D.</p> <p>Contact Telephone 301-910-8230</p> <p>Contact Email mary.acri@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-May-2025 [Optional][LOI/Pre-App], 16-Jun-2025 , 16-Sep-2025 [Optional][LOI/Pre-App], 16-Oct-2025 , 17-Jan-2026 [Optional][LOI/Pre-App], 16-Feb-2026 , 17-May-2026 [Optional][LOI/Pre-App], 16-Jun-2026 , 16-Sep-2026 [Optional][LOI/Pre-App], 16-Oct-2026 , 17-Jan-2027 [Optional][LOI/Pre-App], 16-Feb-2027 , 17-May-2027 [Optional][LOI/Pre-App], 16-Jun-2027 , 16-Sep-2027 [Optional][LOI/Pre-App], 16-Oct-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to encourage research applications that pilot test patient navigation Emergency Department (ED) diversion models for non-urgent mental health problems. A non-urgent ED visit is that for which a delay of several hours would not increase the potential for an adverse outcome to occur. For the purposes of this NOFO, NIMH defines a patient navigation model as an evidence-based intervention that is delivered by a mental health provider, an allied provider such as a nurse, or a lay provider (e.g., peer, community health worker) whose role is to (a) utilize</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>triage tools to identify mental health acuity, (b) provide emotional support and build mental health knowledge amongst caregivers, c) facilitate linkages to mental health services and additional resources as needed to support the family, and (d) address barriers to help-seeking. This NOFO is for 1) established navigator models that have limited evidence and need pilot testing to detect a signal, and (2) development and pilot testing of components of navigator models. Support for larger-scale or fully powered studies is provided through a companion NOFO that utilizes the R01 mechanism: PAR-25-289 (R01 Clinical Trial Required).</p>				
128913	Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-282	16-Jun-2025	275,000 USD
	Contact Name	Laura M. Rowland, Ph.D.			
	Contact Telephone	301-792-3242			
	Contact Email	laura.rowland@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts. This NOFO uses the R21 mechanism, while the companion NOFO PAR-25-281 uses the R01 grant mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism, while applicants with preliminary data who seek longer-term funding may wish to apply using the R01 mechanism.</p>			
128914	Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-291	16-Jun-2025	275,000 USD
	Contact Name	Jessica Tilghman, Ph.D.			
	Contact Telephone	301-827-0439			
	Contact Email	jessica.tilghman@nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This NOFO aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Intervention-development clinical trials of therapeutic devices are outside the scope of this NOFO, though development of novel tools/methods to enable relevant mental health studies is encouraged. This NOFO uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity, PAR-25-290, seeks R01 grant applications.</p>				
128987	Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25-184	18-May-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Margaret Grabb, Ph.D.</p> <p>Contact Telephone 301-443-3563</p> <p>Contact Email mgrabb@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025 , 15-Sep-2025 [Optional][LOI/Pre-App], 15-Oct-2025 , 14-Jan-2026 [Optional][LOI/Pre-App], 13-Feb-2026 , 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026 , 15-Sep-2026 [Optional][LOI/Pre-App], 15-Oct-2026 , 18-Jan-2027 [Optional][LOI/Pre-App], 17-Feb-2027 , 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-2027 , 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027</p> <p>Synopsis NIMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this NOFO is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or neuromodulatory device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>subjects (a prodromal phase) prior to full diagnostic criteria being met. Ultimately, this NOFO is intended to support evaluation of pharmacologic or neuromodulatory device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult, and geriatric-focused interventions are appropriate for this NOFO. The R61/R33 NOFOs are intended to support biphasic high-risk applications. Support for a single phased award that does not need the developmental (R61) phase is available in the companion R33, PAR-25-183. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion NOFOs listed above.</p>				
128986	Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33 - Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25-183	18-May-2025 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Margaret Grabb, Ph.D.			
	Contact Telephone	301-443-3563			
	Contact Email	mgrabb@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025 , 15-Sep-2025 [Optional][LOI/Pre-App], 15-Oct-2025 , 14-Jan-2026 [Optional][LOI/Pre-App], 13-Feb-2026 , 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026 , 15-Sep-2026 [Optional][LOI/Pre-App], 15-Oct-2026 , 18-Jan-2027 [Optional][LOI/Pre-App], 17-Feb-2027 , 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-2027 , 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027			
	Synopsis	<p>NIMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this NOFO is to support the early-stage testing of pharmacologic interventions with novel mechanisms of action or neuromodulatory device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness. Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this NOFO is intended to support early-stage testing of pharmacologic or neuromodulatory device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult, and geriatric-focused interventions are appropriate for this NOFO. This R33 NOFO supports single-phased clinical trial awards. Applicants proposing high-risk projects are encouraged to apply to one of the companion NOFOs, PAR-25-</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	184 or PAR-25-180.				
128988	Effectiveness Trials to Test Mental Health System Interventions (R61/R33 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25-285	18-May-2025 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Shahrzad Mavandadi, PhD			
	Contact Telephone	301-827-1167			
	Contact Email	shahrzad.mavandadi@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025 , 15-Sep-2025 [Optional][LOI/Pre-App], 15-Oct-2025 , 14-Jan-2026 [Optional][LOI/Pre-App], 13-Feb-2026 , 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026 , 15-Sep-2026 [Optional][LOI/Pre-App], 15-Oct-2026 , 18-Jan-2027 [Optional][LOI/Pre-App], 17-Feb-2027 , 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-2027 , 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027			
	Synopsis	<p>NIMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. This NOFO complements NIMH's suite of clinical trial funding opportunities by supporting milestone-driven feasibility and infrastructure development (R61) research followed by well-powered clinical trials (R33) to test the effectiveness of system interventions or strategies that improve the organization, delivery, coordination, and outcomes of mental health care for priority populations. System interventions - which may span, for example, structural, policy, and organizational domains - attend to issues about the access, equity, engagement/utilization, value (cost/financing), management, or quality and safety of mental health services, with the goal of improved care processes and clinical, functional, or population level outcomes. Accordingly, the focus of system interventions may include multiple factors/levels related to care delivered within or across a variety of care settings, such as health systems and organizations, mental health and community clinics, schools, and social welfare or justice systems. Projects may test the impact of policies and practices, interventions to facilitate care transitions and continuity across settings, and interventions to improve linkages/coordination across systems. Researchers will have up to two years in the R61 phase to demonstrate feasibility and adequate infrastructure to justify conducting the main trial (R33). Applicants pursuing other stages of intervention development and testing should refer to companion NOFOs listed at Support for Clinical Trials at NIMH.</p>			
128982	First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders (U01	National Institute of Mental Health/NIH/DHHS	PAR-25-180	18-May-2025 [Optional][LOI/Pre-	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Clinical Trial Required)		App]			
	<p>Contact Name Enrique Michelotti, Ph.D.</p> <p>Contact Telephone 301-443-5415</p> <p>Contact Email michelottiel@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025 , 15-Sep-2025 [Optional][LOI/Pre-App], 15-Oct-2025 , 14-Jan-2026 [Optional][LOI/Pre-App], 13-Feb-2026 , 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026 , 15-Sep-2026 [Optional][LOI/Pre-App], 15-Oct-2026 , 18-Jan-2027 [Optional][LOI/Pre-App], 17-Feb-2027 , 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-2027 , 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027</p> <p>Synopsis NIMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this NOFO is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action investigational drugs or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The NOFO will support milestone-driven early stage trials, including First-in-human (FIH), Phase Ib, Phase II/PoC and early feasibility studies (EFS), in pediatric and adult populations. These studies are designed to objectively and dose dependently assess target engagement in the central nervous system (CNS), along with safety and tolerability. Phase II/PoC studies additionally must evaluate the drug's/device's impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The overall objective of this NOFO is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private or other public funding (when appropriate) for further clinical development as Food and Drug Administration (FDA)-approved treatments. A key aspect of this NOFO is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development. This NOFO is designed for applicants seeking funding for cooperative agreements supporting early stage clinical trials as outlined above. Applicants pursuing other stages of the clinical trial pipeline or funding for clinical research not involving cooperative agreements should consider one of the companion NOFOs listed above.</p>				
128979	Confirmatory Efficacy Clinical Trials of Non-Pharmacological and Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25-179	18-May-2025 [Optional][LOI/Pre-App]	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Joel Sherrill, Ph.D.</p> <p>Contact Telephone 301-443-2477</p> <p>Contact Email jsherril@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025 , 15-Sep-2025 [Optional][LOI/Pre-App], 15-Oct-2025 , 14-Jan-2026 [Optional][LOI/Pre-App], 13-Feb-2026 , 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026 , 15-Sep-2026 [Optional][LOI/Pre-App], 15-Oct-2026 , 18-Jan-2027 [Optional][LOI/Pre-App], 17-Feb-2027 , 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-2027 , 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027</p> <p>Synopsis NIMH solicits clinical trial applications through a series of notices of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this NOFO is to support confirmatory efficacy testing of non-pharmacological preventive and therapeutic interventions, and under certain conditions, selected pharmacological interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to, behavioral, cognitive, interpersonal, and device-based (both invasive/surgically implanted as well as noninvasive/transcranial) approaches, or a combination thereof. Pharmacological interventions to be studied under this grant mechanism are expected to primarily focus on drugs approved for marketing by the FDA (for any indication). These will include medications off-patent which are undergoing development for a new mental health indication. Confirmatory efficacy trials studying monotherapy, combination treatments, and stepped approaches, including multiple treatment modalities, may be supported. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action (target), a preliminary efficacy signal, and must address an unmet therapeutic need. Support will be provided for a trial of the intervention's efficacy that includes measurement of the hypothesized mechanism of action and the relationship between change in the target mechanism and change in functional or clinical effects. Ultimately, this NOFO is intended to support a sufficiently-powered efficacy trial to determine the intervention's potential for significant clinical benefit. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion NOFOs listed above.</p>				
128978	Pilot Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 – Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25-178	18-May-2025 [Optional][LOI/Pre-App]	750,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Joel Sherrill, Ph.D.</p> <p>Contact Telephone 301-443-2477</p> <p>Contact Email jsherril@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025 , 15-Sep-2025 [Optional][LOI/Pre-App], 15-Oct-2025 , 14-Jan-2026 [Optional][LOI/Pre-App], 13-Feb-2026 , 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026 , 15-Sep-2026 [Optional][LOI/Pre-App], 15-Oct-2026 , 18-Jan-2027 [Optional][LOI/Pre-App], 17-Feb-2027 , 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-2027 , 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027</p> <p>Synopsis NIMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of interventions, confirmatory efficacy trials, through to effectiveness trials. This NOFO seeks pilot hybrid effectiveness implementation research consistent with NIMH's priorities for: 1) refining and optimizing preventive and therapeutic interventions with previously demonstrated efficacy for use with broader target populations or for delivery routine care, school, community, or online settings, and 2) research on implementation strategies that support the delivery and sustainability of evidence supported interventions in accessible settings. This NOFO supports pilot research designed to generate the preliminary data needed as a prerequisite to a well powered clinical trial. This includes research designed to assess the feasibility, acceptability, safety, and fit of approach, and explore the impact of the approach on both the outcomes of interest and at least one hypothesized mechanism of action. Support for well powered hybrid effectiveness implementation studies is provided through separate NOFOs that are described on the NIMH Support for Clinical Trials web page.</p>				
119255	Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-064	16-Jun-2025	275,000 USD
	<p>Contact Name Laura M. Rowland, Ph.D.</p> <p>Contact Telephone 301-480-8335</p> <p>Contact Email laura.rowland@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026</p> <p>Synopsis The goal of this Notice of Funding Opportunity (NOFO) is to encourage applications for studies that will enhance knowledge</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This NOFO uses the R21 mechanism, while the companion PAR-25-065 uses the R01 grant mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism, while applicants with preliminary data who seek longer-term funding should apply using the R01 mechanism.</p>				
115199	Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25-034	20-Jun-2025	Not Specified
	Contact Name	Jamie Driscoll			
	Contact Telephone	301-443-5288			
	Contact Email	jdrisco1@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	20-Jun-2025			
	Synopsis	<p>The goal of this initiative is to identify neurophysiological measures as potential assays for treatment development research. The Funding Opportunity Announcement (FOA) will support efforts to optimize and evaluate pharmacodynamic (PD) measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data may also reveal assay measures where performance is dissimilar between preclinical animal species and humans, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate goal of this FOA is to improve the efficiency of the therapeutic development process by identifying congruent measures as well as inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates. The objectives of the FOA will be accomplished by supporting partnerships among basic and translational neuroscientists who are committed to advancing the discovery of in vivo physiological measures as tools for target validation and therapeutic development. Groups will be tasked with developing and optimizing in vivo assays of brain processes in both animals and in healthy humans. Groups will evaluate assay performance across both species in response to pharmacologic manipulations. In this way, projects will reveal the potential of specific assays to translate from animals to humans, suggesting assays for further development as tools in the treatment development pipeline.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
125860	NINDS Research Education Opportunities (R25 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-200	16-Jun-2025 [Optional][LOI/Pre-App]	1,250,000 USD
<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Letitia Weigand, Ph.D.</div> <div>301-496-4188</div> <div>DirectorOTWD@ninds.nih.gov</div> <div></div> <div>Link to program URL</div> <div>16-Jun-2025 [Optional][LOI/Pre-App], 15-Jul-2025 , 15-Jun-2026 [Optional][LOI/Pre-App], 14-Jul-2026</div> <div> <p>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development Research Experiences The purpose of this funding opportunity announcement is to encourage applications for the initiation or continuation of nationally available neuroscience research education programs that will significantly advance the mission of NINDS. The primary focus of programs submitted under this FOA should be on intensive hands-on experience that will provide research experience, an in-depth understanding of techniques, analytic approaches and theory, and expertise that is only possible from a nationally organized program. Within the context of gaining expertise primarily through hands-on experience, programs must also include immersive coursework and expert discussion when appropriate. Programs appropriate for this NOFO must include a nationwide recruitment process to encourage applications from prospective participants and an established application and selection process.</p> </div> </div>					
128115	Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-294	15-Jun-2025 [Optional][LOI/Pre-App]	Not Specified
<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> </div> <div> <div>Lauren Friedman, Ph.D.</div> <div>301-827-5065</div> <div>lauren.friedman@nih.gov</div> <div></div> <div>Link to program URL</div> </div>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 15-Jun-2025 [Optional][LOI/Pre-App], 15-Jul-2025 , 16-Dec-2025 [Optional][LOI/Pre-App], 15-Jan-2026 , 15-Jun-2026 [Optional][LOI/Pre-App], 15-Jul-2026 , 16-Dec-2026 [Optional][LOI/Pre-App], 15-Jan-2027 , 15-Jun-2027 [Optional][LOI/Pre-App], 15-Jul-2027</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to provide funding, resources, and expertise to accelerate the development of diverse biotherapeutic modalities — including but not limited to antibodies, peptides, proteins, oligonucleotides, gene therapies, cell therapies, and other emerging therapeutic modalities — for the treatment of nervous and neuromuscular system disorders. The Blueprint Neurotherapeutics Network for Biologics (BPN Biologics) program provides support for biologics-based therapy discovery and development activities from lead optimization through first-in-human clinical trials. This NOFO is a phased, milestone-driven cooperative agreement that involves close collaboration and regular interactions with NIH program staff. Awarded projects will receive funding for investigator-led research activities to be conducted in their own laboratories and assistance from NIH-funded consultants with industry and regulatory experience. Participants may also augment their project through collaboration with NIH-funded contract research organizations that specialize in manufacturing, nonclinical studies, and early phase clinical trials. Recipient institutions will retain their rights to existing intellectual property and are assigned rights to any new IP developed within the program.</p>				
128113	Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-293	15-Jun-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Lauren Friedman, Ph.D.</p> <p>Contact Telephone 301-827-5065</p> <p>Contact Email lauren.friedman@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2025 [Optional][LOI/Pre-App], 15-Jul-2025 , 16-Dec-2025 [Optional][LOI/Pre-App], 15-Jan-2026 , 15-Jun-2026 [Optional][LOI/Pre-App], 15-Jul-2026 , 16-Dec-2026 [Optional][LOI/Pre-App], 15-Jan-2027 , 15-Jun-2027 [Optional][LOI/Pre-App], 15-Jul-2027</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to provide funding, resources, and expertise to accelerate the development of diverse biotherapeutic modalities — including but not limited to antibodies, peptides, proteins, oligonucleotides, gene therapies, cell therapies, and other emerging therapeutic modalities — for the treatment of nervous and neuromuscular system disorders. The Blueprint Neurotherapeutics Network for Biologics (BPN Biologics) program provides support for biologics-based therapy discovery and development activities from lead optimization through first-in-human clinical trials. This NOFO is a phased, milestone-driven cooperative agreement that involves close collaboration and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>regular interactions with NIH program staff. Awarded projects will receive funding for investigator-led research activities to be conducted in their own laboratories and assistance from NIH-funded consultants with industry and regulatory experience. Participants may also augment their project through collaboration with NIH-funded contract research organizations that specialize in manufacturing, nonclinical studies, and early phase clinical trials. Recipient institutions will retain their rights to existing intellectual property and are assigned rights to any new IP developed within the program.</p>				
116940	RFA-NS-25-017 -- BRAIN Initiative: Optimization of Instrumentation and Device Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-25-017	03-Apr-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Grace M. Hwang, PhD</p> <p></p> <p>BRAIN-FOAs@nih.gov</p> <p></p> <p>Link to program URL</p> <p>03-Apr-2025 [Optional][LOI/Pre-App], 02-Jun-2025 , 21-Nov-2025 [Optional][LOI/Pre-App], 20-Jan-2026</p> <p>This Notice of Funding Opportunity (NOFO) seeks applications to optimize instrumentation and device technologies for recording and modulation of neural cells and circuits, to address major challenges and to enable transformative understanding of dynamic signaling in the central nervous system. It is expected that the proposed technologies and approaches have previously demonstrated their transformative potential through initial proof-of-concept testing, and are ready for accelerated refinement through iterative engineering and end-user feedback, appropriate for a path towards sustainable dissemination and user-friendly incorporation into routine neuroscience research. Applications may propose development of instrumentation hardware and/or devices and associated software. Approaches may utilize any modality such as optical, electrical, magnetic, or acoustic recording/manipulation, to target neuronal electrical signals or other forms of neural activity, including intracellular signaling and engagement of non-neuronal cells in circuit function. This NOFO is a re-issue of RFA-NS-21-027, but unlike the previous NOFO the focus is narrowed to technologies associated with recording/manipulation instrumentation and devices, and excludes projects primarily focused on development of molecular reagents. Potential applicants primarily optimizing molecular constructs should consider RFA-MH-22-245 (or its reissue), BRAIN Initiative: Engineering and optimization of molecular technologies for functional dissection of neural circuits (UM1 Clinical Trial Not Allowed). For projects at an earlier stage of development of molecular reagents, potential applicants should consider the companion FOA (RFA-NS-25-018) or alternative BRAIN Initiative announcements including RFA-MH-21-175 and RFA-EY-21-001 (or their reissues). For this and the companion NOFO, the aim of the proposed technologies should be to reduce major barriers to conducting neurobiological experiments, including considerations of cost and ease of access, and</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>to enable new discoveries for understanding neural circuit function. Technologies should address major challenges associated with recording and modulating CNS activity, at cellular or circuit resolution, and should contribute to an overall ecosystem of technologies spanning multiple spatial and temporal scales in any region throughout the CNS. The approaches should be compatible with experiments in behaving animals, with an expectation that they will be validated with in vivo experiments during the course of the project. Proposed validation experiments must focus on demonstrating the capabilities and potential impact of the technology, rather than advancing the state of biological knowledge as the primary project goal. Applications are encouraged to integrate multiple approaches, and where appropriate, to leverage diverse domains of expertise from biological, chemical, and physical sciences, engineering, computational modeling, and statistical analysis. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
116939	RFA-NS-25-018 -- BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-25-018	03-Apr-2025 [Optional][LOI/Pre-App]	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Grace M. Hwang, PhD BRAIN-FOAs@nih.gov Link to program URL 03-Apr-2025 [Optional][LOI/Pre-App], 02-Jun-2025 , 21-Nov-2025 [Optional][LOI/Pre-App], 20-Jan-2026 This FOA seeks applications for proof-of-concept testing and development of new technologies and novel approaches for recording and modulation of neural cells and circuits, to address major challenges and enable transformative understanding of dynamic signaling in the central nervous system. Preliminary feasibility data are not required, and it is expected that the proposed research may be high-risk, but if successful could profoundly change the course of neuroscience research. Applications may propose development of instrumentation hardware and/or devices and associated software, and/or molecular constructs for sensing and manipulating neural activity. Approaches may utilize any modality such as optical, electrical, magnetic, or acoustic recording/manipulation, to target neuronal electrical signals or other forms of neural activity, including intracellular signaling and engagement of non-neuronal cells in circuit function. A companion FOA (RFA-NS-24-005) is targeted to projects focused on optimization of instrumentation and devices that are later in the development cycle, where iterative optimization and end-user testing is needed. The companion FOA does not allow projects primarily focused on development or optimization of molecular constructs for recording and manipulating neural activity. Projects of this nature are supported by this FOA and other BRAIN Initiative announcements including RFA-MH-22-245, RFA-MH-21-175, and RFA-EY-21-001. For this and the companion FOA, the aim of the proposed technologies should be to reduce major			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>barriers to conducting neurobiological experiments, including considerations of cost and ease of access, and to enable new discoveries for understanding neural circuit function. Technologies should address major challenges associated with recording and modulating CNS activity, at cellular or circuit resolution, and should contribute to an overall ecosystem of technologies spanning multiple spatial and temporal scales in any region throughout the CNS. The approaches should be compatible with experiments in behaving animals, with an expectation that they will be validated with in vivo experiments during the course of the project. Proposed validation experiments must focus on demonstrating the capabilities and potential impact of the technology, rather than advancing the state of biological knowledge as the primary project goal. Applications are encouraged to integrate multiple approaches, and where appropriate, to leverage diverse domains of expertise from biological, chemical, and physical sciences, engineering, computational modeling, and statistical analysis. This FOA requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.</p>				
111360	Notice of Special Interest (NOSI): Disease Mechanisms of Prenatal and Pediatric Hydrocephalus	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS-23-004	07-May-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Jill Morris, Ph.D.</p> <p>301-496-5754</p> <p>jill.morris@nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025</p> <p>The purpose of this Notice is to inform potential applicants about an area of special interest to NINDS in hypothesis-driven research projects that focus on deciphering the molecular, cellular and developmental mechanisms involved in the pathogenesis of prenatal and/or pediatric hydrocephalus and to examine new approaches for treatment.</p>			
128304	Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-116	06-May-2025 [Optional][LOI/Pre-App]	2,499,995 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p>	<p>William Daley, Ph.D.</p> <p>301-496-1431</p> <p>william.daley@nih.gov</p> <p></p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications focused on the neurological and/or mental health-related manifestations of infection-associated chronic illnesses, including the post-acute sequelae of COVID-19 (Neuro-PASC) as well as other chronic illnesses with a potential infectious trigger (post-treatment Lyme Disease, myalgic encephalomyelitis/chronic fatigue syndrome [ME/CFS], postural orthostatic tachycardia syndrome [POTS], post-viral fatigue syndromes, etc.). Projects that investigate common neurological and/or mental health-related mechanisms across multiple infection-associated chronic illnesses would be of particular interest, although this is not a requirement (i.e., applications can focus on a single condition). Neurologically focused clinical research investigating scientifically compelling pathways that contribute to the development of infection-associated chronic illnesses - including basic experimental studies in humans (BESH) or mechanistic clinical trials that will accelerate the development of effective treatments - are within the scope of this initiative. Preclinical studies utilizing animal, cell culture, and/or human tissue models are also encouraged. All applications must propose such studies in the context of a post-infectious etiology.</p>				
126685	NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-228	07-May-2025	Not Specified
	<p>Contact Name Michelle Jones-London, Ph.D.</p> <p>Contact Telephone 301-451-7966</p> <p>Contact Email NINDSDiversityTraining@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027</p> <p>Synopsis The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to enhance participation in the independent neuroscience research workforce by providing junior faculty from diverse backgrounds, including those from groups underrepresented in biomedical research, with research cost support, protected research time, and career stage-appropriate mentorship and professional development in neuroscience research. Individuals are eligible for support under this award if they are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This notice of funding opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion NOFO (PAR-24-229).				
126698	NINDS Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-212	12-Jun-2025	Not Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Amelie Gubitz, Ph.D.</div> <div>301-451-7966</div> <div>ADRDK99@ninds.nih.gov</div> <div></div> <div>Link to program URL</div> <div>12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027</div> <div>The purpose of the NINDS Alzheimer's Disease-Related Dementias (ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of new and talented, independent investigators from diverse backgrounds, including those from groups underrepresented in biomedical and behavioral sciences (e.g. see NOT-OD-20-031, Notice of NIH's Interest in Diversity), conducting ADRD research. The program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help recipients establish independent research programs in the ADRD field. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO are permitted to propose research experiences in a clinical trial led by a mentor or co-mentor.</div> </div>				
126690	NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-229	07-May-2025	Not Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> </div> <div> <div>Michelle Jones-London</div> <div>301-451-7966</div> <div>NINDSDiversityTraining@mail.nih.gov</div> <div></div> <div>Link to program URL</div> <div>07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-</div> </div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027</p> <p>Synopsis The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to enhance participation in the independent neuroscience research workforce by providing junior faculty from diverse backgrounds, including those from groups underrepresented in biomedical research, with research cost support, protected research time, and career stage-appropriate mentorship and professional development in neuroscience research. Individuals are eligible for support under this award if they are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This notice of funding opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-24-228).</p>				
126699	NINDS Alzheimer's Disease-Related Dementias (ADRD) Advanced Postdoctoral Career Transition Award (K99/R00 Independent Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-213	12-Jun-2025	Not Specified
	<p>Contact Name Amber McCartney, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email amber.mccartney@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027</p> <p>Synopsis The purpose of the NINDS Alzheimer's Disease-Related Dementias (ADRD) Advanced Postdoctoral Career Transition Award (K99/R00) program is to support a cohort of new and talented, independent investigators conducting ADRD research. The program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help recipients establish independent research programs in the ADRD field. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Candidates to this NOFO are permitted to propose research experiences in a clinical trial led by a mentor or co-mentor.</p>				
115920	NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-049	07-May-2025 [Optional][LOI/Pre-App]	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
129401	Contact Name	Jeremy Brown, MD			
	Contact Telephone	301-594-4481			
	Contact Email	jeremy.brown@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 [Optional][LOI/Pre-App], 06-Jun-2025 , 07-Sep-2025 [Optional][LOI/Pre-App], 07-Oct-2025 , 07-Jan-2026 [Optional][LOI/Pre-App], 06-Feb-2026			
	Synopsis	<p>This Notice of Funding Opportunity (NOFO) encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols. Applicants do not need to be part of the existing SIREN infrastructure to apply under this NOFO. The NIH SIREN Network will also be uniquely poised to collaborate with other U.S. and international consortia necessary to conduct larger, definitive trials of promising interventions for neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN.</p>			
129401	Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-327	09-Jun-2025	Not Specified
	Contact Name	Chris Boshoff, Ph.D.			
	Contact Telephone	301-496-1779			
	Contact Email	chris.boshoff@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	09-Jun-2025 , 09-Oct-2025 , 09-Feb-2026 , 09-Jun-2026 , 09-Oct-2026 , 09-Feb-2027 , 09-Jun-2027 , 08-Oct-2027			
	Synopsis	<p>The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this funding opportunity announcement (FOA) is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	specified patient population towards an IND filing and the initiation of a clinical trial.				
128662	NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-234	07-May-2025	Not Specified
	Contact Name	Tish Weigand, Ph.D.			
	Contact Telephone	301-496-4188			
	Contact Email	letitia.weigand@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 09-Jun-2025 , 07-Sep-2025 , 09-Oct-2025 , 07-Jan-2026 , 09-Feb-2026 , 07-May-2026 , 09-Jun-2026 , 07-Sep-2026 , 09-Oct-2026 , 07-Jan-2027 , 09-Feb-2027 , 07-May-2027 , 09-Jun-2027 , 07-Sep-2027 , 08-Oct-2027 , 07-Jan-2028			
	Synopsis	<p>The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months (or 18 months for resubmissions) after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 4 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early, thoughtful planning and timely completion of "mentored training" within a particular lab or environment. This Notice of Funding Opportunity (NOFO) does not allow candidates to propose to lead an independent clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>			
129033	Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-216	12-Jun-2025	Not Specified
	Contact Name	Letitia Weigand, Ph.D.			
	Contact Telephone				
	Contact Email	letitia.weigand@nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
129031	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027 , 12-Oct-2027			
	Synopsis	This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-25-215).			
	Contact Name	Letitia Weigand, Ph.D.			
	Contact Telephone				
128305	Contact Email	letitia.weigand@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027 , 12-Oct-2027			
	Synopsis	This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PAR-25-216).			
128305	Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R21 - Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-115	17-May-2025 [Optional][LOI/Pre-App]	400,000 USD
	Contact Name	William Daley, Ph.D.			
	Contact Telephone	301-496-1431			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email william.daley@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-May-2025 [Optional][LOI/Pre-App], 16-Jun-2025 , 16-Sep-2025 [Optional][LOI/Pre-App], 16-Oct-2025</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications focused on the neurological and/or mental health-related manifestations of infection-associated chronic illnesses, including the post-acute sequelae of COVID-19 (Neuro-PASC) as well as other chronic illnesses with a potential infectious trigger (post-treatment Lyme Disease, myalgic encephalomyelitis/chronic fatigue syndrome [ME/CFS], postural orthostatic tachycardia syndrome [POTS], post-viral fatigue syndromes, etc.). Projects that investigate common neurological and/or mental health-related mechanisms across multiple infection-associated chronic illnesses would be of particular interest, although this is not a requirement (i.e., applications can focus on a single condition). Neurologically focused clinical research investigating scientifically compelling pathways that contribute to the development of infection-associated chronic illnesses - including basic experimental studies in humans (BESH) or mechanistic clinical trials that will accelerate the development of effective treatments - are within the scope of this initiative. Preclinical studies utilizing animal, cell culture, and/or human tissue models are also encouraged. All applications must propose such studies in the context of a post-infectious etiology.</p>				
127141	<p>Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Basic Experimental Studies with Humans Required (BESH))</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-227	07-May-2025	Not Specified
	<p>Contact Name Lanay M. Mudd, Ph.D., FACSM</p> <p>Contact Telephone 301-594-9346</p> <p>Contact Email lanay.mudd@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027</p> <p>Synopsis The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) program is to support a cohort of early career, independent investigators from diverse backgrounds (for example, individuals from underrepresented groups) conducting research in NIH mission areas. The program has two components: an individual career transition award for postdoctoral scholars (K99/R00) and a research education cooperative agreement (UE5) awarded</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>to organizations to provide these scholars with additional mentoring, networking and professional development activities to support their transition to and success in independent, tenure-track or equivalent research-intensive faculty careers. The MOSAIC program supports NIH's efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The goal of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds from their mentored postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The program is designed to support postdoctoral researchers who have demonstrated meaningful contributions and proposed compelling future plans to promote broad participation in the biomedical research workforce, such as activities that promote inclusive, supportive, and accessible biomedical research environments that support the success of trainees and scientists from all backgrounds, including individuals from underrepresented groups. This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>				
128868	Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAS-25-190	05-Jun-2025	Not Specified
	Contact Name	Lauren Ullrich, Ph.D.			
	Contact Telephone	301-451-7966			
	Contact Email	NINDSDiversityTraining@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027			
	Synopsis	This Notice of Funding Opportunity (NOFO) solicits R01 grant applications that would support independent research projects within the scientific mission areas of the participating NIH Institutes or Centers from a diverse cohort of New Investigators and At-Risk Investigators.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
128336	Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-225	18-Jun-2025	750,000 USD
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Becky Roof, PhD</div> <div>301-496-1779</div> <div>rebecca.roof@nih.gov</div> <div></div> <div>Link to program URL</div> <div>18-Jun-2025 , 20-Oct-2025 , 18-Feb-2026 , 18-Jun-2026 , 20-Oct-2026 , 18-Feb-2027 , 18-Jun-2027 , 20-Oct-2027</div> <div>This Notice of Funding Opportunity (NOFO) provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission. Therapeutic agents include small molecules or biologics. This NOFO is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE).</div> </div>				
128339	Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-060	18-Jun-2025	750,000 USD
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Becky Roof, PhD</div> <div>301-496-1779</div> <div>rebecca.roof@nih.gov</div> <div></div> <div>Link to program URL</div> <div>18-Jun-2025 , 20-Oct-2025 , 18-Feb-2026 , 18-Jun-2026 , 20-Oct-2026 , 18-Feb-2027 , 18-Jun-2027 , 20-Oct-2027</div> <div>This Notice of Funding Opportunity (NOFO) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this NOFO is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Models proposed for this NOFO would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention. This NOFO is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery. This Notice of Funding Opportunity (NOFO)</div> </div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	requires a Plan for Enhancing Diverse Perspectives (PEDP).				
123196	NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-052	20-Jun-2025	Not Specified
	Contact Name	Scott Janis, Ph.D.			
	Contact Telephone	301-496-9135			
	Contact Email	moyc@ninds.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	20-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 19-Oct-2026			
	Synopsis	<p>This NOFO encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet. Following peer review, NINDS will prioritize studies among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. The NIH StrokeNet network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for stroke treatment, prevention, and recovery. It is NINDS's intent that all NINDS-supported multi-center clinical trials in stroke treatment, recovery, or prevention will be conducted within the NIH StrokeNet. Only in exceptional circumstances will NINDS consider funding multi-site stroke clinical trials outside of this network. This NOFO uses the bi-phasic, milestone driven UG3/UH3 cooperative agreement activity code. Awards made under this NOFO will initially support a one-year milestone-driven planning and start-up phase, with possible transition to an implementation (UH3) phase of up to 6 additional years. Only UG3 projects that meet the scientific milestones and award requirements of the UG3 phase may transition to the UH3 phase. Applications submitted in response to this FOA must address both the UG3 and UH3 phases and are expected to include plans for project management and performance milestones for each phase. Applicants do not need to be part of the existing NIH StrokeNet infrastructure to apply under this NOFO.</p>			
109940	Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-048	07-May-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Adam L. Hartman, MD</p> <p>Contact Telephone 301-496-9135</p> <p>Contact Email adam.hartman@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 18-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS) (note: only prospective observational studies will be considered). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.</p>				
123614	Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-098	20-Jun-2025	Not Specified
	<p>Contact Name Carol Taylor-Burds, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email carol.taylor-burds@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 20-Jun-2025 , 20-Feb-2026 , 22-Jun-2026</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support rigorous analytical validation of method(s) used for measuring biomarkers for neurological and neuromuscular disorders for use in clinical trials or clinical practice. Applicants must justify the unmet need for the biomarker(s) and measurement methods and specify one or two context(s) of use for the biomarker(s). Activities supported include optimizing and evaluating the accuracy, precision, reportable range, and analytical sensitivity and specificity of the detection method across multiple sites and operators and establishing reference intervals and quality control procedures. Multi-site applications are expected but not required. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: Transdisciplinary research projects and collaborations among neuroscientists and researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. Opportunities to enhance the research environment to benefit early- and mid-career investigators."</p>				
123611	Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-096	20-Jun-2025	Not Specified
	Contact Name	Carol Taylor-Burds, PhD			
	Contact Telephone	301-496-1779			
	Contact Email	carol.taylor-burds@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	20-Jun-2025 , 20-Feb-2026 , 22-Jun-2026			
	Synopsis	<p>The purpose of this notice of funding opportunity (NOFO) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>carefully and view the available PEDP guidance material. The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: Transdisciplinary research projects and collaborations among neuroscientists and researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. Opportunities to enhance the research environment to benefit early- and mid-career investigators."</p>				
123610	Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-050	20-May-2025 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Carol Taylor-Burds, PhD			
	Contact Telephone	301-496-1779			
	Contact Email	carol.taylor-burds@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	20-May-2025 [Optional][LOI/Pre-App], 20-Jun-2025 , 21-Jan-2026 [Optional][LOI/Pre-App], 20-Feb-2026 , 23-May-2026 [Optional][LOI/Pre-App], 22-Jun-2026			
	Synopsis	<p>The purpose of this notice of funding opportunity (NOFO) is to support rigorous analytical validation of method(s) used for measuring biomarkers for neurological and neuromuscular disorders for use in clinical trials or clinical practice. Applicants must justify the unmet need for the biomarker(s) and measurement methods and specify one or two context(s) of use for the biomarker(s). Activities supported include optimizing and evaluating the accuracy, precision, reportable range, and analytical sensitivity and specificity of the detection method across multiple sites and operators and establishing reference intervals and quality control procedures. Multi-site applications are expected but not required. This NOFO requires a Plan for</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: Transdisciplinary research projects and collaborations among neuroscientists and researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. Opportunities to enhance the research environment to benefit early- and mid-career investigators.</p>				
123613	Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-055	21-May-2025 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Carol Taylor-Burds, PhD			
	Contact Telephone	301-496-1779			
	Contact Email	carol.taylor-burds@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	21-May-2025 [Optional][LOI/Pre-App], 20-Jun-2025 , 21-Jan-2026 [Optional][LOI/Pre-App], 20-Feb-2026 , 23-May-2026 [Optional][LOI/Pre-App], 22-Jun-2026			
	Synopsis	<p>The purpose of this notice of funding opportunity (NOFO) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation.				
128451	Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-024	07-May-2025	Not Specified
	Contact Name	Carol Taylor-Burds Ph.D			
	Contact Telephone	301-496-1779			
	Contact Email	carol.taylor-burds@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 21-May-2025 [Optional][LOI/Pre-App], 20-Jun-2025 , 07-Sep-2025 , 20-Sep-2025 [Optional][LOI/Pre-App], 20-Oct-2025 , 07-Jan-2026 , 21-Jan-2026 [Optional][LOI/Pre-App], 20-Feb-2026 , 07-May-2026 , 23-May-2026 [Optional][LOI/Pre-App], 22-Jun-2026 , 07-Sep-2026 , 20-Sep-2026 [Optional][LOI/Pre-App], 20-Oct-2026 , 07-Jan-2027 , 23-Jan-2027 [Optional][LOI/Pre-App], 22-Feb-2027 , 07-May-2027 , 22-May-2027 [Optional][LOI/Pre-App], 21-Jun-2027 , 07-Sep-2027 , 20-Sep-2027 [Optional][LOI/Pre-App], 20-Oct-2027 , 07-Jan-2028			
	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to promote the development of fit-for-purpose candidate biomarkers and composite biomarker that enable more efficient clinical trials advance therapeutic development or clinical practice help guide clinical care decisions. Specifically, the goal of this phased funding mechanism is to first identify or confirm candidate biomarker(s) or biomarker signatures using human samples and/or data, followed by an independent retrospective or prospective clinical study to conduct initial clinical validation of the biomarker/signature's clinical utility for one or two defined Context(s) of Use. In the first phase, applicants are expected to demonstrate that the biomarker acceptably identifies or predicts the concept of interest and may include optimization of the detection method using carefully standardized human samples or datasets. The overarching purpose of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).			
128722	Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 - Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25-170	21-May-2025 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Scott Janis, Ph.D.			
	Contact Telephone	301-496-9135			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email moyc@ninds.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-May-2025 [Optional][LOI/Pre-App], 20-Jun-2025 , 21-Jan-2026 [Optional][LOI/Pre-App], 20-Feb-2026 , 23-May-2026 [Optional][LOI/Pre-App], 22-Jun-2026</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support rigorous development and validation of Digital Health Technology (DHT) derived biomarkers or clinical outcome assessments (COAs) for remote monitoring to fill a defined unmet clinical endpoint for interventional clinical trials. To increase standardization and improve clinical adoption, applicants must propose to develop and evaluate the DHT enabled biomarkers or COAs in three or more diseases or conditions. Applicants must also propose to conduct development studies that are informed by people with lived experience (PWLE) and patient advocacy organizations. The first phase of this funding mechanism is to evaluate the technical performance of the proposed DHTs with PWLE input; the second phase is to support a prospective longitudinal clinical study in representative populations to validate the DHT. Research outcomes should include demonstrating how a meaningful change in the biomarkers or COAs derived from the DHT(s) can be statistically measured and quantified at the individual participant level.</p>				
111323	Notice of Special Interest (NOSI): Tools to Enhance the Study of Prenatal and Pediatric Hydrocephalus	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS-23-003	07-May-2025	Not Specified
	<p>Contact Name Jill Morris, Ph.D.</p> <p>Contact Telephone 301-496-5754</p> <p>Contact Email jill.morris@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025</p> <p>Synopsis The purpose of this Notice is to inform potential applicants about an area of special interest to NINDS in research to develop or substantially modify existing cutting-edge tools that will advance prenatal and/or pediatric hydrocephalus research. Applications should aim to transform the field of prenatal and/or pediatric hydrocephalus research by generating tools including animal and cell models, novel methods and innovative technologies that will be widely used throughout the neuroscience community to understand disease mechanisms and/or developing therapeutics.</p>				
129691	Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PA-25-150	07-May-2025	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Karrah Benson</p> <p>Contact Telephone 301-496-0838</p> <p>Contact Email Karrah.benson@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The Joint NINDS/NIMH Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community. While this funding opportunity also accepts clinical trials, only applications proposing “mechanistic clinical trials or studies” (studying pathophysiology or mechanism of action of an intervention, but not safety or efficacy) or basic experimental studies with humans (BESH) will be supported. For information on NIH clinical trial definitions and the types of clinical trials that are within scope of this funding opportunity announcement refer to the NIH Definition of a Clinical Trial page and the Funding Opportunity Description, below, respectively.</p>				
126781	<p>NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Patient-Oriented Research Career Development award (K23 - Clinical Trial Required)</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-220	12-Jun-2025	Not Specified
	<p>Contact Name Laura D. Wandner</p> <p>Contact Telephone</p> <p>Contact Email Laura.Wandner@nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 12-Nov-2025 , 12-Feb-2026 , 12-Mar-2026 , 12-Jun-2026 , 12-Jul-2026 , 12-Oct-2026 , 12-Nov-2026 , 12-Feb-2027 , 12-Mar-2027 , 12-Jun-2027 , 12-Jul-2027</p> <p>Synopsis The purpose of the NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Patient-Oriented Research Career Development award (K23) (Clinical Trial Required) is to support the career development of individuals with clinical</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>doctoral degrees to create a group of new and well-trained, independent investigators. This supervised career development program will provide independent NIH research support during the early-career phase to help recipients establish independent research programs in areas supported by the NIH HEAL Initiative's Clinical Research in Pain Management program. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion NOFO.</p>				
126790	NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08 - Clinical Trials Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-219	12-Jun-2025	Not Specified
	Contact Name	Laura D. Wandner			
	Contact Telephone				
	Contact Email	Laura.Wandner@nih.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 12-Nov-2025 , 12-Feb-2026 , 12-Mar-2026 , 12-Jun-2026 , 12-Jul-2026 , 12-Oct-2026 , 12-Nov-2026 , 12-Feb-2027 , 12-Mar-2027 , 12-Jun-2027 , 12-Jul-2027			
	Synopsis	<p>The purpose of this NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08 - Clinical Trials Not Allowed) is to support the career development of individuals with clinical doctoral degrees to create a group of new and well-trained, independent investigators. This supervised career development program will provide independent NIH research support during the early-career phase to help recipients establish independent research programs in areas supported by the NIH HEAL Initiative's Clinical Research in Pain Management program. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator should apply to the companion NOFO. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.				
126806	NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08 - Clinical Trials Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-217	12-Jun-2025	Not Specified
	Contact Name	Laura D. Wandner			
	Contact Telephone				
	Contact Email	Laura.Wandner@nih.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 12-Nov-2025 , 12-Feb-2026 , 12-Mar-2026 , 12-Jun-2026 , 12-Jul-2026 , 12-Oct-2026 , 12-Nov-2026 , 12-Feb-2027 , 12-Mar-2027 , 12-Jun-2027 , 12-Jul-2027			
	Synopsis	The purpose of this NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08) (Clinical Trials Required) is to support the career development of individuals with clinical doctoral degrees to create a group of new and well-trained, independent investigators. This supervised career development program will provide independent NIH research support during the early-career phase to help recipients establish independent research programs in areas supported by the NIH HEAL Initiative's Clinical Research in Pain Management program. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to a companion NOFO.			
113465	Notice of Special Interest (NOSI): Development of Radiotracers for Diagnosis and Clinical Studies in Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)	National Institute on Aging/NIH/DHHS	NOT-AG-22-032	05-Apr-2025	Not Specified
	Contact Name	Lorenzo M. Refolo, Ph.D.			
	Contact Telephone	301-594-7576			
	Contact Email	refolol@nia.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<div> <div>Deadline Dates (ALL)</div> <div>05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 05-Sep-2025</div> </div> <div> <div>Synopsis</div> <div>This Notice of Special Interest (NOSI) invites applications for research grants that propose to develop radiotracers for Positron Emission Tomography (PET) for use in Alzheimer's disease (AD) and AD-related dementias (ADRD) research targeting new and/or emerging biological process or molecular pathways that have been shown to be relevant in the etiology and pathophysiology of neurodegeneration.</div> </div>					
126708	Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-25-297	06-May-2025 [Optional][LOI/Pre-App]	Not Specified
<div> <div>Contact Name</div> <div>Lorenzo M. Refolo, Ph.D.</div> </div> <div> <div>Contact Telephone</div> <div>301-594-7576</div> </div> <div> <div>Contact Email</div> <div>refolol@nia.nih.gov</div> </div> <div> <div>Sponsor Website</div> <div>Link to sponsor website</div> </div> <div> <div>Program URL</div> <div>Link to program URL</div> </div> <div> <div>Deadline Dates (ALL)</div> <div>06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 05-Jul-2026 , 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026 , 06-Oct-2026 [Optional][LOI/Pre-App], 05-Nov-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027 , 06-Oct-2027 [Optional][LOI/Pre-App], 05-Nov-2027</div> </div> <div> <div>Synopsis</div> <div>This Notice of Funding Opportunity (NOFO) invites applications proposing pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that aim to prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Grant recipients will receive funding for therapy development activities, such as the following: Medicinal chemistry; Pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); Efficacy in animal models; Development of biomarkers for target engagement; Formulation development chemical synthesis under Good Manufacturing Practices (GMP) ; Investigational New Drug (IND) enabling studies; Initial Phase I clinical testing.</div> </div>					
124752	New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-25-279	05-Jun-2025	Not Specified
<div> <div>Contact Name</div> <div>Elizabeth Newman, Ph.D.</div> </div> <div> <div>Contact Telephone</div> <div>301-480-7937</div> </div>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email elizabeth.newman@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027</p> <p>Synopsis The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop new approaches or apply existing approaches in novel ways to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease. Research can include healthy human participants of any age; specific clinical groups such as those with cognitive, motor, or affective regulation challenges; and/or animal research on these domains of function. The studies can focus on longitudinal neuroanatomical or functional changes at any level, including genetics/genomics, single cells, connectomics, neural population activity patterns, and others. This funding opportunity is intended to encourage technological and conceptual innovation to improve repeated measures across longer epochs of the lifespan, to better predict outcomes at later ages. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				
114120	Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-25-198	07-May-2025	Not Specified
	<p>Contact Name Amanda DiBattista, Ph.D.</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email amanda.dibattista@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function, and aging in healthy and disease states. This NOFO is intended to encourage the further development of projects with feasibility support for the line of investigation. Applicants proposing exploratory research at the early and conceptual stages of project development may instead wish to apply to the</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
companion R21 NOFO, which is identified above under the "Companion Funding Opportunity" heading.					
127749	NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-24-271	12-Jun-2025	Not Specified
<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Yuan Luo, Ph.D.</div> <div>301-496-9350</div> <div>yuan.luo@nih.gov</div> <div></div> <div>Link to program URL</div> <div>12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027</div> <div> <p>The purpose of this Notice of Funding Opportunity (NOFO) is to promote diversity in the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD), including frontotemporal dementia, Lewy body dementia, and vascular dementia. This pathway to independence award will support early career investigators from diverse backgrounds, including those from groups underrepresented in the biomedical sciences, to gain critical translational research skills that they can apply to various aspects of AD/ADRD research (from populations studies to research that can lead to new treatments and diagnostics, including all aspects of behavioral and social research). This program will support highly trained translational researchers as they transition to research independence in the field of AD/ADRD. The long-term goal of this program is to expand the pool of translational researchers who can effectively participate in and/or lead a team-science, interdisciplinary approach to studies of AD/ADRD treatment, prevention, early detection, and disease management and care. This NOFO is designed for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO, candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.</p> </div> </div>					
128615	NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-24-321	12-Jun-2025	Not Specified
<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> </div> <div> <div>Maria Carranza, Ph.D.</div> <div></div> <div>NIATraining@nih.gov</div> <div></div> <div>Link to program URL</div> <div>12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 , 12-Jun-2027 , 12-Oct-2027</div> </div>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The purpose of this notice of funding opportunity (NOFO) is to provide support for established investigators who have the expertise and leadership skills to enhance aging and/or Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) research capacity within their academic institution. Through this award, investigators will endeavor to develop research and educational infrastructure, mentorship, and career development activities in support of new or emerging areas of aging and/or AD/ADRD research. These may include, but are not limited to, courses, curricula, research support, pilot funding, travel awards, visiting scholars, or networks. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (FON).</p>				
129575	Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer's Disease and Related Dementias (R01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-25-374	09-Jun-2025	5,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Jean Yuan, Ph.D.</p> <p>301-496-9350</p> <p>yuanx4@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>09-Jun-2025 , 06-Oct-2025 , 06-Feb-2026 , 09-Jun-2026 , 06-Oct-2026 , 08-Feb-2027 , 09-Jun-2027 , 08-Oct-2027 , 07-Feb-2028</p> <p>This Notice of Funding Opportunity (NOFO) invites applications that combine computational and experimental approaches to enable rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in Alzheimer's Disease (AD) and AD-related dementias (ADRD). This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal of this NOFO is to establish robust proof of concept in mouse models or cell-based models of AD/ADRD that will enable rational drug repositioning and the development of precision combination therapies for the treatment and prevention of AD/ADRD.</p>			
114123	Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-25-199	16-Jun-2025	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Amanda DiBattista, Ph.D.</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email amanda.dibattista@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2025 , 16-Oct-2025</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high reward projects that lack preliminary data may be most appropriate for this NOFO. Applicants with preliminary data may instead wish to apply to the companion R01 NOFO, which is identified above under the "Companion Funding Opportunity" heading.</p>				
114469	NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	PAR-23-057	05-Jun-2025	Not Specified
	<p>Contact Name Sergei Romashkan, M.D., Ph.D.</p> <p>Contact Telephone 301-435-3047</p> <p>Contact Email romashks@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025 , 05-Oct-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the NIA website.</p>				
120970	Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	PAR-25-226	23-Jun-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Akanni Clarke</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email akanni.clarke@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Jun-2025 , 20-Oct-2025 , 20-Feb-2026 , 22-Jun-2026 , 19-Oct-2026</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and AD-related dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum, from pre-symptomatic to more severe stages of disease. This NOFO uses a phased award activity code. Applications must include prespecified, go/no-go safety and tolerability milestones that must be met to advance from phase 1 to latter stages of clinical development.</p>				
117878	Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PA-25-246	16-Jun-2025	200,000 USD
	<p>Contact Name Luci Roberts, Ph.D.</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email roberlu@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026</p> <p>Synopsis This Small Research Grant Program (R03) will support meritorious projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this NOFO will support projects covering a wide range of topics related to AD/ADRD. The overall goal of this NOFO is (i) to encourage the next generation of researchers to pursue research and academic careers in AD/ADRD research; and (ii) to stimulate established researchers who have not had a major award in AD/ADRD research to perform pilot studies to develop new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from diverse backgrounds, including those from underrepresented groups are always encouraged to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>apply for NIH support. Investigators who have not successfully competed for an award under this or prior versions of this announcement are specifically encouraged to apply.</p>					
124754	New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-25-272	16-Jun-2025	400,000 USD
Contact Name		Elizabeth Newman, Ph.D.			
Contact Telephone		301-480-7937			
Contact Email		elizabeth.newman@nih.gov			
Sponsor Website					
Program URL		Link to program URL			
Deadline Dates (ALL)		16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027			
Synopsis		<p>The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop exploratory, highly novel new approaches, or innovative applications of existing approaches, to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease, by improving repeated measures across longer epochs of the lifespan to better predict outcomes at later ages. Research can include healthy human participants of any age; specific clinical groups such those with cognitive, motor, or affective regulation challenges; and/or animal research on these domains of function. The studies can focus on longitudinal neuroanatomical or functional changes at any level, including genetics/genomics, single cells, connectomics, neural population activity patterns, and others. This funding opportunity is intended to encourage technological and conceptual innovation through this high risk, high reward funding mechanism to develop highly innovative ideas that either lack preliminary data or need additional preliminary data. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>			
129570	Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-25-331	16-Jun-2025	275,000 USD
Contact Name		Sanoj K. Suneja, Ph.D			
Contact Telephone		301-402-7710			
Contact Email		sanoj.suneja@nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing new tests, animal models, techniques, etc. to advance research on Alzheimer's disease (AD) and its related dementias (ADRD) that need additional preliminary data with broader dissemination to establish them for more general use in this research field. The priority topics will be announced through a series of Notices published subsequent to this FOA.</p>				
129569	Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-25-332	05-Jun-2025	Not Specified
	<p>Contact Name Jean Yuan, Ph.D.</p> <p>Contact Telephone 301-402-7710</p> <p>Contact Email jean.yuan@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD). Further information on the high-priority topics of interest will be announced through a series of Notices published subsequent to this FOA.</p>				
122532	Aging Research Dissertation Awards to Promote Diversity (R36 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-24-130	16-Jun-2025	Not Specified
	<p>Contact Name Jamie Lahvic, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email NIATraining@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2025 , 16-Jul-2025 , 16-Oct-2025 , 16-Nov-2025 , 16-Feb-2026 , 16-Mar-2026 , 16-Jun-2026 , 16-Jul-2026 , 16-Oct-2026 , 16-Nov-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites R36 applications to promote diversity in the scientific research workforce</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	engaged in research on aging and aging-related health conditions by providing dissertation awards in all areas of research within NIA's strategic priorities.				
123977	NIA Career Transition Award (K22 Independent Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-24-120	12-Jun-2025	Not Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Jamie Lahvic, Ph.D.</div> <div></div> <div>NIATraining@mail.nih.gov</div> <div></div> <div>Link to program URL</div> <div>12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 12-Nov-2025</div> <div> <p>The purpose of the NIA Career Transition Award (CTA) is to facilitate the transition of mentored, postdoctoral researchers to tenure-track or equivalent faculty positions conducting research that advances the mission of NIA. This award does not provide postdoctoral phase funding; therefore, candidates should be prepared to transition to tenure-track or equivalent faculty positions within 12 months after confirmation of a positive funding decision. After transition to an approved faculty position at an extramural institution/organization, the award will provide three years of protected research time through salary and research support. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial.</p> </div> </div>				
120720	Alcohol Health Services Research (R01 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-25-245	05-Jun-2025	500,000 USD
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Laura E. Kwako, Ph.D.</div> <div>301-451-8507</div> <div>laura.kwako@nih.gov</div> <div></div> <div>Link to program URL</div> <div>05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</div> <div> <p>The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2)</p> </div> </div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.				
120718	Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-25-193	16-Jun-2025	450,000 USD
	Contact Name	Brett T. Hagman, Ph.D.			
	Contact Telephone	301-443-0638			
	Contact Email	brett.hagman@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026			
	Synopsis	The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.			
120721	Alcohol Health Services Research (R01 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-25-192	16-Jun-2025	450,000 USD
	Contact Name	Laura E. Kwako, Ph.D.			
	Contact Telephone	301-451-8507			
	Contact Email	laura.kwako@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026			
	Synopsis	The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.				
120716	Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-25-163	05-Jun-2025	2,500,000 USD
	Contact Name	Brett T. Hagman, Ph.D.			
	Contact Telephone	301-443-0638			
	Contact Email	brett.hagman@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026			
	Synopsis	The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.			
122636	Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-25-158	17-Jun-2025	Not Specified
	Contact Name	William Dunty, PhD			
	Contact Telephone	301-443-7351			
	Contact Email	duntyw@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	17-Jun-2025 , 17-Oct-2025 , 18-Feb-2026 , 17-Jun-2026 , 19-Oct-2026			
	Synopsis	This Notice of Funding Opportunity (NOFO) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider NOFO (PAR-25-159, the R34 option).</p>				
107782	Notice of Special Interest (NOSI): Epidemiology and Prevention of Alcohol Misuse in Understudied Young Adult Populations; Military, Workforce, and Community College	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-22-001	05-Apr-2025	Not Specified
	<p>Contact Name: Bradley Kerridge, Ph.D.</p> <p>Contact Telephone: 301-827-7493</p> <p>Contact Email: bradley.kerridge@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025</p> <p>Synopsis: The purpose of this future grant application solicitation is to balance the NIAAA research portfolio by supporting research on alcohol misuse among persons aged 18 to 29 who are not enrolled in four-year colleges or universities. These persons are commonly in the military, workforce, or community college populations, which are understudied relative to their age peers in four-year colleges. Research on epidemiology, prevention, and screening centered on these understudied populations are all encouraged.</p>				
116584	Notice of Special Interest (NOSI): Advancing mHealth Interventions for Understanding and Preventing Alcohol-Related Domestic Violence	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-23-003	07-May-2025	Not Specified
	<p>Contact Name: Robert Freeman, Ph.D.</p> <p>Contact Telephone: 301-443-8820</p> <p>Contact Email: rfreeman@mail.nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 12-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 12-Jun-2026 , 16-Jun-2026 , 07-Sep-2026</p> <p>Synopsis: In light of the documented increases in both alcohol misuse (among some individuals) and domestic violence (DV) as a result</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>of the global COVID-19 pandemic and array of mandated restrictions enacted to mitigate COVID spread, the purpose of this grant application solicitation is to announce NIAAA's interest in addressing the critical need for research related to developing, testing, and intervening proximal to drinking occasions, when risk of DV is elevated, to decrease the likelihood of alcohol consumption at levels sufficient to trigger DV and to provide skills shown to reduce risk of DV perpetration and victimization. In particular, this solicitation seeks to advance the development, feasibility, acceptability, pilot testing, potential efficacy, and implementation of scalable, low resource, and remotely delivered interventions via mobile devices (mHealth) that rely on communication technologies for reducing and preventing alcohol consumption and DV. For this FOA, the term "domestic violence" will extend to child maltreatment (abuse and neglect) and elder abuse, in addition to intimate partner violence (IPV).</p>				
122632	Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-25-159	16-Jun-2025	450,000 USD
	Contact Name	William Dunty, PhD			
	Contact Telephone	301-443-7351			
	Contact Email	duntyw@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026			
	Synopsis	<p>This Notice of Funding Opportunity (NOFO) for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies. Applicants interested in exploratory phased projects may consider NOFO (PAR-25-158, the R61/R33 option).</p>			
122021	NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-051	07-May-2025	2,499,995 USD
	Contact Name	Trinh T. Ly, M.D.			
	Contact Telephone	301-435-4085			
	Contact Email	trinh.ly@nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</p> <p>Synopsis The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This notice of funding opportunity announcement (NOFO) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this NOFO, not require FDA oversight, not an NIH defined Phase III Clinical Trial, have low risks to subjects, and intends to gather scientific data/evidence to inform subsequent studies. This NOFO also supports low risk trials determined to be Basic Science Experimental Studies involving Humans (BESH). These studies fall within the NIH definition of a clinical trial and meet the definition of basic research. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. High risk clinical trials not meeting all the criteria above are referred to companion U01 NOFO, PAR-24-050, NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders.</p>				
129645	RFA-DC-25-005 -- In Vivo High-Resolution Imaging for Inner Ear Visualization (R01 Clinical Trial optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC-25-005	03-Jun-2025	2,499,995 USD
	<p>Contact Name Amy Poremba, Ph.D.</p> <p>Contact Telephone 301-997-3152</p> <p>Contact Email amy.poremba@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Jun-2025 , 01-Oct-2025 , 03-Jun-2026 , 01-Oct-2026</p> <p>Synopsis This funding opportunity aims to support the development of in vivo high-resolution structural and functional imaging technologies for the living human inner ear. Proposed projects should focus on improving the resolution of current imaging techniques or developing new imaging techniques that can visualize inner ear structures in vivo with significantly greater detail and accuracy than currently possible. Both structural and functional aspects, including visualizing dynamic elements are important to the development of new and improved techniques. Projects may also focus on developing new imaging probes or contrast agents that can enhance visualization of the inner ear structures. Research supported in response to this funding opportunity is expected to significantly advance the ability to visualize auditory and vestibular components, such as hair cells,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>otoliths, membranes, ions, and vasculature, in detail in awake patients in a clinical setting using non-invasive techniques. To achieve this goal, a multidisciplinary team approach that takes advantage of the expertise of each team member is highly encouraged. Studies in humans and intermediate studies in mammalian animal models may be proposed to develop or advance the needed technology. Any intermediate studies must articulate a clear path of the proposed methodology to application in awake humans or define the limitations and the usefulness in anesthetized humans. This notice of funding opportunity announcement (NOFO) also supports investigator initiated low-risk clinical trials addressing the development or improvement of human in vivo structural and functional imaging technologies. Clinical trials must meet ALL the following criteria: meet the budget limits of this NOFO, not require FDA oversight, not be an NIH-defined Phase III Clinical Trial, have low risks to subjects, and intend to gather scientific data/evidence to inform subsequent studies. This NOFO also supports low-risk trials determined to be Basic Experimental Studies with Humans (BESH). These studies fall within the NIH definition of a clinical trial and meet the definition of basic research. Only one clinical trial is allowed in each application. High-risk clinical trials not meeting all the criteria above are referred to the companion U01 Cooperative Agreement for In Vivo High-Resolution Imaging for Inner Ear Visualization (Clinical Trial required) NOFO RFA-DC-25-003.</p>				
129643	RFA-DC-25-003 -- Cooperative Agreement for In Vivo High-Resolution Imaging for Inner Ear Visualization (U01 Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC-25-003	03-Jun-2025	2,499,995 USD
	Contact Name	Amy Poremba, Ph.D.			
	Contact Telephone	301-997-3152			
	Contact Email	amy.poremba@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-Jun-2025 , 01-Oct-2025 , 03-Jun-2026 , 01-Oct-2026			
	Synopsis	<p>This funding opportunity aims to support high risk clinical trials for the development of in vivo high-resolution structural and functional imaging technologies for the living human inner ear. Proposed projects should focus on improving the resolution of current imaging techniques or developing new imaging techniques that can visualize inner ear structures in vivo with significantly greater detail and accuracy than currently possible. Structural and functional aspects, including visualizing dynamic elements, are important to developing new and improved techniques. Projects may also focus on developing new imaging probes or contrast agents that can enhance visualization of the inner ear structures. Research supported in response to this funding opportunity is expected to significantly advance the ability to visualize auditory and vestibular components, such as hair cells, otoliths, membranes, ions, and vasculature, in detail in awake patients in a clinical setting using non-invasive techniques. To achieve this goal, a multidisciplinary team approach that takes advantage of the expertise of each</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>team member is highly encouraged. Studies in humans must be proposed to develop, advance, or test the needed technology. Any intermediate studies must articulate a clear path of the proposed methodology to application in awake humans or define the limitations and the usefulness in anesthetized humans. This funding opportunity supports a cooperative agreement between an NIDCD Project Scientist and an Investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has potentially higher risks to participants. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed per application submitted to this funding opportunity. Low risk clinical trials not meeting any of the criteria above are referred to the companion In Vivo High-Resolution Imaging for Inner Ear Visualization (R01 - Clinical Trial Optional) RFA-DC-25-005. Investigators are strongly encouraged to contact the scientific/research contact, prior to submission, to ensure this is the correct NOFO for their proposed research.</p>				
129385	RFA-DC-25-004 -- NIDCD Research Opportunities for New Investigators to Promote Workforce Development (R01 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC-25-004	06-Jun-2025	2,499,995 USD
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div></div> <div>301-402-3458</div> <div>NIDCDRFADC25004@nidcd.nih.gov</div> <div></div> <div>Link to program URL</div> <div>06-Jun-2025 , 07-Oct-2025 , 06-Feb-2026 , 08-Jun-2026 , 06-Oct-2026</div> <div> <p>This Notice of Funding Opportunity (NOFO) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Institute on Deafness and Other Communication Disorders (NIDCD).</p> <p>This program is intended to support Early Stage and New Investigators from diverse backgrounds, including individuals from groups underrepresented in the health-related sciences. Preliminary data are not required for this NOFO, however, the project should be supported by sufficient information to give confidence to the reviewers that the proposed work is feasible.</p> </div> </div>				
123925	NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-142	07-May-2025	Not Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> </div> <div> <div>Alberto L. Rivera-Rentas, Ph.D.</div> <div>301-496-1804</div> </div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email riverara@nidcd.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 09-Jun-2025 , 07-Sep-2025 , 08-Oct-2025 , 07-Jan-2026 , 09-Feb-2026 , 07-May-2026 , 08-Jun-2026 , 07-Sep-2026 , 08-Oct-2026 , 07-Jan-2027 , 08-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFOs PAR-24-140 and PAR-24-143</p>				
123928	NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Clinical Trial Not Allowed)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-143	07-May-2025	Not Specified
	<p>Contact Name Alberto L. Rivera-Rentas, Ph.D.</p> <p>Contact Telephone 301-496-1804</p> <p>Contact Email riverara@nidcd.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
123922	<p>Deadline Dates (ALL) 07-May-2025 , 09-Jun-2025 , 07-Sep-2025 , 08-Oct-2025 , 07-Jan-2026 , 09-Feb-2026 , 07-May-2026 , 08-Jun-2026 , 07-Sep-2026 , 08-Oct-2026 , 07-Jan-2027 , 08-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (NOFO# PAR-24-140 and PAR-24-142).</p>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-140	07-May-2025	Not Specified
	<p>NIDCD Research Career Enhancement Award for Established Investigators (K18 Clinical Trial Required)</p> <p>Contact Name Alberto L. Rivera-Rentas, Ph.D.</p> <p>Contact Telephone 301-496-1804</p> <p>Contact Email riverara@nidcd.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 09-Jun-2025 , 07-Sep-2025 , 08-Oct-2025 , 07-Jan-2026 , 09-Feb-2026 , 07-May-2026 , 08-Jun-2026 , 07-Sep-2026 , 08-Oct-2026 , 07-Jan-2027 , 08-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFOs PAR-24-142 and PAR-24-143.</p>				
124315	<p>NIDCD Early Career Research (ECR) Award (R21 Clinical Trial Optional)</p> <p>Contact Name Bracie Watson, Jr.</p>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-25-120	17-Jun-2025	375,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-402-3458</p> <p>Contact Email watsonb@nidcd.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Jun-2025 , 17-Oct-2025 , 18-Feb-2026 , 17-Jun-2026 , 19-Oct-2026 , 17-Feb-2027 , 17-Jun-2027 , 15-Oct-2027</p> <p>Synopsis The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.</p>				
117259	<p>Notice of Special Interest (NOSI): Encouraging Women's Health Research within the NIDCD Mission Areas</p>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-23-006	07-May-2025	Not Specified
	<p>Contact Name Christopher Myers</p> <p>Contact Telephone 301-435-0713</p> <p>Contact Email myersc@nidcd.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 25-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 25-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 25-Feb-2026 , 07-May-2026</p> <p>Synopsis The National Institute on Deafness and Other Communication Disorders (NIDCD) is issuing this Notice of Special Interest (NOSI) to stimulate research in areas regarding the health of women within the scope of NIDCD's mission. NIDCD's mission is to conduct and support research and research training in the normal and disordered processes of hearing, balance, taste, smell, voice, speech, and language. As noted in the recently issued 2023–2027 NIDCD Strategic Plan (2023-2027 NIDCD Strategic Plan NIDCD), research projects to improve the health of women covering the lifespan are encouraged across all the NIDCD mission areas. These projects may include biological studies which may incorporate anatomical, structural, hormonal, or genetic aspects, behavioral traits, societal aspects, or healthcare related activities that may benefit a women's</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	quality of life.				
124298	NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-150	07-May-2025	315,000 USD
	Contact Name	Alberto L. Rivera-Rentas, Ph.D.			
	Contact Telephone	301-496-1804			
	Contact Email	riverara@nidcd.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 15-Oct-2025 , 07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 15-Jun-2026 , 07-Sep-2026 , 14-Oct-2026 , 07-Jan-2027 , 17-Feb-2027 , 07-May-2027			
	Synopsis	The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-24-159).			
124297	NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-149	07-May-2025	315,000 USD
	Contact Name	Alberto L. Rivera-Rentas, Ph.D.			
	Contact Telephone	301-496-1804			
	Contact Email	riverara@nidcd.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 15-Oct-2025 , 07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 15-Jun-2026 , 07-Sep-2026 , 14-Oct-2026 , 07-Jan-2027 , 17-Feb-2027 , 07-May-2027			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-085 for Clinical Trial Required or for PAR-21-087 for Independent Basic Experimental Studies with Humans Required..</p>				
124299	NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Clinical Trial Not Allowed)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-159	07-May-2025	315,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Alberto L. Rivera-Rentas, Ph.D.</p> <p>301-496-1804</p> <p>riverara@nidcd.nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 15-Oct-2025 , 07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 15-Jun-2026 , 07-Sep-2026 , 14-Oct-2026 , 07-Jan-2027 , 17-Feb-2027 , 07-May-2027</p> <p>The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFOs (PAR-24-149 and PAR-24-150).</p>			
114999	Notice of Special Interest (NOSI): Fundamental Science Research on the Neural Circuits Underlying Sensory Processing	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-23-001	07-May-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
117406	Contact Name	Merav Sabri, Ph.D.			
	Contact Telephone	301-827-0908			
	Contact Email	merav.sabri@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026			
	Synopsis	The National Institute on Deafness and Other Communication Disorders (NIDCD) is issuing this Notice to highlight priorities from its new strategic plan, in basic and mechanistic research on neural circuits underlying sensory processing in hearing, balance, taste and smell. NIDCD encourages multidisciplinary and innovative projects, from diverse teams, to advance a mechanistic understanding of the behavior of neural circuits at cellular and sub-second temporal resolution by integrating cutting-edge technologies and approaches for recording and modulation of cells and circuits (e.g., electrophysiology, optical imaging, optogenetics, chemogenetics, sonogenetics, magnetogenetics, pharmacologic modulation). Applications are expected to integrate appropriate domains of expertise, including but not limited to biological, chemical and physical sciences, engineering, computational modeling, statistical analysis, and bioethics, as appropriate. Mechanistic human studies and comparative, cross-species projects are highly encouraged.			
117406	Notice of Special Interest (NOSI): Promoting Language and Communication in Minimally Verbal/Non-Speaking Individuals with Autism	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-23-009	05-Apr-2025	Not Specified
	Contact Name	Holly L. Storkel, Ph.D.			
	Contact Telephone	301-496-5061			
	Contact Email	holly.storkel@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 05-Apr-2026 , 07-May-2026 , 05-Jun-2026			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to encourage applications for research to promote language and communication in autistic individuals who are minimally verbal/non-speaking. Further research is needed to evaluate and tailor existing interventions, develop novel interventions, develop and apply new research designs and methods to intervention efforts, and identify meaningful outcome measures.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
122020	NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-25-343	18-Jun-2025	Not Specified
<div> <div>Contact Name</div> <div>Trinh T. Ly, M.D.</div> </div> <div> <div>Contact Telephone</div> <div>301-435-4085</div> </div> <div> <div>Contact Email</div> <div>trinh.ly@nih.gov</div> </div> <div> <div>Sponsor Website</div> <div></div> </div> <div> <div>Program URL</div> <div>Link to program URL</div> </div> <div> <div>Deadline Dates (ALL)</div> <div>18-Jun-2025 , 17-Oct-2025 , 18-Feb-2026 , 18-Jun-2026 , 19-Oct-2026 , 18-Feb-2027 , 18-Jun-2027 , 18-Oct-2027</div> </div> <div> <div>Synopsis</div> <div> <p>The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting well-designed and well-executed clinical trials. This funding opportunity supports a cooperative agreement between an NIDCD Project Scientist and an Investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has potentially higher risks to participants. Clinical trial applications exceeding the annual direct costs of \$700,000 or more, in certain cases, may also be a criterion for this funding opportunity. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed per application submitted to this funding opportunity.</p> </div> </div>					
129136	RFA-DA-26-056 -- Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-26-056	18-Jun-2025 [Optional][LOI/Pre-App]	400,000 USD
<div> <div>Contact Name</div> <div>Marsha F. Lopez, Ph.D., M.H.S.</div> </div> <div> <div>Contact Telephone</div> <div>301-443-6504</div> </div> <div> <div>Contact Email</div> <div>marsha.lopez@nih.gov</div> </div> <div> <div>Sponsor Website</div> <div></div> </div> <div> <div>Program URL</div> <div>Link to program URL</div> </div> <div> <div>Deadline Dates (ALL)</div> <div>18-Jun-2025 [Optional][LOI/Pre-App], 17-Jul-2025 , 03-Nov-2025 [Optional][LOI/Pre-App], 03-Dec-2025 , 18-Jun-2026 [Optional][LOI/Pre-App], 17-Jul-2026 , 03-Nov-2026 [Optional][LOI/Pre-App], 03-Dec-2026 , 16-Jun-2027 [Optional][LOI/Pre-App], 15-Jul-2027 , 03-Nov-2027 [Optional][LOI/Pre-App], 03-Dec-2027</div> </div> <div> <div>Synopsis</div> <div>The purpose of this notice of funding opportunity (NOFO) is to invite applications proposing innovative analysis of existing</div> </div>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This NOFO encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. Primary data collection is not allowed for applications in response to this NOFO.</p>				
129134	RFA-DA-26-055 -- Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-26-055	18-Jun-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Marsha F. Lopez, Ph.D., M.H.S.</p> <p>301-443-6504</p> <p>marsha.lopez@nih.gov</p> <p></p> <p>Link to program URL</p> <p>18-Jun-2025 [Optional][LOI/Pre-App], 17-Jul-2025 , 03-Nov-2025 [Optional][LOI/Pre-App], 03-Dec-2025 , 18-Jun-2026 [Optional][LOI/Pre-App], 17-Jul-2026 , 03-Nov-2026 [Optional][LOI/Pre-App], 03-Dec-2026 , 16-Jun-2027 [Optional][LOI/Pre-App], 15-Jul-2027 , 03-Nov-2027 [Optional][LOI/Pre-App], 03-Dec-2027</p> <p>The purpose of this notice of funding opportunity (NOFO) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This NOFO encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. Primary data collection is not allowed for applications in response to this NOFO.</p>			
114003	Notice of Special Interest (NOSI): Targeting Epigenetic Regulators for Treating Addiction and Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-004	08-Apr-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
113995	Contact Name	Sam Ananthan, Ph.D.			
	Contact Telephone	301-435-2199			
	Contact Email	sam.ananthan@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 08-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 08-Dec-2025 , 07-Jan-2026			
	Synopsis	The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to inform applicants about NIDA's special interest in innovative research that uses chemical and pharmacological approaches to identify and target epigenetic regulators and mechanisms for the treatment of addiction and substance use disorders.			
113995	Notice of Special Interest (NOSI): Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R01, R21, R03)	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-23-012	07-May-2025	Not Specified
114150	Contact Name	Tisha Wiley, Ph.D.			
	Contact Telephone	301-594-4381			
	Contact Email	tisha.wiley@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026			
	Synopsis	The purpose of this Notice is to inform potential applications to the National Institute on Drug Abuse (NIDA) of special interest in grant applications to conduct rigorous health services and economic research to maximize the availability and delivery of efficient, effective drug, alcohol, and tobacco treatment and recovery support services. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation science; (4) availability, demand, access, and financing; (5) effectiveness; and (6) development or improvement of research methodology, analytic approaches, and measurement instrumentation.			
114150	Notice of Special Interest (NOSI): Chemsex and HIV: Prevalence, Medical/Psychosocial Consequences, and Treatment	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-002	07-May-2025	Not Specified
	Contact Name	Raul Mandler, MD			
	Contact Telephone	240-281-0569			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email mandlerr@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The purpose of this notice is to support research on the epidemiology, medical/psychosocial impact, and preventive and therapeutic measures for chemsex in people with HIV and HIV-vulnerable populations including sexual minorities (SM) e.g. lesbian, gay, bisexual.</p>				
114048	Notice of Special Interest (NOSI): Chemoproteomic Approaches for Discovery of Targets and Therapeutics to Treat Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-005	08-Apr-2025	Not Specified
	<p>Contact Name Sam Ananthan, Ph.D.</p> <p>Contact Telephone 301-435-2199</p> <p>Contact Email sam.ananthan@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 08-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 08-Dec-2025 , 07-Jan-2026</p> <p>Synopsis The purpose of this Notice is to inform potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in supporting basic research on the application of chemoproteomic approaches for the discovery of targets and for development of drugs to treat addiction and substance use disorders.</p>				
114151	Notice of Special Interest (NOSI): Chemsex and HIV: Prevalence, Medical/Psychosocial Consequences, and Treatment	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-002	07-May-2025	Not Specified
	<p>Contact Name Raul Mandler, MD</p> <p>Contact Telephone 240-281-0569</p> <p>Contact Email mandlerr@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this notice is to support research on the epidemiology, medical/psychosocial impact, and preventive and therapeutic measures for chemsex in people with HIV and HIV-vulnerable populations including sexual minorities (SM) e.g. lesbian, gay, bisexual.			
115450	Notice of Special Interest (NOSI): Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A Jump Into Precision Medicine.	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-001	07-May-2025	Not Specified
	Contact Name	Guifang Lao, Ph.D.			
	Contact Telephone	301-827-5931			
	Contact Email	laog@nih.gov			
	Sponsor Website				
	Program URL				
	Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026			
	Synopsis	NIDA is interested in receiving research proposals focusing on studying pharmacogenomics in PLWH with SUD as a crucial step in the science of Precision Medicine, in the path of personalized care for HIV and drug abuse..			
129345	D-START: Data Science Track Award for Research Transition (D/START) (R03-Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAS-25-236	07-May-2025	200,000 USD
	Contact Name	Susan N. Wright, Ph.D.			
	Contact Telephone	301-402-6683			
	Contact Email	susan.wright@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027			
	Synopsis	This notice of funding opportunity (NOFO) seeks to support investigators interested in applying cutting-edge data science techniques to address timely and challenging research questions related to substance use and/or substance use disorder (SUD) in all areas of research supported by the National Institute on Drug Abuse (NIDA). This NOFO requests Small Research Grant (R03) applications to support research projects that can be carried out in a short period of time with limited			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

resources.

129186	Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-25-100	07-May-2025	450,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Carrie Mulford
Contact Telephone	301-827-6473
Contact Email	Carrie.Mulford@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027
Synopsis	This Funding Opportunity Announcement (FOA) encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches, in addition to usual trial preparation activities. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

109484	Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance use Prevention and Treatment	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-23-006	07-May-2025	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name	Janet Kuramoto-Crawford, PhD
Contact Telephone	301-443-8856
Contact Email	janet.kuramoto-crawford@nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<div> <div>Deadline Dates (ALL)</div> <div>07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</div> </div> <div> <div>Synopsis</div> <div> <p>This Notice encourages research projects that 1) leverage data science to provide actionable insights for substance use prevention and treatment 2) shorten the time between data capture and data availability so that data are available real-time or near real-time, and 3) explore methods and tools that may allow for faster or better localized responses for substance use treatment and prevention. Priority will be given to projects that emphasize the use of existing data streams (e.g., electronic health records, syndromic surveillance, claims data, registry data, pharmacy dispensing, social media, and mortality records).</p> </div> </div>					
109268	Notice of Special Interest (NOSI): Epidemiology of Drug Abuse	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-22-004	07-May-2025	Not Specified
<div> <div>Contact Name</div> <div>Marsha Lopez, PhD, MHS</div> </div> <div> <div>Contact Telephone</div> <div>301-443-6504</div> </div> <div> <div>Contact Email</div> <div>Marsha.Lopez@nih.gov</div> </div> <div> <div>Sponsor Website</div> <div></div> </div> <div> <div>Program URL</div> <div>Link to program URL</div> </div> <div> <div>Deadline Dates (ALL)</div> <div>07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</div> </div> <div> <div>Synopsis</div> <div> <p>The purpose of this Notice is to encourage the submission of research project applications that enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse, and addiction across individuals, families, communities, and diverse population groups. Of interest are applications that address multiple levels of risk, resilience, and causation across scientific disciplines, and that apply novel methods to advance knowledge of the interplay among genetic, environmental, neurobiological, and developmental factors and associated health and disease outcomes. Priority will be given to research with a well described path towards translation and/or public health impact. In addition to novel data collection, approaches are encouraged that build on the research investments of NIH and sister HHS agencies to harness existing data on the epidemiology and etiology of drug misuse to improve public health prevention and treatment programs. The research areas noted below should be considered in the context of topics such as health disparities or inequities, familial/genetic liability, and physical, psychiatric, and polysubstance comorbidities and interactions.</p> </div> </div>					
111673	Notice of Special Interest (NOSI): High Priority Areas in Integrative Neuroscience Branch in the Division of Neuroscience and Behavior	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-22-058	07-May-2025	Not Specified
<div> <div>Contact Name</div> <div>Olivier Berton, Ph.D.</div> </div> <div> <div>Contact Telephone</div> <div>301-827-7771</div> </div>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email Olivier.berton@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The mission of the Division of Neuroscience and Behavior (DNB) is to facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of substance use and substance use disorders (SUD) across the lifespan and to guide treatment strategies. The Integrative Neuroscience (IN) Branch within DNB supports research on the cellular mechanisms and circuitry that underlie substance use and SUD. Research supported by the Branch covers: 1) the regulation and plasticity of neurotransmitter and neuromodulatory systems induced by chronic or intermittent exposure to, and/or withdrawal from, addictive substances, 2) the study of substance-induced neurotoxicity, 3) neuron-glia interactions and their modification by substance use and SUD 4) neuroendocrine modulation of neural systems in relation to substance use and SUD , and 5) neuroimmune modulation of the brain including the influences of neuroAIDS and substance-induced neuroinflammation.</p>				
119295	Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR-25-347	07-May-2025	100,000 USD
	<p>Contact Name Marsha F. Lopez, Ph.D., M.H.S.</p> <p>Contact Telephone 301-443-6504</p> <p>Contact Email marsha.lopez@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026</p> <p>Synopsis The goal of this Notice of Funding Opportunity (NOFO) is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with the NIDA Strategic Plan (2022-2026 NIDA Strategic Plan Director's Message National Institute on Drug Abuse (NIDA) (nih.gov). This award will facilitate the entry of promising new investigators into the field of substance use/substance use disorder (SU(D) research, enhancing the pool of highly talented SU(D) researchers. Applications are particularly encouraged from individuals from diverse backgrounds, including those from underrepresented groups as described in the Notice of NIH's Interest in Diversity (NOT-OD-20-031). This NOFO is designed specifically for applicants proposing research that does not</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.					
117405	Notice of Special Interest (NOSI): Leveraging Glial Cells to Treat Addiction	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-006	07-May-2025	Not Specified
	Contact Name	Shang-Yi Anne Tsai, Ph.D.			
	Contact Telephone	301-827-5842			
	Contact Email	stsai@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 12-Feb-2026 [LOI/Pre-App], 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 12-Jun-2026 , 16-Jun-2026 , 07-Sep-2026			
	Synopsis	This Notice of Special Interest (NOSI) encourages studies to exploit the unique properties and functions of glial cells and develop strategies to mitigate Central Nervous System (CNS) damage due to acute or chronic exposure to addictive substances or therapeutic avenues for addiction treatments.			
127894	Imaging - Science Track Award for Research Transition (I/START) (R03-Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-24-297	07-May-2025	150,000 USD
	Contact Name	Hoang Le, Ph.D.			
	Contact Telephone	301-451-8849			
	Contact Email	hoang.le@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028			
	Synopsis	This Funding Opportunity Announcement (FOA) encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both newly independent investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	limited resources.				
117589	Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)	National Institute on Drug Abuse/NIH/DHHS	PAR-23-158	20-Jun-2025	Not Specified
	Contact Name	Vani Pariyadath, Ph.D.			
	Contact Telephone	301-443-3209			
	Contact Email	vani.pariyadath@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	20-Jun-2025 , 09-Oct-2025 , 13-Mar-2026			
	Synopsis	<p>This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. This NOFO is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and studies that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion NOFO - Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) PAR-23-157. For projects not requiring a phased research approach, applicants are encouraged to apply under a different activity code (e.g., PA-20-184 “Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)”).</p>			
117587	Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-23-157	20-Jun-2025	Not Specified
	Contact Name	Vani Pariyadath, Ph.D.			
	Contact Telephone	301-443-3209			
	Contact Email	vani.pariyadath@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<div> <div>Deadline Dates (ALL)</div> <div>20-Jun-2025 , 09-Oct-2025 , 13-Mar-2026</div> </div> <div> <div>Synopsis</div> <div> <p>This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. Note: For basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants” please use the companion NOFO - Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH)) PAR-23-282 For projects not requiring a phased research approach, applicants are encouraged to apply under a different funding activity code (e.g., PA-20-183 “Research Project Grant (Parent R01 Clinical Trial Required)”).</p> </div> </div>					
121868	Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-25-377	07-May-2025	Not Specified
<div> <div>Contact Name</div> <div>Larissa Avilés-Santa, MD, MPH, Director</div> </div> <div> <div>Contact Telephone</div> <div>301-827-6924</div> </div> <div> <div>Contact Email</div> <div>avilessantal@nih.gov</div> </div> <div> <div>Sponsor Website</div> <div></div> </div> <div> <div>Program URL</div> <div>Link to program URL</div> </div> <div> <div>Deadline Dates (ALL)</div> <div>07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</div> </div> <div> <div>Synopsis</div> <div> <p>This Notice of Funding Opportunity (NOFO) is being reissued in accordance with the simplified review criteria in effect for application due dates after January 25, 2025. This Notice of Funding Opportunity (NOFO) will support innovative, collaborative, and interdisciplinary research focused on clinical epidemiology, evaluation of public and/or health care policies, and validation of measurements that address health and healthcare disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos.</p> </div> </div>					
125421	Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-24-330	07-May-2025	Not Specified
<div> <div>Contact Name</div> <div>Arielle S. Gillman, PhD, MPH</div> </div> <div> <div>Contact Telephone</div> <div>301-435-0060</div> </div>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email arielle.gillman@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027</p> <p>Synopsis The purpose of this initiative is to support non-pharmacological interventions to promote sleep health, reduce sleep health disparities, and examine sleep as a modifiable factor to reduce disparities for other health outcomes among populations that experience health disparities.</p>				
127614	Advancing Healthcare for Older Adults from Populations that Experience Health Disparities (R01 - Clinical Trial Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-24-273	07-May-2025	Not Specified
	<p>Contact Name Yewande Oladeinde, PhD</p> <p>Contact Telephone 301-402-4307</p> <p>Contact Email yewande.oladeinde@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of this initiative is to advance the science and implementation of innovative multi-level health care research for older adults from populations that experience health disparities. The initiative will support research designed to (1) gain a better understanding of appropriate screening, diagnostic, and clinical care guidelines in a primary care setting, (2) explore shared decision-making that is needed to enhance care planning and patient agency between clinicians and care teams with the older adult and their caregiver(s), and (3) identify effective strategies for care coordination.</p>				
128943	The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-25-292	07-May-2025	Not Specified
	<p>Contact Name Rada K. Dagher, PhD, MPH</p> <p>Contact Telephone 301-451-2187</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email rada.dagher@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support innovative population-based research that can contribute to identifying and characterizing pathways and mechanisms through which work or occupation influences health outcomes and health status among populations with health and/or health care disparities, and how work functions as a social determinant of health.</p>				
129148	Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-25-299	05-Jun-2025	Not Specified
	<p>Contact Name Olga M. Herren, Ph.D.</p> <p>Contact Telephone 301-402-4492</p> <p>Contact Email olga.herren@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027</p> <p>Synopsis This initiative will support multi-level and/or multi-domain intervention research to reduce disparities in liver diseases and liver cancer among populations who experience health disparities in the United States (U.S.).</p>				
115679	NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-23-111	07-May-2025	275,000 USD
	<p>Contact Name</p> <p>Contact Telephone 301-402-1366</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<div> <div>Deadline Dates (ALL)</div> <div>07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026</div> <div>Synopsis</div> <div>NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S.</div> </div>					
121524	RFA-DA-24-067 -- HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-DA-24-067	18-May-2025 [Optional][LOI/Pre-App]	Not Specified
<div> <div>Contact Name</div> <div>Amy B. Goldstein, PhD</div> <div>Contact Telephone</div> <div>301-827-4124</div> <div>Contact Email</div> <div>amy.goldstein@nih.gov</div> <div>Sponsor Website</div> <div></div> <div>Program URL</div> <div>Link to program URL</div> <div>Deadline Dates (ALL)</div> <div>18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025 , 17-Dec-2025 [Optional][LOI/Pre-App], 16-Jan-2026</div> <div>Synopsis</div> <div> <p>Despite an evidence base of effective programs to prevent the initiation of substance use, misuse and disorder, a substantial research to practice gap exists. The goal of this initiative is to support projects that fill this research to practice gap, improving public health and responding to the opioid crisis by increasing knowledge pertaining to the delivery of prevention services.</p> <p>This notice of funding opportunity (NOFO) solicits applications to address understudied areas of opportunity that, if researched, could create the foundation needed to inform a prevention infrastructure for ongoing delivery and sustainment of interventions to prevent opioid and other substance misuse and use disorders. This NOFO invites projects for which preliminary or feasibility data is available. This NOFO is a companion to RFA-DA-24-066 which solicits applications for which pilot data is unavailable.</p> </div> </div>					
121525	RFA-DA-24-066 -- HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R61/R33 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-DA-24-066	18-May-2025 [Optional][LOI/Pre-App]	Not Specified
<div> <div>Contact Name</div> <div>Amy B. Goldstein, PhD</div> <div>Contact Telephone</div> <div>301-827-4124</div> <div>Contact Email</div> <div>amy.goldstein@nih.gov</div> <div>Sponsor Website</div> <div></div> </div>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<div>Program URL Link to program URL</div> <div>Deadline Dates (ALL) 18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025 , 17-Dec-2025 [Optional][LOI/Pre-App], 16-Jan-2026</div> <div>Synopsis Despite an evidence base of effective programs to prevent the initiation of substance use, misuse and disorder, a substantial research to practice gap exists. The goal of this initiative is to support projects that fill this research to practice gap, improving public health and responding to the opioid crisis by increasing knowledge pertaining to the delivery of prevention services. This notice of funding opportunity (NOFO) solicits applications to address understudied areas of opportunity that, if researched, could create the foundation needed to inform a prevention infrastructure for ongoing delivery and sustainment of interventions to prevent opioid and other substance misuse and use disorders. This NOFO invites projects for which preliminary or feasibility data is not available. This NOFO is a companion to RFA-DA-24-067 which solicits applications for which pilot data is available.</div>				
119458	Notice of Special Interest (NOSI): Administrative Supplements for Enhancing Recruitment and Retention of Diverse Populations to Cancer Screening, Cancer Prevention and Symptom Management Clinical Trials	National Institutes of Health/DHHS	NOT-CA-23-071	30-Jun-2025	100,000 USD
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL Link to program URL</div> <div>Deadline Dates (ALL) 30-Jun-2025</div> <div>Synopsis The Division of Cancer Prevention (DCP) at the National Cancer Institute (NCI) announces this Notice of Special Interest to encourage current grant or cooperative agreement awardees to apply for administrative supplement funds to support the development of tools and strategies to increase the participation of individuals from all population subgroups who are representative of people for whom the parent grant intervention may be indicated. DCP led or co-led programs appropriate for this opportunity include Cancer Prevention and Control Clinical Trials Grant Program, Cancer Prevention Clinical Trials Network (CP-CTNet), NCI Community Oncology Research Program (NCORP) Research Bases, NCORP Community Sites and NCORP Minority/Underserved Community Sites, Prevention of HPV-related Cancers in HIV-infected individuals: United States-Latin American-Caribbean Clinical Trials Network: Partnership Centers Program and the NCI Cancer Screening Research Network: ACCrual, Enrollment, and Screening Sites (ACCESS) Hub. The proposed strategies and tools should be designed to promote inclusion of historically underserved populations in clinical trials - by identifying and reducing enrollment barriers at the organizational, participant, or protocol design level.</div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
113055	RFA-EB-22-002 -- HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-EB-22-002	18-May-2025 [Optional][LOI/Pre-App]	2,250,000 USD
<div> <div>Contact Name</div> <div>Moria F. Bittmann</div> </div> <div> <div>Contact Telephone</div> <div>301-496-7699</div> </div> <div> <div>Contact Email</div> <div>moria.bittmann@nih.gov</div> </div> <div> <div>Sponsor Website</div> <div></div> </div> <div> <div>Program URL</div> <div>Link to program URL</div> </div> <div> <div>Deadline Dates (ALL)</div> <div>18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025</div> </div> <div> <div>Synopsis</div> <div> <p>The purpose of this Funding Opportunity Announcement (FOA) is to develop clinical-grade prototype devices intended for use as safe, effective, and non-addictive diagnostics and treatments for pain or opioid use disorder (OUD). The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain or OUD, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain or OUD. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use.</p> </div> </div>					
111746	Notice of Special Interest (NOSI): Availability of Administrative Supplements for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project	National Institutes of Health/DHHS	NOT-OD-22-137	01-Jun-2025	500,000 USD
<div> <div>Contact Name</div> <div></div> </div> <div> <div>Contact Telephone</div> <div></div> </div> <div> <div>Contact Email</div> <div></div> </div> <div> <div>Sponsor Website</div> <div></div> </div> <div> <div>Program URL</div> <div>Link to program URL</div> </div> <div> <div>Deadline Dates (ALL)</div> <div>01-Jun-2025</div> </div> <div> <div>Synopsis</div> <div> <p>The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH's continued support for administrative supplement applications for actively funded projects to meet NIH</p> </div> </div>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Down syndrome research objectives related to the NIH INCLUDE Project as listed below.

117410	NIH Science Education Partnership Award (SEPA) (R25 - Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-23-137	06-Jun-2025	1,250,000 USD
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Tony Beck, Ph.D.
Contact Telephone	301-480-4623
Contact Email	beckl@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	06-Jun-2025
Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on: Courses for Skills Development Research Experiences Mentoring Activities Curriculum or Methods Development Outreach

117962	RFA-NS-23-028 -- HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-NS-23-028	10-May-2025 [Optional][LOI/Pre-App]	Not Specified
--------	--	------------------------------------	---------------	-------------------------------------	---------------

Contact Name	Eric Hudak, Ph.D.
Contact Telephone	301-496-1779
Contact Email	NINDS-Devices@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	10-May-2025 [Optional][LOI/Pre-App], 09-Jun-2025
Synopsis	This funding opportunity announcement (FOA) is designed to support interdisciplinary research teams of multiple PDs/PIs to investigate the mechanism of action of pain relief by medical devices with the overall goal of optimizing therapeutic outcomes for FDA-approved or -cleared technologies. Teams must leverage appropriate multi-disciplinary expertise to develop new principles and methods for experimentation, analysis, and interpretation. Teams are encouraged to consider

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
objectives that will produce major advances in the understanding of pain relief by medical devices.					
117659	Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23-098	09-May-2025 [Optional][LOI/Pre-App]	7,500,000 USD
Contact Name		Stephanie A. Morris, Ph.D.			
Contact Telephone		301-435-5738			
Contact Email		morriss2@mail.nih.gov			
Sponsor Website					
Program URL		Link to program URL			
Deadline Dates (ALL)		09-May-2025 [Optional][LOI/Pre-App], 24-Jun-2025			
Synopsis		<p>The Centers of Excellence in Genomic Science (CEGS) program establishes academic Centers for advanced genome research. Each CEGS award supports a multi-investigator, interdisciplinary team to develop integrated, transformative genomic approaches to address a biomedical problem. A CEGS project will address a critical issue in genomic science, genomic medicine, or computational genomics, proposing a highly innovative solution that would be a major advance. The research will entail substantial risk, balanced by outstanding scientific and management plans and very high potential payoff. A CEGS will focus on the development of novel technological or computational methods for the production or analysis of comprehensive data sets, on a genome-scale biomedical problem, or on other ways to develop and use genomic approaches for understanding biological systems or furthering the application of genomic knowledge, data, and methods towards clinical applications. Each CEGS will nurture genomics by facilitating the interaction of investigators from several disciplines. Along with its scientific goals, CEGS will also expand the pool of genomic scientists and engineers that can use and apply the novel methods, concepts, and knowledge developed by the CEGS by providing education and outreach experiences to scientists at all career levels.</p>			
113526	INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (INCLUDE) Clinical Research Short Course (R25 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-195	27-Jun-2025	2,000,000 USD
Contact Name		Cara Finley, M.P.H.			
Contact Telephone		202-557-4354			
Contact Email		cara.finley@nih.gov			
Sponsor Website					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
119046	Program URL	Link to program URL			
	Deadline Dates (ALL)	27-Jun-2025			
	Synopsis	The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). As part of the INCLUDE Project, NIH is interested in expanding and diversifying the skilled DS clinical research workforce. The intent of this Funding Opportunity Announcement (FOA) is to encourage applications that develop creative and innovative short courses to train the next generation of DS researchers in state-of-the-art clinical research skills that will improve the understanding of the co-occurring clinical features in DS and support development of new treatments for health conditions experienced by those with DS.			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Jun-2025 [Optional][LOI/Pre-App], 08-Jul-2025			
119046	RFA-HG-23-018 --Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-HG-23-018	08-Jun-2025 [Optional][LOI/Pre-App]	400,000 USD
119045	Contact Name	Lucia Hindorff, Ph.D.			
	Contact Telephone	240-271-1509			
	Contact Email	hindorffl@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
119045	Synopsis	The purpose of this initiative is to support investigator-initiated research in genomics and health equity, with the ultimate goal of developing approaches, generating and disseminating data, and implementing metrics or interventions that will advance the equitable use of genomics to improve health in U.S. populations. Awardees will conduct innovative and generalizable research in genomics and health equity spanning across genomic research areas and will incorporate a plan for enhancing diverse perspectives. This R21 Notice of Funding Opportunity (NOFO) will support small research projects that can be carried out in a short period of time with limited resources. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Applications supporting New or Early Stage Investigators from diverse backgrounds, including those from groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce, as described in the NIH Notice of Interest in Diversity (NOT-OD-20-031), are encouraged. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications without a PEDP will not be reviewed.			
	Deadline Dates (ALL)	08-Jun-2025 [Optional][LOI/Pre-App], 08-Jul-2025			
119045	RFA-HG-23-017 -- Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-HG-23-017	08-Jun-2025	2,500,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Equity (R01 Clinical Trial Optional)	Health/DHHS	23-017	[Optional][LOI/Pre-App]	USD
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Lucia Hindorff, Ph.D.</div> <div>240-271-1509</div> <div>hindorffl@mail.nih.gov</div> <div></div> <div>Link to program URL</div> <div>08-Jun-2025 [Optional][LOI/Pre-App], 08-Jul-2025</div> <div> <p>The purpose of this initiative is to support investigator-initiated research in genomics and health equity, with the ultimate goal of developing approaches, generating and disseminating data, and implementing metrics or interventions that will advance the equitable use of genomics to improve health in U.S. populations. Awardees will conduct innovative and generalizable research in genomics and health equity spanning across genomic research areas and will incorporate a plan for enhancing diverse perspectives. Applications supporting New or Early Stage Investigators from diverse backgrounds, including those from groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce, as described in the NIH Notice of Interest in Diversity (NOT-OD-20-031), are encouraged. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications without a PEDP will not be reviewed.</p> </div> </div>				
119945	DataWorks! Prize	National Institutes of Health/DHHS		14-Jun-2025	Not Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div></div> <div></div> <div>dataworks@faseb.org</div> <div>Link to sponsor website</div> <div>Link to program URL</div> <div>14-Jun-2025</div> <div> <p>The DataWorks! Prize recognizes excellence, and rewards researchers for integrating data sharing and reuse into their research processes. Through the 2024 Prize, FASEB and NIH will recognize and reward research teams who propose and execute innovative secondary analysis and data reuse to generate novel scientific findings and create a valuable set of case studies and examples that can be used by the broader research community.</p> </div> </div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
124566	RFA-MD-24-006 -- Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-MD-24-006	10-Jun-2025	Not Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>LCDR Michael Banyas, USPHS, MPA</div> <div>240-619-9483</div> <div>nimhdsbirsttr@mail.nih.gov</div> <div></div> <div>Link to program URL</div> <div>10-Jun-2025 , 04-Aug-2025 , 09-Dec-2025 , 10-Jun-2026 , 03-Aug-2026 , 09-Dec-2026</div> <div>This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications that propose to develop a product, process or service for commercialization with the aim of improving minority health and/or reducing and ultimately eliminating health disparities in one or more populations that experience health disparities. Appropriate technologies should be effective, affordable, and culturally acceptable.</div> </div>				
124567	RFA-MD-2D-24-007 -- Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-MD-24-007	11-May-2025 [Optional][LOI/Pre-App]	Not Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>LCDR Michael Banyas, USPHS, MPA</div> <div>240-619-9483</div> <div>nimhdsbirsttr@mail.nih.gov</div> <div></div> <div>Link to program URL</div> <div>11-May-2025 [Optional][LOI/Pre-App], 10-Jun-2025 , 07-Jul-2025 , 10-Nov-2025 [Optional][LOI/Pre-App], 09-Dec-2025 , 11-May-2026 [Optional][LOI/Pre-App], 10-Jun-2026 , 06-Jul-2026 , 10-Nov-2026 [Optional][LOI/Pre-App], 09-Dec-2026</div> <div>This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications that propose to develop a product, process or service for commercialization with the aim of improving minority health and/or reducing and ultimately eliminating health disparities in one or more NIH-defined populations that experience health disparities. Appropriate technologies should be effective, affordable, and culturally acceptable.</div> </div>				
123794	NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award	National Institutes of	PAR-25-	23-Jun-2025	1,750,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	(R61/R33 Clinical Trial Required)	Health/DHHS	269		USD
	<p>Contact Name Sekai Chideya, M.D., MPH</p> <p>Contact Telephone 301-827-1916</p> <p>Contact Email sekai.chideya@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Jun-2025 , 17-Jul-2025 , 23-Feb-2026 , 17-Mar-2026 , 20-Oct-2026 , 13-Nov-2026</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to three years (R61 phase) of support for milestone-driven testing of pharmacokinetics, bioavailability, and assessment of the natural product's effect (i.e., measure of mechanism of action) when used by humans on a biological signature(s). If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications are encouraged to design R33 studies to determine how to optimize the impact of the natural product on the biological signature by optimizing the delivery of the natural product by examining different doses or formulation. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same biological signature; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R61/R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer. A maximum of 5 years will be supported by the two phases of the R61/R33 award. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.</p>				
123784	NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)	National Institutes of Health/DHHS	PAR-25-270	23-Jun-2025	1,050,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Sekai Chideya, M.D., MPH</p> <p>Contact Telephone 301-827-1916</p> <p>Contact Email sekai.chideya@nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL </p> <p>Deadline Dates (ALL) 23-Jun-2025 , 17-Jul-2025 , 23-Feb-2026 , 17-Mar-2026 , 20-Oct-2026 , 13-Nov-2026</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to 3 years support for studies to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications are encouraged to design studies to determine how to optimize the impact of the natural product on the biological signature by optimizing the delivery of the natural product by examining different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same biological signature; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer.</p>				
128846	Leveraging Extant Data to Understand Developmental Trajectories of Late Talking Children (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-25-220	02-Jun-2025	275,000 USD
	<p>Contact Name Holly Storkel, PhD, CCC-SLP</p> <p>Contact Telephone 301-451-6842</p> <p>Contact Email holly.storkel@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Jun-2025 , 02-Oct-2025</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The National Institutes of Health (NIH) Tackling Acquisition of Language in Kids (TALK) initiative seeks to support activities to better understand early language learning and delay. NIH TALK invites applications for research projects that aim to further understanding of the developmental trajectories of late talking children by leveraging existing data and creating open and shared data resources to aid in identifying patterns and predictors of developmental outcomes in late talking children, and exploring potential underlying mechanisms, risk factors, and sequelae. Late talking, also known as late language emergence, is diagnosed when a child, usually over the age of 18 months, is not meeting expressive language milestones, for any reason. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).</p>				
128847	Information and Practice Needs Relevant to Late Talking Children (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-25-217	02-Jun-2025	275,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Holly Storkel, PhD, CCC-SLP</p> <p>301-451-6842</p> <p>holly.storkel@nih.gov</p> <p></p> <p>Link to program URL</p> <p>02-Jun-2025 , 02-Oct-2025</p> <p>The National Institutes of Health (NIH) Tackling Acquisition of Language in Kids (TALK) initiative seeks to support activities to better understand early language learning and delay. NIH TALK invites applications for research projects that aim to better understand the information and practice needs of caregivers, professionals, and other invested parties who support late talking children and to determine whether those needs are being effectively met. Late talking, also known as late language emergence, is diagnosed when a child, usually over the age of 18 months, is not meeting expressive language milestones, for any reason. Community engaged research combined with rigorous qualitative research and diverse research teams are needed to enrich our understanding of how to get state-of-the-science information and practice to those who need it most to guide decisions about late talking children. This Notice of Funding Opportunity (NOFO) requires a Community Engagement Plan (CEP).</p>			
110513	Notice of Special Interest (NOSI): High Priority Areas in Genetics, Epigenetics, and Developmental Neuroscience Branch in the Division of Neuroscience and Behavior	National Institutes of Health/DHHS	NOT-DA-23-004	07-May-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p>	<p>Jonathan D. Pollock, Ph.D.</p> <p>301-435-1309</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email ipollock@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The mission of the Division of Neuroscience and Behavior (DNB) is to discover, facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of drug addiction across the lifespan and to guide treatment strategies. The Genetics, Epigenetics, and Development (GED) Branch within DNB supports research on the genetics, epigenetics, and developmental mechanisms that underlie addiction and substance use disorders (SUD).</p>				
116476	Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-25-110	05-Jun-2025	Not Specified
	<p>Contact Name Katie M. Vance, Ph.D.</p> <p>Contact Telephone 301-435-6640</p> <p>Contact Email Katie.Vance@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.</p>				
115307	Notice of Special Interest (NOSI): Understanding Sudden Death in the Young Through Research	National Institutes of Health/DHHS	NOT-HL-22-040	07-May-2025	Not Specified
	<p>Contact Name Kristin M. Burns, MD</p> <p>Contact Telephone 301-594-6859</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email kristin.burns@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</p> <p>Synopsis This Notice of Special Interest (NOSI) highlights interest in receiving grant applications focused on mechanistic, genetic, and other studies to evaluate causes and consequences of, and risk factors for sudden death in the young (SDY). Studies are required to use phenotypic data and/or DNA samples and/or associated sequence data from the NIH/CDC Sudden Death in the Young (SDY) Case Registry as foundations for their research. Studies may use SDY Case Registry phenotypic data and/or samples and/or sequence data alone or in combination with other cohorts. Results of such studies are required to adhere to the NIH Data Sharing Policy so that the data is disseminated widely and provides an evidence base to advance discussions about screening and prevention of SDY.</p>				
116310	Notice of Special Interest (NOSI): Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy	National Institutes of Health/DHHS	NOT-HL-23-003	05-Jun-2025	Not Specified
	<p>Contact Name Anthony Agresti</p> <p>Contact Telephone 301-827-8014</p> <p>Contact Email agrestia@nhlbi.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025</p> <p>Synopsis This Notice of Special Interest (NOSI) aims to accelerate a comprehensive understanding of the mechanisms of COVID-19-Associated Coagulopathy (CAC) which are provoked by vascular endothelial cell injury, hyperimmune responses, and hypercoagulability at genomic, molecular, and cellular levels. Knowledge obtained from such studies may be applied to the future design of early diagnostics and effective treatment for high-risk patients as well as enable CAC research findings to be applied to on-going COVID-19 clinical trials.</p>				
121565	Health and Health Care Disparities Among Persons Living with Disabilities (R01 - Clinical Trials Optional)	National Institutes of Health/DHHS	PAR-23-309	05-Jun-2025	Not Specified
	<p>Contact Name Sundania J. W. Wonnum, PhD, LCSW</p> <p>Contact Telephone</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email sundania.wonnum@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to support novel and innovative research that examines and/or intervenes on the underlying and multilevel causes, pathways, and factors adversely impacting the health and well-being of persons with disabilities at the intersections of race and ethnicity, and socioeconomic status.</p>				
121869	Interventions on Health and Healthcare Disparities on Non-Communicable and Chronic Diseases in Latin America: Improving Health Outcomes Across the Hemisphere (R01 - Clinical Trial Required)	National Institutes of Health/DHHS	PAR-25-342	07-May-2025	Not Specified
	<p>Contact Name Larissa Avilés-Santa, MD, MPH, Director</p> <p>Contact Telephone 301-827-6924</p> <p>Contact Email avilessantal@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 07-May-2027</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to support innovative and interdisciplinary team research focused on clinical, health services, and/or community-based interventions that address health and healthcare disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos.</p>				
121337	NIAID and NIDDK Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PA-25-249	07-May-2025	Not Specified
	<p>Contact Name Carmen Moten, Ph.D., MPH</p> <p>Contact Telephone 240-669-2924</p> <p>Contact Email Altraininghelpdesk@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to encourage researchers from diverse backgrounds to work with their institutions to submit applications for research projects within the mission of either NIAID or NIDDK. This NOFO seeks to support either (a) a New Investigator (NI), who has not previously competed successfully for substantial, independent funding from NIH, or (b) an 'At-Risk' investigator, who had prior support as a PD/PI on a substantial independent research award and unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year.</p>				
116616	Notice of Special Interest (NOSI): Research Project Grants in Valvular Heart Disease (CAROL Act)	National Institutes of Health/DHHS	NOT-HL-23-079	07-May-2025	Not Specified
	<p>Contact Name Frank Evans, PhD</p> <p>Contact Telephone 301-435-0510</p> <p>Contact Email evansf@nhlbi.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis As part of the National Heart, Lung, and Blood Institute's implementation of the Cardiovascular Advances in Research and Opportunities Legacy (CAROL) Act, this Notice of Special Interest is seeking R01 applications that propose research in valvular heart disease.</p>				
128630	Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-25-227	06-May-2025 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Melissa Parisi, MD, PhD</p> <p>Contact Telephone 301-435-6880</p> <p>Contact Email parisima@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 , 06-Sep-2026 [Optional][LOI/Pre-App]</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>App], 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027 , 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027 , 06-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027</p> <p>This Notice of Funding Opportunity (NOFO) encourages applications that will expand knowledge of the natural history of disorders that currently are, or may become, part of statewide newborn screening programs. A comprehensive understanding of the natural history of a condition is necessary to facilitate appropriate interventions for infants identified by newborn screening. Characterization of the sequence and timing of symptom development provides information crucial for developing targeted, age-appropriate treatments and for establishing a baseline against which to assess novel interventions. In addition, for some conditions, establishment of genotype-phenotype correlations may facilitate prediction of the clinical course; for others, identification of modifying genetic, epigenetic, or environmental factors may enhance understanding of clinical outcomes. Comprehensive data on the natural history of a condition will facilitate the field's ability to: 1) identify the underlying biological mechanisms; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the condition; 3) improve diagnostic accuracy; 4) facilitate clinical trials by providing comprehensive natural history data; 5) prevent, manage, and treat symptoms and complications of the condition; 6) furnish physicians and families with needed support and predictive information about the condition; and 7) establish data collection systems or patient registries to collect longitudinal data (e.g., child/family outcomes following newborn screening).</p>				
122756	<p>Addressing Health and Health Care Disparities among Sexual and Gender Minority Populations (R01 - Clinical Trials Optional)</p>	National Institutes of Health/DHHS	PAR-24-077	07-May-2025	2,500,000 USD
	<p>Contact Name Rada K. Dagher, Ph.D., M.P.H.</p> <p>Contact Telephone 301-451-2187</p> <p>Contact Email ada.dagher@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to support innovative observational and intervention-based research to identify and characterize the pathways and mechanisms through which health and health care disparities occur among sexual and gender minority populations of minoritized racial/ethnic and socio-economic statuses. Per Notice Number: NOT-MH-24-170: Research Priorities The National Institute of Mental Health (NIMH) will only accept nonclinical trials applications that reflect the mission and scientific priorities as identified in the strategic plan NIMH » The National Institute of Mental Health Strategic Plan (nih.gov) and also NIMH's Approach to Mental Health Disparities Research. Clinical trial applications will not be accepted under this notice. Per NOT-MH-20-067, NIMH expects that grant applications involving</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	human research participants will collect a minimum set of Common Data Elements.				
122024	Understanding the Impact of Healthcare System and Clinician Factors on Disparities in Maternal Morbidity and Mortality (R01 - Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-24-059	05-Jun-2025	Not Specified
	Contact Name	Rada K. Dagher, PhD, MPH			
	Contact Telephone	301-451-2187			
	Contact Email	rada.dagher@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026			
	Synopsis				
124219	Long-Term Effects of Disasters on Healthcare Systems in Populations with Health Disparities (R01- Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-24-109	06-May-2025 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Carolina Solis-Sanabria, MD, MPH, FACS			
	Contact Telephone	301-827-3460			
	Contact Email	carolina.solissanabria@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	06-May-2025 [Optional][LOI/Pre-App], 07-May-2025 , 05-Jun-2025 , 06-Sep-2025 [Optional][LOI/Pre-App], 07-Sep-2025 , 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 07-Jan-2026 , 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 07-May-2026 , 05-Jun-2026 , 06-Sep-2026 [Optional][LOI/Pre-App], 07-Sep-2026 , 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 07-Jan-2027 , 05-Feb-2027 , 07-May-2027			
	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to support collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on healthcare systems serving populations that experience health disparities living in the U.S. and its territories.			
120101	Social Disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-25-067	05-Jun-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Jovier Evans, Ph.D.</p> <p>Contact Telephone 301-443-6328</p> <p>Contact Email jevans1@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental. This NOFO solicits R01 applications, while the companion announcement PAR-25-066 solicits R21 applications. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism.</p>				
108065	Notice of Special Interest (NOSI): Pediatric COVID-19 and Respiratory Viral Co-infection	National Institutes of Health/DHHS	NOT-HL-22-004	07-May-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>Synopsis This NOSI is intended to support projects that will employ existing and new clinical trial cohorts/observational cohorts to screen for co-infection, phenotype and collect biospecimens to answer some of these questions and to encourage investigator-initiated applications for basic, translational and human subject research (not clinical trials) in this space.</p>				
117793	Interventions to Expand Cancer Screening and Preventive Services to ADVANCE Health in Populations that Experience Health Disparities (R01, Clinical Trial Required)	National Institutes of Health/DHHS	PAR-25-098	07-May-2025	Not Specified
	Contact Name JoyAnn Courtney, Ph.D.				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-402-3911</p> <p>Contact Email joyann.courtney@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</p> <p>Synopsis The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this R01 to solicit applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. Interventions should include screening, preventive services, or other healthcare processes, including timely follow-up of abnormal findings, and referral to accessible care. Projects are encouraged to leverage collaborations with community partners and service providers. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community. Specific research interests of participating NIH ICs are detailed within. Projects are encouraged to leverage collaborations with community partners and service providers to promote or enhance existing interventions and/or adapt new combinations of evidence-based strategies. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community.</p>				
112441	Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-22-210	05-Jun-2025	2,500,000 USD
	<p>Contact Name Liam O'Fallon</p> <p>Contact Telephone 984-287-3298</p> <p>Contact Email ofallon@niehs.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages multidisciplinary projects to investigate the potential health risks of environmental exposures of concern to a community and to develop and implement an environmental public health action plan based on research findings. Projects supported under this program will employ community-engaged research methods to conduct research and to translate research findings into public health action. This announcement reflects NIEHS' and NIMHD's commitment to environmental health disparities and environmental justice research. This FOA also advances efforts to nurture and sustain trust and bi-directional communication between academic researchers and affected communities. The</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Research to Action program is part of the National Institute of Environmental Health Sciences (NIEHS) "Partnerships for Environmental Public Health" (PEPH) network (https://www.niehs.nih.gov/research/supported/translational/peph/index.cfm).				
120869	Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for Alcohol, Tobacco, and Other Drugs (ATOD) Use and Misuse in Adult Populations That Experience Health Disparities (R01, Clinical Trial Required)	National Institutes of Health/DHHS	PAR-26-001	07-May-2025	Not Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> Denise Stredrick, Ph.D. 301-402-9749 denise.stredrick@nih.gov Link to program URL 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICOs) are issuing this NOFO seeking applications to test innovative approaches to implementing SBIRT/P for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities. SBIRT/P, (a term used for purposes of this funding announcement), involves screening individuals for risk of ATOD use and misuse, briefly intervening with a conversation about harmful substance use, and referring individuals for treatment or preventive services, as needed. Proposed research should include prospective tests of SBIRT/P and should leverage collaborations with healthcare and community partners Specific research interests of participating NIH ICOs are detailed within. </div>				
120817	Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-25-221	05-Jun-2025	Not Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> </div> <div> David Berrigan 240-276-6752 berrigad@mail.nih.gov Link to program URL 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 </div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Applications that address multiple levels of consumption, such as moderate and heavy drinking, are of particular interest, as well as those focusing on alcohol use disorder (AUD) from the perspective of cancer prevention and control. Proposals addressing understudied areas are encouraged, as is attention to underrepresented minority (URM) populations experiencing cancer and alcohol-related disparities such as American Indian, Alaskan Native, and sexual and gender minority populations.			
125485	Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-192	07-May-2025	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	GrantsInfo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027			
	Synopsis	The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
NIH Institutes and Centers (ICs) based on their scientific missions.					
125482	Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-190	07-May-2025	Not Specified
<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email GrantsInfo@nih.gov</div> <div>Sponsor Website</div> <div>Program URL Link to program URL</div> <div>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</div> <div>Synopsis <p>The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Candidates not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-191).</p> </div> </div>					
125483	Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-191	07-May-2025	Not Specified
<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email GrantsInfo@nih.gov</div> <div>Sponsor Website</div> <div>Program URL Link to program URL</div> <div>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</div> </div>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-192).</p>				
125230	<p>Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)</p> <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis</p> <p>The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>	National Institutes of Health/DHHS	PA-24-186	07-May-2025	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
125516	Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-183	07-May-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone301-496-8580</div> <div>Contact Emailgrantinfo@nih.gov</div> <div>Sponsor Website</div> <div>Program URLLink to program URL</div> <div>Deadline Dates (ALL)07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</div> <div>Synopsis<p>The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research.</p><p>Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p></div>				
125228	Mentored Patient-Oriented Research Career Development Award (Parent K23 – Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-185	07-May-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Emailgrantinfo@nih.gov</div> <div>Sponsor Website</div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-184).</p>				
125512	Mentored Clinical Scientist Research Career Development Award (Parent K08 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-181	07-May-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-496-8580</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-182).</p>				
125513	Mentored Clinical Scientist Research Career Development Award (Parent K08 – Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-182	07-May-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-496-8580</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-181).</p>				
125524	Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-175	07-May-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email grantsinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-176).</p>				
112749	Notice of Special Interest (NOSI): HEAL Initiative: Opioid Use Disorder Care Pathways for Individuals with Histories of Exposure to Violence	National Institutes of Health/DHHS	NOT-DA-23-007	12-Jun-2025	Not Specified
	<p>Contact Name Carrie Mulford</p> <p>Contact Telephone 301-827-6473</p> <p>Contact Email Carrie.Mulford@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2025</p> <p>Synopsis The proposed initiative seeks to test innovative models of service delivery to improve substance use and mental health outcomes for individuals who have actionable needs following exposure to violence.</p>				
125559	Midcareer Investigator Award in Patient-Oriented Research (Parent K24 - Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-189	07-May-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and junior clinical faculty. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>				
125583	Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-180	07-May-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>				
129398	NIH Research Project Grant (Parent R01 Clinical Trial Required)	National Institutes of Health/DHHS	PA-25-305	07-May-2025	Not Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> grantsinfo@nih.gov Link to program URL 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028 The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Notice of Funding Opportunity requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement. </div>				
129396	NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-25-303	07-May-2025	Not Specified
	Contact Name				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email grantsinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</p> <p>Synopsis This Parent Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ NOFO.</p>				
129589	Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-25-338	05-Jun-2025	2,495,000 USD
	<p>Contact Name Miguel Ossandon MS</p> <p>Contact Telephone 240-276-5714</p> <p>Contact Email ossandom@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines "innovation" as likelihood to deliver a new capability to end users.</p>				
129395	NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-25-301	07-May-2025	Not Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>grantsinfo@nih.gov</div> <div>Link to program URL</div> <div>07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</div> <div>The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).</div> </div>				
112444	HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K23 - Clinical Trial Required)	National Institutes of Health/DHHS	PAS-22-207	12-Jun-2025	Not Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Lori Ducharme, Ph.D.</div> <div>301-827-6331</div> <div>Lori.Ducharme@nih.gov</div> <div></div> <div>Link to program URL</div> <div>12-Jun-2025 , 12-Oct-2025</div> <div>The purpose of this Mentored Patient-Oriented Research Career Development Award in Implementation Science for</div> </div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Substance Use Prevention and Treatment (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research from an implementation science perspective. These awards provide salary and research support for a sustained period of “protected time” (3-5 years) for an intensive, supervised career development experience leading to research independence in this area of specialization. Realizing the return on public investment in the development of evidence-based treatments and preventive interventions to address the ongoing overdose crisis depends on a cadre of skilled clinician researchers with expertise in implementation science, who can help move these interventions into routine clinical practice. Implementation science focuses on identifying modifiable barriers to the uptake and sustained use of evidence-based practices in real world clinical settings, and developing replicable and scalable strategies to overcome those barriers. While this field has grown rapidly over the past 15 years, there remain a limited number of independent clinician researchers with dual expertise in substance use and implementation science, limiting the field’s capacity to address persistent gaps in this area. There is a pressing need for a deeper bench of clinician researchers who can be called upon to meet ongoing and emerging implementation challenges in the substance use field. This Funding Opportunity Announcement (FOA) will support early career investigators who have foundational clinical training in substance use prevention or treatment and/or co-occurring mental illness, and will provide support and protected time to acquire training and research experience in implementation science. Development and execution of an independent NIH-defined clinical trial applying implementation science methods to patient-oriented research in one or more of the four domains of the HHS Overdose Prevention Strategy (prevention; evidence-based addiction treatment; harm reduction; or recovery research) is required. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, should consult the NIH Research Career Development Awards website for alternative funding opportunities.</p>				
112443	HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required)	National Institutes of Health/DHHS	PAS-22-206	12-Jun-2025	Not Specified
	Contact Name	Lori Ducharme, Ph.D.			
	Contact Telephone	301-827-6331			
	Contact Email	Lori.Ducharme@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Jun-2025 , 12-Oct-2025			
	Synopsis	The purpose of this Mentored Research Scientist Development Award in Implementation Science for Substance Use			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Prevention and Treatment (K01) is to provide support and “protected time” (3-5 years) for an intensive, supervised career development experience leading to research independence in this area of specialization. Realizing the return on public investment in the development of evidence-based treatments and preventive interventions to address the ongoing overdose crisis depends on a cadre of skilled researchers with expertise in implementation science, who can help move these interventions into routine practice. Implementation science focuses on identifying modifiable barriers to the uptake and sustained use of evidence-based practices in real world settings and developing replicable and scalable strategies to overcome those barriers. While this field has grown rapidly over the past 15 years, there remain a limited number of independent researchers with dual expertise in addiction research and implementation science, constraining the field’s capacity to respond to continued calls for research in this area. There is a pressing need for a deeper bench of researchers who can be called upon to meet ongoing and emerging implementation challenges in the addiction field. This Funding Opportunity Announcement (FOA) will support early career investigators who have foundational training in substance use prevention or treatment research and will provide support and protected time to acquire training and research experience in implementation science. Development and execution of an independent NIH-defined clinical trial applying implementation science methods to one of the four domains of the HHS Overdose Prevention Strategy (prevention; evidence-based addiction treatment; harm reduction; or recovery research) is required. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, should consult the NIH Research Career Development Awards website for alternative funding opportunities.</p>				
115095	Mentored Career Development Program for Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-23-073	07-May-2025	Not Specified
	Contact Name Contact Telephone Contact Email AITraininghelpdesk@niaid.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to provide early-stage investigators with support and “protected time” (up to five years) for intensive, research-focused career development program activities under the guidance of an experienced mentorship team with expertise in both the preclinical application of nonhuman primate (NHP) models and				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>in translation of the results from such studies to clinical application. The focus of this program is to increase the number of highly skilled scientists using NHP models to address complex translational biomedical research designed to foster translation of outcomes into the clinic. The expectation is that through this sustained period of research career development and training, awardees will launch independent research careers and become competitive for new research project grant (e.g., R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p>				
125538	NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-195	07-May-2025	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	grantinfo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027			
	Synopsis	<p>The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
125534	NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-193	07-May-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email grantinfo@nih.gov</div> <div>Sponsor Website</div> <div>Program URL Link to program URL</div> <div>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</div> <div>Synopsis <p>The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Candidates not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-194).</p> </div>				
125537	NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-194	07-May-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email grantinfo@nih.gov</div> <div>Sponsor Website</div> <div>Program URL Link to program URL</div> <div>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</div> <div>Synopsis <p>The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support</p> </div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>during this transition in order to help awardees to launch competitive, independent research careers. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-193).</p>				
125557	Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-187	07-May-2025	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	grantinfo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027			
	Synopsis	<p>The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-188).</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
125527	Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-177	07-May-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email grantsinfo@nih.gov</div> <div>Sponsor Website</div> <div>Program URL Link to program URL</div> <div>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</div> <div>Synopsis<p>The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p></div>				
125530	Independent Scientist Award (Parent K02 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-178	07-May-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email grantinfo@nih.gov</div> <div>Sponsor Website</div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-179).</p>				
125558	Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-188	07-May-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and/or junior clinical faculty. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-187).</p>				
125532	Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-179	07-May-2025	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	grantinfo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027			
	Synopsis	<p>The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by another investigator. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-178). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-179).</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
125526	Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-24-176	07-May-2025	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	grantsinfo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027			
	Synopsis	The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs use the K01 to support career development in specific fields. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-175).			
117692	RFA-MH-23-331 -- BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-MH-23-331	13-Jun-2025	Not Specified
	Contact Name	James Churchill, Ph.D.			
	Contact Telephone	301-326-8800			
	Contact Email	BRAINDIVERSITYK99R00@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	13-Jun-2025 , 15-Oct-2025 , 13-Feb-2026			
	Synopsis	The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00)			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>program is to enhance diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds, including those from underrepresented groups in the biomedical and behavioral sciences, in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to assist awardees in launching independent research careers. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this Notice of Funding Opportunity (NOFO) are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (RFA-MH-22-330).</p>				
117690	RFA-MH-23-330 -- BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Required)	National Institutes of Health/DHHS	RFA-MH-23-330	13-Jun-2025	Not Specified
	Contact Name	James Churchill, Ph.D.			
	Contact Telephone	301-326-8800			
	Contact Email	BRAINDIVERSITYK99R00@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	13-Jun-2025 , 15-Oct-2025 , 13-Feb-2026			
	Synopsis	<p>The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds, including those from underrepresented groups in the biomedical and behavioral sciences, in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to assist awardees in launching independent research careers. This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (RFA-MH-22-331).</p>				
121493	RFA-EY-25-001 -- BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-EY-25-001	17-Jun-2025	400,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Martha Flanders, PhD 301-827-5191 BRAIN-FOAs@nih.gov Link to program URL 17-Jun-2025 , 15-Jun-2026 <p>This NOFO seeks applications for unique and innovative recording and/or modulation technologies that are in the earliest stage of development, including new and untested ideas that are in the initial stages of conceptualization. Some projects may aim to increase recording or modulation capabilities by many orders of magnitude, while others may aim to improve the precision and selectivity of recording or modulation (also referred to as stimulation, perturbation, or manipulation). A wide range of modalities are appropriate including acoustic, chemical, electrical, magnetic, and optical, as well as the use of genetic tools. Invasive or non-invasive approaches are sought that will enable large-scale recording and/or precise manipulation of neural activity, and that would ultimately be compatible with experiments in humans or behaving animals. Applications are encouraged from any qualified individual, including chemists, physicists, engineers, theoreticians, materials scientists, and others from fields not typically involved with neuroscience research. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.</p>			
113804	Notice of Special Interest (NOSI): Research on the Impact of Policy Changes	National Institutes of	NOT-HD-	07-May-2025	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	and Emerging and Evolving Public Health Crises on NICHD Populations of Interest	Health/DHHS	22-038		Specified
	<div>Contact NameElyse R. Grossman</div> <div>Contact Telephone240-551-3628</div> <div>Contact Emailelyse.grossman@nih.gov</div> <div>Sponsor Website</div> <div>Program URLLink to program URL</div> <div>Deadline Dates (ALL)07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</div> <div>Synopsis<p>This notice informs applicants of an expansion to the NOT-HD-22-038 "Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest" to include research priority areas for the National Institute on Drug Abuse (NIDA). The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to announce that research on the effects of: emerging and evolving public health crises; and/or policy changes on the health, development, and well-being of populations of interest to the NIDA is of high program priority. The NIDA populations of interest include neonates, infants, children, adolescents, young adults, adults, and older adults, people using or misusing substances, people with substance use disorders, as well as the families of these individuals. The NIDA supports research on the impact of policy in understanding and addressing substance use risk and behavior across the life span. For information on the NIDA Strategic Goals and Mission, see https://nida.nih.gov/about-nida/strategic-plan/nidas-mission.</p></div>				
114061	Notice of Special Interest (NOSI): Explainable Artificial Intelligence for Decoding and Modulating Neural Circuit Activity Linked to Behavior	National Institutes of Health/DHHS	NOT-MH-23-110	07-May-2025	Not Specified
	<div>Contact NameMauricio Rangel-Gomez, Ph.D.</div> <div>Contact Telephone301-435-6908</div> <div>Contact Emailmauricio.rangel-gomez@nih.gov</div> <div>Sponsor Website</div> <div>Program URLLink to program URL</div> <div>Deadline Dates (ALL)07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026</div> <div>Synopsis<p>This Notice of Special Interest (NOSI) solicits applications in the area of XAI applied to neuroscientific questions of encoding, decoding, and modulation of neural circuits linked to behavior. This NOSI encourages collaborations between computationally and experimentally focused investigators. This NOSI seeks the development of machine learning algorithms</p></div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	that are able to mechanistically explain how experimental manipulations affect cognitive, affective, or social processing in humans or animals. Proof-of-concept applications aimed at improving the current state of the technology that uses XAI to provide unbiased, hierarchical explanations of causal relationships between complex neural and behavioral data are also appropriate.				
114367	Notice of Special Interest (NOSI): Advancing Development of Rapid Point-of-Care Hepatitis C Virus Diagnostics	National Institutes of Health/DHHS	NOT-AI-23-001	05-Apr-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Julie Dyall, PhD</div> <div>301-631-7296</div> <div>dyallj@niaid.nih.gov</div> <div></div> <div>Link to program URL</div> <div>05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026</div> <div>The purpose of this Notice of Special Interest is to announce that the National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) and the National Cancer Institute (NCI) are encouraging applications in the area of translational research and development of rapid Point-of-Care diagnostics that will diagnose active viremic HCV infections.</div>			
115062	Notice of Special Interest (NOSI): argeting the Endocannabinoid System for Brain Health and Acute and Chronic Diseases	National Institutes of Health/DHHS	NOT-DA-22-048	07-May-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Yu (Woody) Lin, PhD</div> <div>301-435-1318</div> <div>ylin1@mail.nih.gov</div> <div></div> <div>Link to program URL</div> <div>07-May-2025 , 25-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 25-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</div> <div>This Notice of Special Interest (NOSI) encourages studies of the endocannabinoid system (ECS) and its roles in brain health and acute and chronic disease, substance use, and substance use disorder (SUD). The desired outcomes of research will be a</div>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	mechanistic understanding of how cannabinoids and manipulation of the ECS can elicit both therapeutic and deleterious effects as well as the role of cannabinoids and ECS in symptom management.				
120102	Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-25-066	16-Jun-2025	275,000 USD
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Jovier Evans, Ph.D.</div> <div>301-443-6328</div> <div>jevans1@mail.nih.gov</div> <div></div> <div>Link to program URL</div> <div>16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026</div> <div> <p>The purpose of this Notice of Funding Opportunity (NOFO) is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental. This NOFO solicits R21 applications, while the companion announcement PAR-25-067 solicits R01 applications. High risk/high payoff projects that lack preliminary data may be most appropriate for this R21 mechanism, while applications with preliminary data should apply to the R01 mechanism.</p> </div> </div>				
120393	Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-25-096	16-Jun-2025	400,000 USD
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Melissa Rotunno, Ph.D.</div> <div>240-276-7245</div> <div>rotunnom@mail.nih.gov</div> <div></div> <div>Link to program URL</div> <div>16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026</div> <div> <p>Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or</p> </div> </div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.</p>				
125227	Mentored Patient-Oriented Research Career Development Award (Parent K23 – Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-184	07-May-2025	Not Specified
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email grantinfo@nih.gov</div> <div>Sponsor Website</div> <div>Program URL Link to program URL</div> <div>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027</div> <div>Synopsis <p>The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-185).</p> </div>				
127139	Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	PAR-24-226	07-May-2025	Not Specified
	<div>Contact Name Lanay M. Mudd, Ph.D., FACS</div> <div>Contact Telephone 301-594-9346</div> <div>Contact Email lanay.mudd@nih.gov</div> <div>Sponsor Website</div>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027</p> <p>Synopsis The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) program is to support a cohort of early career, independent investigators from diverse backgrounds (for example, individuals from underrepresented groups) conducting research in NIH mission areas. The program has two components: an individual career transition award for postdoctoral scholars (K99/R00) and a research education cooperative agreement (UE5) awarded to organizations to provide these scholars with additional mentoring, networking and professional development activities to support their transition to and success in independent, tenure-track or equivalent research-intensive faculty careers. The MOSAIC program supports NIH's efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The goal of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds from their mentored postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The program is designed to support postdoctoral researchers who have demonstrated meaningful contributions and proposed compelling future plans to promote broad participation in the biomedical research workforce, such as activities that promote inclusive, supportive, and accessible biomedical research environments that support the success of trainees and scientists from all backgrounds, including individuals from underrepresented groups. This Notice of Funding Opportunity (NOFO) is designed specifically to support candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Candidates not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must work with their institutions to apply to companion NOFO PAR-24-225.</p>				
108571	Notice of Special Interest (NOSI): Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy	National Institutes of Health/DHHS	NOT-HL-23-003	05-Jun-2025	Not Specified
	<p>Contact Name Anthony Agresti</p> <p>Contact Telephone 301-827-8014</p> <p>Contact Email agrestia@nhlbi.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2025</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>This Notice of Special Interest (NOSI) aims to accelerate a comprehensive understanding of the mechanisms of COVID-19-Associated Coagulopathy (CAC) which are provoked by vascular endothelial cell injury, hyperimmune responses, and hypercoagulability at genomic, molecular, and cellular levels. Knowledge obtained from such studies may be applied to the future design of early diagnostics and effective treatment for high-risk patients as well as enable CAC research findings to be applied to on-going COVID-19 clinical trials.</p>				
120387	Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-25-095	05-Jun-2025	1,750,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Melissa Rotunno, Ph.D.</p> <p>240-276-7245</p> <p>rotunnom@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.</p>			
128812	Investigator Initiated Research in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-25-228	05-Jun-2025	2,500,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p>	<p>Jean Gao, Ph.D.</p> <p></p> <p>jean.gao@nih.gov</p> <p></p> <p>Link to program URL</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
122207	<p>Deadline Dates (ALL) 05-Jun-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Feb-2027 , 05-Jun-2027</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research that develops innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems.</p>	National Institutes of Health/DHHS	PAR-25-371	17-Jun-2025	Not Specified
	Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)				
	<p>Contact Name Dave Kaufman</p> <p>Contact Telephone 301-402-4997</p> <p>Contact Email dave.kaufman@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 20-Oct-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genetic or genomic research. Applications may propose studies using either single or mixed methods. Approaches may include but are not limited to empirical qualitative and quantitative methods, and conceptual, legal, and normative analyses. Applied research designed to address ELSI issues in genetics and genomics will also be considered responsive. Direct engagement with communities and other interested groups is encouraged, but not required. Plan for Enhancing Diverse Perspectives The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: Transdisciplinary research projects and collaborations among researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. Opportunities to enhance the research environment to benefit early- and mid-career investigators. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				
122256	Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-25-369	17-Jun-2025	275,000 USD
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Dave Kaufman</div> <div>301-402-4997</div> <div>dave.kaufman@nih.gov</div> <div></div> <div>Link to program URL</div> <div>17-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 20-Oct-2026</div> <div> <p>This Notice of Funding Opportunity (NOFO) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genetic or genomic research. Applications may propose studies using either single or mixed methods, that break new ground, extend previous discoveries in new directions, or develop preliminary data in preparation for larger studies. Approaches may include but are not limited to empirical qualitative and quantitative methods, and conceptual, legal, and normative analyses. Applied research designed to address ELSI issues in genetics and genomics will also be considered responsive. Direct engagement with communities and other stakeholders is encouraged, but not required.</p> </div>			
128338	Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-25-059	18-Jun-2025	750,000 USD
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div>	<div>Becky Roof, PhD</div> <div>301-496-1779</div> <div>rebecca.roof@nih.gov</div> <div></div>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL Link to program URL Deadline Dates (ALL) 18-Jun-2025 , 20-Oct-2025 , 18-Feb-2026 , 18-Jun-2026 , 20-Oct-2026 , 18-Feb-2027 , 18-Jun-2027 , 20-Oct-2027 Synopsis This Notice of Funding Opportunity (NOFO) encourages research grant applications to develop in vitro, ex vivo or in vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This NOFO is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE). This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).				
114675	Notice of Special Interest (NOSI): Optimization of Data Storage and Utilization for the Sequence Read Archive (SRA)	National Institutes of Health/DHHS	NOT-GM-23-015	05-Apr-2025	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Apr-2025 , 12-Apr-2025 , 07-May-2025 , 16-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 25-Jun-2025 , 08-Aug-2025 , 05-Sep-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 25-Oct-2025 , 08-Dec-2025 Synopsis The purpose of this Notice of Special Interest (NOSI) is to inform the scientific community of the interest of NIGMS, NLM, and ODSS in supporting efficiency optimization and cost reduction for Sequence Read Archive (SRA) data storage and utilization.				
129270	Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-25-296	16-Jun-2025	3,250,000 USD
	Contact Name Kristopher Bough, Ph.D. Contact Telephone 240-987-9930 Contact Email kristopher.bough@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 16-Jun-2025 , 17-Oct-2025 , 18-Feb-2026 , 15-Jun-2026 , 19-Oct-2026 , 17-Feb-2027 , 15-Jun-2027 , 19-Oct-2027 Synopsis The CTSA Collaborative and Innovative Acceleration Award (CCIA) aims to accelerate the pace of translational research by supporting the collaborative development, dissemination, and sustainable implementation of innovative solutions across the				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>CTSA Program Consortium and beyond. This limited competition Notice of Funding Opportunity (NOFO) invites investigator-initiated applications to develop, demonstrate, and disseminate innovative new approaches, technologies, resources, or models that increase the impact of research across diseases, transform the field of translational science, and bring more treatments for all people more quickly.</p>				
129182	Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-25-298	07-May-2025	375,000 USD
	Contact Name	Lynn Mertens King, Ph.D.			
	Contact Telephone	301-757-5538			
	Contact Email	lynn.king@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 25-Jun-2025 , 07-Sep-2025 , 25-Oct-2025 , 07-Jan-2026 , 25-Feb-2026 , 07-May-2026 , 25-Jun-2026 , 07-Sep-2026 , 25-Oct-2026 , 07-Jan-2027 , 25-Feb-2027 , 07-May-2027 , 25-Jun-2027 , 07-Sep-2027 , 25-Oct-2027 , 07-Jan-2028			
	Synopsis	<p>The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for health professional, undergraduate and graduate students and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate or advanced science degrees and have received no more than \$6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the schools and colleges within the institution as a whole. Help determining the Organization Funding Level can be found here or https://grants.nih.gov/grants/funding/r15.htm.</p>			
129392	NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-25-304	07-May-2025	275,000 USD
	Contact Name				
	Contact Telephone	301-480-7075			
	Contact Email	grantsinfo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Notice of Funding Opportunity does not accept applications proposing clinical trial(s).</p>				
129393		National Institutes of Health/DHHS	PA-25-306	07-May-2025	275,000 USD

Contact Name	
Contact Telephone	
Contact Email	grantsinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028
Synopsis	<p>The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (see Related Notices) only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement.</p>

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
122258	Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-25-370	17-Jun-2025	100,000 USD
	Contact Name	Dave Kaufman			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-402-4997</p> <p>Contact Email dave.kaufman@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Jun-2025 , 20-Oct-2025 , 17-Feb-2026 , 18-Jun-2026 , 16-Oct-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites Small Research Grant (R03) applications that propose to study the ethical, legal and social implications (ELSI) of human genetic or genomic research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data. Applications may propose studies using either single or mixed methods. Applied research designed to address ELSI issues in genetics and genomics will also be considered responsive. Direct engagement with communities and other stakeholders is encouraged, but not required.</p>				
129834	National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-25-353	25-Jun-2025	Not Specified
	<p>Contact Name Yael Mandelblat-Cerf, Ph.D.</p> <p>Contact Telephone 301-793-7563</p> <p>Contact Email yael.mandelblat-cerf@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Jun-2025 , 25-Oct-2025 , 25-Feb-2026 , 25-Jun-2026 , 25-Oct-2026 , 25-Feb-2027 , 25-Jun-2027 , 25-Oct-2027</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health, develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders, and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders. This NOFO encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>academia and industry are strongly encouraged. This NOFO supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary, and often long-term approach. Projects seeking support for a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies should consider the companion NOFO (PAR-25-352). This NOFO will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral vector-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).</p>				
112346	Notice of Special Interest (NOSI): Research on the Health of Sexual and Gender Minority (SGM)	National Institutes of Health/DHHS	NOT-MD-22-012	07-May-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Crystal L. Barksdale, PhD MPH</p> <p>301-827-4228</p> <p>crystal.barksdale@nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025</p> <p>This Notice calls for research on the health of sexual and gender minority populations. SGM populations include, but are not limited to, individuals who identify as lesbian, gay, bisexual, asexual, transgender, Two-Spirit, queer, and/or intersex. Individuals with same-sex or -gender attractions or behaviors and those with a difference in sex development are also included. These populations also encompass those who do not self-identify with one of these terms but whose sexual orientation, gender identity or expression, or reproductive development is characterized by non-binary constructs of sexual orientation, gender, and/or sex.</p>			
112325	Notice of Special Interest (NOSI): Research on Addressing Violence to Improve Health Outcomes	National Institutes of Health/DHHS	NOT-OD-22-167	07-May-2025	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p>	<p>Dara R. Blachman, Ph.D.</p> <p>301-496-8522</p> <p>Dara.blachman-demner@nih.gov</p> <p></p> <p>Link to program URL</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<div> <div>Deadline Dates (ALL)</div> <div>07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025</div> </div> <div> <div>Synopsis</div> <div>The purpose of this Notice is to highlight interest in addressing the role of violence in health outcomes and integrating violence-related screening and interventions into health care settings. This Notice is to encourage intervention research focused on addressing exposure to violence - including but not limited to child maltreatment, intimate partner violence/teen dating violence, elder mistreatment, peer violence/bullying, and community violence – to improve individual-level health processes and outcomes.</div> </div>					
112471	Notice of Special Interest (NOSI): Single-Cell Level Spatiotemporal Mapping of Dental and Craniofacial Embryogenesis	National Institutes of Health/DHHS	NOT-DE-22-003	07-May-2025	Not Specified
<div> <div>Contact Name</div> <div>Kathryn Stein, PhD</div> </div> <div> <div>Contact Telephone</div> <div>301-827-4653</div> </div> <div> <div>Contact Email</div> <div>kathryn.stein@nih.gov</div> </div> <div> <div>Sponsor Website</div> <div></div> </div> <div> <div>Program URL</div> <div>Link to program URL</div> </div> <div> <div>Deadline Dates (ALL)</div> <div>07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025</div> </div> <div> <div>Synopsis</div> <div>The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research that applies cutting edge imaging and high-throughput ‘omics approaches at the single-cell level to understand the complex spatiotemporal context of the developing dental and craniofacial tissues in the embryo.</div> </div>					
112267	Notice of Special Interest (NOSI): Advancing Research on Early Pregnancy Loss	National Institutes of Health/DHHS	NOT-HD-22-026	07-May-2025	Not Specified
<div> <div>Contact Name</div> <div>Clara Cheng, PhD</div> </div> <div> <div>Contact Telephone</div> <div>301-435-6992</div> </div> <div> <div>Contact Email</div> <div>clara.cheng@nih.gov</div> </div> <div> <div>Sponsor Website</div> <div></div> </div> <div> <div>Program URL</div> <div>Link to program URL</div> </div> <div> <div>Deadline Dates (ALL)</div> <div>07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</div> </div> <div> <div>Synopsis</div> <div>Early Pregnancy loss (EPL), defined as a pregnancy loss occurring up to 20 weeks gestation, is a very common pregnancy complication, occurring in 12-15% of clinically recognized pregnancies, with increased prevalence associated with increasing maternal age. The use of highly sensitive hCG assays allows the detection of pregnancy earlier in gestation than the time of</div> </div>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>clinical recognition, and gives an even higher estimated loss of 50-70% of conceptions prior to the second trimester. To achieve a successful pregnancy, a series of strict embryonic and maternal conditions must be met, that include high quality embryos, favorable conditions for embryo implantation, receptive maternal endometrium and optimal uterine environment to sustain the conceptus to term. In addition, maternal immune tolerance and hormonal factors play a critical role. While approximately half of all cases of EPL appear to be due to embryonic aneuploidy, very little is known about the physiologic and pathophysiologic processes that underlie non-aneuploid EPL. As a result, there is also a lack of understanding for the underlying causes of recurrent pregnancy loss (RPL). This NOSI seeks to address these critical knowledge gaps by encouraging basic, translational and clinical studies on biological processes that may uncover potential etiologies of EPL and RPL. This includes research to understand implantation mechanistically and identify a range of key factors, involved in implantation and placentation that are important for early pregnancy establishment, including abnormalities that contribute to sporadic EPL and recurrent pregnancy loss.</p>				
117360	Notice of Special Interest (NOSI): Research to Address Vaccine Uptake and Implementation among Populations Experiencing Health Disparities	National Institutes of Health/DHHS	NOT-MD-23-008	05-Jun-2025	Not Specified
	Contact Name	Deborah E. Linares, Ph.D., M.A.			
	Contact Telephone	301-402-2516			
	Contact Email	deborah.linares@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2025 , 16-Jun-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Feb-2026 , 16-Feb-2026 , 05-Jun-2026			
	Synopsis	<p>This Notice of Special Interest (NOSI) highlights the need for research on strategies and interventions to increase vaccine uptake and implementation among populations experiencing health disparities in the United States (U.S.) and its territories. Research is needed to understand and address misinformation, uncertainty, distrust, and hesitancy regarding uptake of vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV), varicella, tetanus, diphtheria, and pertussis [Tdap]) among individuals in the U.S. and its territories, especially in populations at increased risk for morbidity and mortality due to long-standing systemic health and social inequities, as well as chronic medical conditions. This NOSI is focused on individuals across the life span (i.e., all ages). The purpose of this NOSI is to solicit research that will: 1) understand and address barriers to increasing reach, access, and uptake of vaccinations among populations experiencing health disparities; 2) evaluate organizational, local, state, and federal policies and initiatives that mitigate or exacerbate disparities in vaccine access, uptake, and series completion, and 3) evaluate community-engaged interventions (e.g., expand reach, address psychosocial barriers, and social determinants of health [SDOH]) to facilitate vaccination uptake in clinical and community contexts.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
116487	Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-25-111	16-Jun-2025	275,000 USD
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Katie M. Vance, Ph.D.</div> <div>301-435-6640</div> <div>Katie.Vance@nih.gov</div> <div></div> <div>Link to program URL</div> <div>16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026</div> <div>The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.</div>			
121564	Developing Novel Theory and Methods for Understanding the Genetic Architecture of Complex Human Traits (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-25-256	16-Jun-2025	275,000 USD
	<div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div>	<div>Alexander Arguello, Ph.D.</div> <div>240-731-3753</div> <div>alexander.arguello@nih.gov</div> <div></div> <div>Link to program URL</div> <div>16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026</div> <div>The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should account for interdependencies across scales of biological, social, and ecological organization, make extensive use of theory, modeling, and validation with available large-scale datasets, and may be interdisciplinary drawing from the natural and social sciences.</div>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
128814	Investigator Initiated Research in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-25-229	16-Jun-2025	275,000 USD
	<div>Contact NameDaniel Gilchrist, Ph.D.</div> <div>Contact Telephone</div> <div>Contact Emaildaniel.gilchrist@nih.gov</div> <div>Sponsor Website</div> <div>Program URLLink to program URL</div> <div>Deadline Dates (ALL)16-Jun-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Feb-2027 , 16-Jun-2027</div> <div>SynopsisThe purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research that develops innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems.</div>				
107545	Notice of Special Interest (NOSI): Expanding the Otitis Media Research Workforce: Focus on Early Stage Investigators	National Institutes of Health/DHHS	NOT-DC-22-001	07-May-2025	Not Specified
	<div>Contact NameBracie Watson, Jr., Ph.D.</div> <div>Contact Telephone301-402-3458</div> <div>Contact Emailwatsonb@nidcd.nih.gov</div> <div>Sponsor Website</div> <div>Program URLLink to program URL</div> <div>Deadline Dates (ALL)07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</div> <div>SynopsisThe National Institute on Deafness and Other Communication Disorderse (NIDCD) is interested in expanding the cadre of basic and clinical scientists who conduct research on otitis media (OM). The purpose of this Notice of Special Interest (NOSI) is to invite Early Stage Investigators (ESIs), as defined by the NIH https://grants.nih.gov/grants/new_investigators/index.htm#earlystage, to submit research applications that focus on OM—commonly known as ear infections. There is a critical need for focused, novel, creative and innovative research approaches that accelerate the development of effective ways to prevent and treat OM.</div>				
107484	Notice of Special Interest (NOSI): The Functional Oral Microbiome	National Institutes of	NOT-DE-21-	07-May-	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Health/DHHS	015	2025	Specified
	Contact Name Tamara McNealy, PhD. Contact Telephone 202-430-1474 Contact Email tamara.mcnealy@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 Synopsis The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research studies that focus beyond the bacteria to the multispecies communities making up the oral microbiome.				
114765	Notice of Special Interest (NOSI): Firearm Injury and Mortality Prevention Research	National Institutes of Health/DHHS	NOT-OD-23-039	07-May-2025	Not Specified
	Contact Name Dara R. Blachman, Ph.D. Contact Telephone Contact Email Dara.blachman-demner@nih.gov Sponsor Website Program URL Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 Synopsis The purpose of this Notice is to highlight interest in research to improve understanding of the determinants of firearm injury, the identification of those at risk of firearm injury (including self- and other-directed, victims and perpetrators, accidental injury), the development, piloting, and testing of innovative interventions to prevent firearm injury and mortality, and the examination of approaches to improve the implementation of existing, evidence-based interventions to prevent firearm injury and mortality.				
114596	Development of Animal Models and Related Biological Materials for Down Syndrome Research (R21 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-25-214	16-Jun-2025	275,000 USD
	Contact Name Sige Zou, PhD Contact Telephone 301-435-0749 Contact Email zous@mail.nih.gov				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jun-2025 , 16-Oct-2025			
	Synopsis	<p>The INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (INCLUDE) Project encourages exploratory and innovative research to develop, characterize, or improve animal models and related biological materials for Down syndrome (DS) related research and to improve access to information about or from the use of animal models for DS research. The animal models and related biological materials developed must have utility in targeted or basic science studies in areas highly relevant to DS. With this funding opportunity announcement, the INCLUDE Project encourages, but is not limited to, projects focusing on development of various animal models, genetic resources, atlases at a single cell or subcellular level, advanced informatics technologies including artificial intelligence (AI) or machine learning (ML), and integration of multiple animal models and technology platforms for enhancing rigor and reproducibility of preclinical DS research.</p>			
114377	Notice of Special Interest (NOSI): Advancing Research for Tickborne Diseases (TBDs)	National Institutes of Health/DHHS	NOT-AI-23-013	05-Apr-2025	Not Specified
	Contact Name	Samuel Perdue, Ph.D.			
	Contact Telephone	240-627-3341			
	Contact Email	sperdue@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026			
	Synopsis	<p>The purpose of this Notice of Special Interest (NOSI) is to announce that the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Mental Health (NIMH), and the National Institute of Neurological Disorders and Stroke (NINDS), encourage applications to advance research activities relevant to the five strategic priorities identified in the recently released NIH Strategic Plan for Tickborne Disease Research: Improve fundamental knowledge of Tickborne Diseases (TBDs) to understand the host, vector, and pathogen factors that drive TBD pathogenesis and transmission. Elucidate the host immune mechanisms in response to and exploited by TBD pathogens. Advance research to improve the diagnosis of TBDs using both host- and pathogen-targeted approaches, including research for rapid diagnostics and multiplex platform approaches that detect multiple tickborne pathogens. Accelerate research to improve TBD prevention by supporting science to design, develop, and evaluate vaccines,</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	vector control strategies, and other prevention approaches. Promote research to improve treatment for all forms of TBDs, including studies to develop effective therapies to treat symptoms that persist after TBD treatment, therapies for non-infectious TBDs, and new antimicrobials. Support tools and resources to advance research in understanding, preventing, diagnosing, and treating TBDs, including repositories, genomic resources, animal models, and preclinical services to aid the development and assessment of diagnostic, vaccine, and therapeutic candidates.				
114250	Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PA-25-169	07-May-2025	400,000 USD
	Contact Name	Randy King, Ph.D.			
	Contact Telephone	301-451-0707			
	Contact Email	Randy.King@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 16-Jun-2025 , 16-Jul-2025 , 07-Sep-2025 , 16-Oct-2025 , 16-Nov-2025 , 07-Jan-2026			
	Synopsis	This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators (https://grants.nih.gov/policy/early-investigators/index.htm) to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal. All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review.			
129320	Risk and Protective Factors of Family Health and Family Level Interventions (R01 - Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-25-317	07-May-2025	Not Specified
	Contact Name	Arundhati Gogineni, PhD			
	Contact Telephone	301-827-9545			
	Contact Email	Arundhati.Gogineni@nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of this initiative is to advance the science of minority health and health disparities by supporting research on family health and well-being and resilience. The NIMHD Research Framework recognizes family health, family well-being, and family resilience as critically important areas of research to decrease disparities and promote equity.</p>				
129391	NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-25-302	07-May-2025	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone 301-480-7075</p> <p>Contact Email grantsinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).</p>				
129394	NIH Exploratory/Developmental Research Project Grant Program (Parent R21 Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-25-307	07-May-2025	275,000 USD
	<p>Contact Name</p> <p>Contact Telephone 301-496-4000</p> <p>Contact Email grantsinfo@od.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This Parent Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ NOFO.			
126793	NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08 - Basic Experimental Studies with Humans (BESH) Required)	National Institutes of Health/DHHS	PAR-24-218	12-Jun-2025	Not Specified
	Contact Name	Laura D. Wandner			
	Contact Telephone				
	Contact Email	Laura.Wandner@nih.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 12-Nov-2025 , 12-Feb-2026 , 12-Mar-2026 , 12-Jun-2026 , 12-Jul-2026 , 12-Oct-2026 , 12-Nov-2026 , 12-Feb-2027 , 12-Mar-2027 , 12-Jun-2027 , 12-Jul-2027			
	Synopsis	The purpose of this NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08) (BESH) is to support the career development of individuals with clinical doctoral degrees to create a group of new and well-trained, independent investigators. This supervised career development program will provide independent NIH research support during the early-career phase to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative’s Clinical Research in Pain Management program. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial basic experimental study with humans led by another investigator, must apply to the Independent Clinical Trial Not Allowed companion NOFO.</p>				
114589	Notice of Special Interest (NOSI): Research to Address 'Ending the HIV Epidemic' Initiative Goals Relevant to Substance Using Populations At-Risk for or Living with HIV	National Institutes of Health/DHHS	NOT-DA-23-013	07-May-2025	Not Specified
	<p>Contact Name Vasundhara Varthakavi, PhD</p> <p>Contact Telephone 301-443-2146</p> <p>Contact Email vasundhara.varthakavi@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Oct-2027</p> <p>Synopsis The purpose of this NOSI is to support a broad spectrum of multi-disciplinary, substance use research to address the goals of the four pillars, including Diagnose, Treat, Prevent, and Respond of the 'Ending the HIV Epidemic in the U.S. (EHE)' initiative. Projects proposed in response to this NOSI are required to meet the needs of the substance using populations who are at high risk for contracting HIV or living with HIV in the geographically defined EHE priority areas within the U.S.</p>				
115310	Notice of Special Interest (NOSI): Computational and Statistical Methods to Enhance Discovery from Health Data	National Library of Medicine/NIH/DHHS	NOT-LM-23-001	07-May-2025	Not Specified
	<p>Contact Name Meryl Sufian, PhD</p> <p>Contact Telephone 301-496-4671</p> <p>Contact Email sufianm@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The National Library of Medicine is issuing this Notice to highlight its interest in receiving grant applications focused on research that aims to reduce or mitigate gaps and errors in health data sets.			
113609	NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)	National Library of Medicine/NIH/DHHS	PAR-25-238	07-May-2025	1,000,000 USD
	Contact Name	Meryl Sufian, PhD			
	Contact Telephone	301-496-4671			
	Contact Email	sufianm@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026			
	Synopsis	The National Library of Medicine (NLM) supports innovative research and development in biomedical informatics and data science. This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. The scope of NLM's interest in these research domains is broad, with emphasis on new and innovative methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, scalable, and reusable/reproducible approaches to discovery, curation, analysis, organization, and management of health-related digital objects.			
120715	Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional)	National Library of Medicine/NIH/DHHS	PAR-25-235	05-Jun-2025	1,000,000 USD
	Contact Name	Allison Dennis, PhD			
	Contact Telephone	301-827-9721			
	Contact Email	allison.dennis@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026			
	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to advance the development of novel informatics and data science approaches that can help individuals understand and improve their health through actionable insights. The NLM and participating institutes listed in this NOFO seek applications that further the science of personal health informatics			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>by providing meaningful and actionable insights to individuals through innovative personal health data collection, integration, analysis, and personalized risk assessments and interpretation. Applications seeking to advance the understanding of how informatics tools, systems, and platforms can best present the results, interpretation, and limitations of personalized assessments for the benefit of individuals are encouraged. Applications should include end user engaged approaches and real-world evaluation to inform the design of generalizable, reusable, and scalable personal health informatics tools, systems, and platforms for the benefit of individuals in understanding and improving their health.</p>				
128482	Limited Competition: Basic Instrumentation Grant (BIG) Program (S10 Clinical Trial Not Allowed)	Office of Research Infrastructure Programs/NIH/DHHS	PAR-24-326	02-Jun-2025	350,000 USD
	<p>Contact Name Yong Chen, PhD</p> <p>Contact Telephone 301-594-1187</p> <p>Contact Email yong.chen@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Jun-2025 , 01-Jun-2026 , 01-Jun-2027</p> <p>Synopsis The Basic Instrumentation Grant (BIG) Program encourages applications from groups of NIH-supported investigators to purchase a single high-priced, specialized, commercially available instrument or an integrated instrumentation system. The BIG Program is limited to institutions that have not received S10 instrumentation funding of \$500,001 or greater in any of the preceding 3 Federal fiscal years (FY). Use the following to determine applicable funding periods: for submission in CY 2025, consider S10 funding in FYs 2022-2024; for submission in CY 2026, consider S10 funding in FYs 2023-2025; for submission in CY 2027, consider S10 funding in FYs 2024-2026. The minimum award is \$25,000. There is no maximum price limit for the instrument; however, the maximum award is \$350,000. Instruments supported include, but are not limited to, basic cell sorters, confocal microscopes, ultramicrotomes, gel imagers, or computer systems.</p>				
128480	High-End Instrumentation (HEI) Grant Program (S10 Clinical Trial Not Allowed)	Office of Research Infrastructure Programs/NIH/DHHS	PAR-24-264	02-Jun-2025	2,000,000 USD
	<p>Contact Name Monika Aggarwal, Ph.D.</p> <p>Contact Telephone 301-435-0783</p> <p>Contact Email monika.aggarwal@nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 02-Jun-2025 , 01-Jun-2026 , 01-Jun-2027</p> <p>Synopsis The High-End Instrumentation (HEI) Grant Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-end, specialized, commercially available instruments or integrated systems. The minimum award is \$750,001. There is no maximum price limit for the instrument; however, the maximum award is \$2,000,000. Instruments supported include, but are not limited to, nuclear magnetic resonance spectrometers, X-ray diffractometers, mass spectrometers, high throughput robotic screening systems, DNA and protein sequencers, biosensors, electron and light microscopes, flow cytometers, and biomedical imagers.</p>				
128481	Shared Instrumentation Grant (SIG) Program (\$10 Clinical Trial Not Allowed)	Office of Research Infrastructure Programs/NIH/DHHS	PAR-24-265	02-Jun-2025	750,000 USD
	<p>Contact Name Xiang-Ning Li, M.D., Ph.D.</p> <p>Contact Telephone 301-435-0777</p> <p>Contact Email xiang-ning.li@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Jun-2025 , 01-Jun-2026 , 01-Jun-2027</p> <p>Synopsis The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially available instruments or integrated instrumentation system. The minimum award is \$50,000. There is no maximum price limit for the instrument; however, the maximum award is \$750,000. Instruments supported include, but are not limited to: X-ray diffractometers, mass spectrometers, nuclear magnetic resonance spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, flow cytometers, and biomedical imagers.</p>				
113926	Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research (R01)	Office of Research Infrastructure Programs/NIH/DHHS	PAR-25-076	05-Jun-2025	Not Specified
	<p>Contact Name Sige Zou, Ph.D.</p> <p>Contact Telephone 301-435-0749</p> <p>Contact Email zous@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 05-Jun-2025</p> <p>Synopsis The Office of Research Infrastructure Programs (ORIP) encourages research project grant applications aimed at developing and implementing broadly applicable technologies, tools, and resources for validating animal models and enhancing rigor, reproducibility, and translatability of animal research. Research projects submitted under this Funding Opportunity Announcement (FOA) should be hypothesis driven with strong preliminary data. Proposed studies, models, resources, or technologies under this FOA must either address research interests of multiple NIH Institutes and Centers (ICs), explore multiple organ systems, or be applicable to diseases and processes that impact multiple organ systems in order to align with ORIP's NIH-wide mission and programs. Applications should aim to enhance the rigor, reproducibility, and translatability of animal research through the development and implementation of technologies, tools, and resources that have significant impact across a broad range of research areas using animal models. Applications must demonstrate how the proposed resources and technologies impact rigor and reproducibility of animal studies.</p>				
128780	Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)	Office of Research Infrastructure Programs/NIH/DHHS	PAR-25-273	07-May-2025	275,000 USD
	<p>Contact Name Sige Zou, Ph.D.</p> <p>Contact Telephone 301-435-0749</p> <p>Contact Email sige.zou@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>Synopsis This notice of funding opportunity (NOFO) encourages innovative research to develop, improve, characterize, and preserve animal models as well as animal model related biological materials, technologies, and new approach methodologies (NAMs) for studies relevant to human health and disease. This NOFO also seeks projects aimed at improving the diagnosis and control of diseases that could confound or interfere with animal use in biomedical research. The proposed project must have broad applicability to multiple NIH Institutes or Centers (ICs) to align with the NIH-wide mission of the Office of Research Infrastructure Programs (ORIP). The proposed studies must include animal models and explore multiple body systems or multiple categories of diseases. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC, will be considered not acceptable to this NOFO and will be withdrawn.</p>				
128808	Limited Competition: Small Grant Program for ORIP Special Emphasis Research Career Award (SERCA) K01 Recipients (R03 Clinical Trials Not Allowed)	Office of Research Infrastructure Programs/NIH/DHHS	PAR-25-176	07-May-2025	150,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Stephanie Murphy, VMD, PhD				
Contact Telephone	301-451-7818				
Contact Email	stephanie.murphy@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026				
Synopsis	<p>The Office of Research Infrastructure Programs (ORIP) within the Division of Program Coordination, Planning, and Strategic Initiatives announces an opportunity to apply for small grant support for ORIP-supported Special Emphasis Research Career Award (SERCA) K01 recipients who have completed the first two years (24 months) of the SERCA K01 award. ORIP seeks to enhance the ability of ORIP SERCA K01 recipients to conduct research as they transition to fully independent investigator status. The R03 mechanism supports projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support research projects that can realistically be completed in two years and that require limited levels of funding. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).</p>				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
127421	Science and Technology Centers: Integrative Partnerships	National Science Foundation	24-594	02-Jun-2025	150,000,000 USD
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Dragana Brzakovic</div> <div>703-292-5033</div> <div>stc2026@nsf.gov</div> <div>Link to sponsor website</div> <div>Link to program URL</div> <div>02-Jun-2025</div> <div> <p>The Science and Technology Centers (STC): Integrative Partnerships program supports exceptionally innovative, complex research and education projects that require large-scale, long-term awards. STCs focus on creating new scientific paradigms, establishing entirely new scientific disciplines, and developing transformative technologies which have the potential for broad scientific or societal impact. STCs conduct world-class research through partnerships among institutions of higher education, national laboratories, industrial organizations, other public or private entities, and via international collaborations, as appropriate. They provide a means to undertake potentially groundbreaking investigations at the interfaces of disciplines and/or highly innovative approaches within disciplines. STCs may involve any area of science and engineering that NSF supports. STC investments support the NSF vision of creating and exploiting new concepts in science and engineering and providing global leadership in research and education.</p> </div> </div>				
126934	NSF EPSCoR Graduate Fellowship Program	National Science Foundation	24-588	02-Jun-2025	Not Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Narcisha S. Norman</div> <div>703-292-7965</div> <div>nnorman@nsf.gov</div> <div>Link to sponsor website</div> <div>Link to program URL</div> <div>02-Jun-2025 , 01-Jun-2026</div> <div> <p>The NSF EPSCoR Graduate Fellowship Program (EGFP) provides an opportunity for applicants who received the distinction of GRFP Honorable Mention no more than three years before the proposal due date to be named NSF EPSCoR Graduate Fellows and obtain financial support for their graduate education at an institution in an EPSCoR jurisdiction. EGFP aims to enhance</p> </div> </div>				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>the capacity and competitiveness of EPSCoR jurisdictions by providing funding to graduate degree-awarding institutions to support NSF EPSCoR Graduate Fellows as they pursue graduate degrees in the disciplines specified by the NSF Directorates and Office that are participating in the EGFP funding program. Fellows may pursue degrees in field that differ from the field or sub-field of study that the GRFP Honorable Mention recipients previously listed in their GRFP application. EGFP awards will be made to institutions in EPSCoR jurisdictions. Awards will provide three years of stipend and associated cost-of-education allowance for each NSF EPSCoR Graduate Fellow. Stipends must be budgeted at the level of \$37,000 per year per Fellow and cost-of-education allowances must be budgeted at the level of \$16,000 per year per Fellow. A total of three years of support must be budgeted per Fellow. Each Fellow must be given up to five years to utilize the support. Awardees will administer the awards such that the Fellows receive the full stipend amount and the institution retains the full cost-of-education allowance during the three years that each Fellow receives support. All submissions must request support for a minimum of three Fellows.</p>				
127973	Dear Colleague Letter: NSF ANR Chemistry Lead Agency Opportunity on Sustainable Chemistry: Catalysis with Earth-Abundant Elements	National Science Foundation	NSF 24-129	02-Jun-2025 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 703-292-5111</p> <p>Contact Email nsfanr@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Jun-2025 [LOI/Pre-App], 03-Jun-2025 [LOI/Pre-App]</p> <p>Synopsis</p>	<p>The U.S. National Science Foundation (NSF) and the French National Research Agency (ANR) have signed a Memorandum of Understanding (MOU) on Research Cooperation. The MOU provides a framework to encourage collaboration between U.S. and French research communities and sets out the principles by which jointly supported activities might be developed. The MOU provides for an international collaboration arrangement whereby U.S. researchers may receive funding from NSF and French researchers may receive funding from ANR. Through a "Lead Agency Opportunity", NSF and ANR will allow proposers from both countries to submit a collaborative proposal that will undergo a single review process at the Lead Agency. NSF will be the Lead Agency for the current fiscal year. ANR and NSF anticipate that the Lead Agency will alternate annually thereafter.</p>			
129520	Antarctic Research Not Requiring U.S. Antarctic Program (USAP) Field Support	National Science Foundation	25-526	02-Jun-2025	60,000,000 USD

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div>Kelly M. Brunt</div> <div>703-292-8457</div> <div>kbrunt@nsf.gov</div> <div></div> <div>Link to program URL</div> <div>02-Jun-2025 , 15-Jan-2026</div> <div>Through this solicitation, the Antarctic Sciences Section (ANT) of the Office of Polar Programs (OPP) funds cutting-edge research that: improves understanding of interactions among the Antarctic region and global systems; improves understanding of the dynamic linkages among processes operating in the Antarctic and Southern Ocean and linkages to global Earth systems, which helps inform decision making regarding environmental change; advances fundamental understanding of Earth systems and the biological, geochemical, and physical processes in the Antarctic and Southern Ocean as drivers and responders to changes on a global scale; expands fundamental knowledge of Antarctic systems, biota, and processes; utilizes the unique characteristics of the Antarctic region as a science observing platform; and builds capacity and enhances diversity in the US workforce for polar-related science.</div> </div>				
113761	Expanding AI Innovation through Capacity Building and Partnerships	National Science Foundation	23-506	23-Jun-2025	Not Specified
	<div> <div>Contact Name</div> <div>Contact Telephone</div> <div>Contact Email</div> <div>Sponsor Website</div> <div>Program URL</div> <div>Deadline Dates (ALL)</div> <div>Synopsis</div> </div> <div> <div></div> <div>703-292-5111</div> <div>ExpandAIProgram@nsf.gov</div> <div>Link to sponsor website</div> <div>Link to program URL</div> <div>23-Jun-2025</div> <div>The National Science Foundation and its partners support the continued growth of a broad and diverse interdisciplinary research community for the advancement of AI and AI-powered innovation, providing a unique opportunity to broadly promote the NSF vision and core values, especially inclusion and collaboration. The Expanding AI Innovation through Capacity Building and Partnerships (ExpandAI) program aims to significantly broaden participation in AI research, education, and workforce development through capacity development projects and through partnerships within the National AI Research Institutes ecosystem.</div> </div>				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
109414	Industry-University Cooperative Research Centers Program	National Science Foundation	20-570	11-Jun-2025	Not Specified
<div> <div>Contact Name</div> <div>Prakash G. Balan</div> </div> <div> <div>Contact Telephone</div> <div>703-292-5341</div> </div> <div> <div>Contact Email</div> <div>pbalan@nsf.gov</div> </div> <div> <div>Sponsor Website</div> <div>Link to sponsor website</div> </div> <div> <div>Program URL</div> <div>Link to program URL</div> </div> <div> <div>Deadline Dates (ALL)</div> <div>11-Jun-2025 , 10-Sep-2025 [LOI/Pre-App], 10-Dec-2025</div> </div> <div> <div>Synopsis</div> <div> <p>The IUCRC program catalyzes breakthrough pre-competitive research by enabling close and sustained engagement between industry innovators, world-class academic teams, and government agencies. IUCRCs help industry partners and government agencies connect directly and efficiently with university researchers to achieve three primary objectives: 1) Conduct high-impact research to meet shared and critical industrial needs in companies of all sizes; 2) Enhance U.S. global leadership in driving innovative technology development, and 3) Identify, mentor and develop a diverse, highly skilled science and engineering workforce.</p> </div> </div>					

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
115139	Special Emphasis Notice (SEN):Research on Climate Change and Healthcare	Agency for Healthcare Research and Quality/DHHS	NOT-HS-23-006	08-Apr-2025	Not Specified
	<div>Contact NameBrent Sandmeyer, MPH</div> <div>Contact Telephone301-427-1441</div> <div>Contact EmailBrent.sandmeyer@ahrq.hhs.gov</div> <div>Sponsor Website</div> <div>Program URLLink to program URL</div> <div>Deadline Dates (ALL)08-Apr-2025 , 12-Apr-2025 , 25-May-2025 , 12-Jun-2025 , 08-Aug-2025 , 12-Aug-2025 , 25-Sep-2025 , 25-Sep-2025 , 12-Oct-2025 , 12-Dec-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027</div> <div>SynopsisThis Special Emphasis Notice (SEN) announces AHRQ’s interest in receiving health services research grant applications that address the intersection of climate change and healthcare.</div>				
123850	AHRQ Small Health Services Research Grant Program (R03)	Agency for Healthcare Research and Quality/DHHS	PA-24-155	16-Jun-2025	100,000 USD
	<div>Contact Name</div> <div>Contact Telephone301-427-1025</div> <div>Contact Emailkathryn.woolridge@ahrq.hhs.gov</div> <div>Sponsor Website</div> <div>Program URLLink to program URL</div> <div>Deadline Dates (ALL)16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027 , 16-Feb-2028 , 16-Jun-2028 , 16-Oct-2028 , 16-Feb-2029 , 16-Jun-2029</div> <div>SynopsisThe purpose of this Notice of Funding Opportunity (NOFO) is to seek health services research grant applications focused on AHRQ research priorities, including improving healthcare quality and patient safety, improving healthcare delivery and practice improvement, and enhancing whole-person healthcare delivery. AHRQ supports research in all healthcare settings, including the hospital, long-term care, ambulatory care, home healthcare, pharmacy, and care transitions between settings. Research may involve many partners and other groups, including patients, families, clinicians, non-clinical healthcare staff, policymakers, payers, healthcare organizations, providers and accreditors, local and State governments, the Federal Government, and others.</div>				
123849	AHRQ Health Services Research Projects (R01)	Agency for Healthcare Research and	PA-24-154	05-Jun-2025	2,000,000

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Quality/DHHS			USD		
	Contact Name				
	Contact Telephone	301-427-1025			
	Contact Email	kathryn.woolridge@ahrq.hhs.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027 , 05-Feb-2028 , 05-Jun-2028 , 05-Oct-2028 , 05-Feb-2029 , 05-Jun-2029			
	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to seek health services research grant applications focused on AHRQ research priorities, including improving healthcare quality and patient safety, improving healthcare delivery and practice improvement, and enhancing whole-person healthcare delivery. AHRQ supports research in all healthcare settings, including the hospital, long-term care, ambulatory care, home healthcare, pharmacy, and care transitions between settings. Research may involve many partners and other groups, including patients, families, clinicians, non-clinical healthcare staff, policymakers, payers, healthcare organizations, providers and accreditors, local and State governments, the Federal Government, and others.			
114270	Special Emphasis Notice (SEN): Interest in Healthcare Associated Infections and Combating Antibiotic Resistant Bacteria Research	Agency for Healthcare Research and Quality/DHHS	NOT-HS-23-003	25-May-2025	Not Specified
	Contact Name	Leyi Lin, MD			
	Contact Telephone	301-427-1333			
	Contact Email	leyi.lin@ahrq.hhs.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-May-2025 , 05-Jun-2025 , 25-Sep-2025 , 25-Jan-2026 , 05-Feb-2026 , 25-May-2026 , 05-Jun-2026 , 25-Sep-2026 , 05-Oct-2026 , 05-Oct-2026			
	Synopsis	The purpose of this Special Emphasis Notice (SEN) is to inform the research community of the Agency for Healthcare Research and Quality (AHRQ) continued interest in, and available funding for, supporting innovative research seeking to reduce the burden of healthcare-associated infections (HAIs) and to address the growing threat posed by antimicrobial resistant organisms. HAIs continue to cause significant patient harm and are also associated with considerable financial			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		consequences for healthcare facilities and for patients. Unfortunately, the COVID-19 pandemic has been associated with observed increases of several types of HAIs as well as increases in antimicrobial resistance, highlighting the importance of developing and studying resilient and adaptable countermeasures.			
107009	Large Research Projects for Combating Antibiotic-Resistant Bacteria (CARB) (R01)	Agency for Healthcare Research and Quality/DHHS	PA-22-047	05-Jun-2025	2,500,000 USD
	Contact Name	James Cleeman, MD			
	Contact Telephone	301-427-1330			
	Contact Email	james.cleeman@ahrq.hhs.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026			
	Synopsis	Agency for Healthcare Research and Quality (AHRQ) invites applications to conduct Large Health Services Research Demonstration and Dissemination Projects (R18) focused on Combating Antibiotic-Resistant Bacteria (CARB). This FOA will use the R01 Research Project Grant award mechanism.			
126658	TTO (Tactical Technology Office) Office Wide (OW) BAA	Defense Advanced Research Projects Agency/Department of Defense	HR001124S0023	19-Apr-2025 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	HR001124S0023@darpa.mil			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	19-Apr-2025 [LOI/Pre-App], 20-Jun-2025			
	Synopsis	The DARPA Tactical Technology Office (TTO) creates technological surprise and provides new options for national security, by demonstrating revolutionary platforms and systems with cutting-edge technology. TTO demonstrates compelling hardware at scales that demonstrate disruptive capability, with designs that reduce risk and cost by managing complexity, and which can be manufactured responsively and affordably. TTO is soliciting innovative executive summaries and proposals that enhance the nation's ability to rapidly build, adapt and sustain force structures with the following focus areas: Platform Innovation, Missionized Autonomy, Managing Complexity, Freedom's Forge 2.0, and Disruptive Emergent Technology.			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
126675	Naval Air Warfare Center Aircraft Division (NAWCAD) Office-Wide Broad Agency Announcement	Department of the Navy/Department of Defense	N00421-24-S-0001	20-Jun-2025 [LOI/Pre-App]	Not Specified
Contact Name					
Contact Telephone					
Contact Email		NAWCAD-Academia-BAA@us.navy.mil			
Sponsor Website					
Program URL		Link to program URL			
Deadline Dates (ALL)		20-Jun-2025 [LOI/Pre-App]			
Synopsis		The Naval Air Warfare Center Aircraft Division (NAWCAD) is interested in receiving white papers for Research and Development projects which offer potential for advancement and improvement of NAWCAD operations.			

Non Federal Funding Opportunities

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
098360	Singapore International Graduate Award	Agency for Science, Technology & Research		01-Jun-2025	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	singa_enquiries@hq.a-star.edu.sg			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2025			
	Synopsis	The Singapore International Graduate Award (SINGA) is a collaboration among the Agency for Science, Technology & Research (A*STAR), the Nanyang Technological University (NTU), the National University of Singapore (NUS), the Singapore University of Technology and Design (SUTD), the Singapore Management University (SMU), and the Singapore Institute of Technology (SIT). It is a bond-free award offered to international students with excellent academic undergraduate and/or master's results, and strong interest in doing research leading to a doctorate (PhD) or an EngD in Science and Engineering at a Singapore University.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
115901	R Accelerated Award Grant	Alex's Lemonade Stand		05-Jun-2025	800,000 USD
	Contact Name				
	Contact Telephone	866-333-1213			
	Contact Email	Grants@AlexsLemonade.org			

Non Federal Funding Opportunities

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2025			
	Synopsis	The purpose of the R Accelerated Award Grant is to advance ALSF's mission to find cures and better treatments for childhood cancers by providing support to scientists focused on pediatric oncology research. Applicants must have an original project that is not currently being funded that has a clear focus on accelerating the discovery of more effective, less toxic therapies for childhood cancers. Research projects should address a testable hypothesis based on strong scientific rationale. Applicants must be first-time recipients of a pediatric cancer research focused NIH R01 award or equivalent independent award. Demonstration of continued commitment to pediatric cancer investigation as well as institutional support are critical components of a successful application. The R Accelerated Award is a four-year grant.			
	Applicant Types				
	Funding Limit	200,000.00 per year			
	Limited Submission	No			
064670	SkinCare for Developing Countries Program	American Academy of Dermatology		30-Jun-2025	5,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	RIGNAHS@aad.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2025			

Non Federal Funding Opportunities

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The American Academy of Dermatology offers grants to individuals and organizations to fund international volunteer and humanitarian projects under the Skin Care for Developing Countries program. Grants vary between \$2,500 and \$5,000 depending on the proposal, scope of the project, and availability of funds.			
	Applicant Types				
	Funding Limit	5,000.00 maximum			
	Limited Submission	No			
042399	Research Grants	American Academy of Otolaryngic Allergy Foundation		01-Jun-2025	10,000 USD
	Contact Name	Kate Chenal			
	Contact Telephone	202-955-5010 x 600			
	Contact Email	foundation@aaoallergy.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2025			
	Synopsis	The American Academy of Otolaryngic Allergy (AAOA) Foundation seeks to advance allergy research and knowledge for the treatment of otolaryngic conditions by inviting applications for grants to conduct research in the pathogenesis, pathophysiology, diagnosis, prevention, or treatment of otolaryngic allergy. Funds are available to support multiple projects each year; each project may have total direct costs of \$10,000.			
	Applicant Types				
	Funding Limit	10,000.00 maximum			
	Limited Submission	No			

Non Federal Funding Opportunities

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
115485	Richman Family Foundation Scholarship	American Academy of Periodontology Foundation		01-Jun-2025	20,000 USD
	Contact Name	Ariel A. Medoff			
	Contact Telephone	312-573-3254			
	Contact Email	ariel@perio.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2025			
	Synopsis	The Award will be made to an individual performing clinical or basic science research related to the orthodontic/periodontal interface. A \$20,000 fellowship will be awarded annually to one or more individuals.			
	Applicant Types				
	Funding Limit	20,000.00 maximum			
	Limited Submission	No			
092553	AAP Teaching Fellowships	American Academy of Periodontology Foundation		01-Jun-2025	25,000 USD
	Contact Name	Ariel A. Medoff, MA, MLIS; Awards Coordinator			
	Contact Telephone	800-282-4867 x3254			
	Contact Email	ariel@perio.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	01-Jun-2025			
	Synopsis	AAP Teaching Fellowships are intended to support the young periodontal educator's commitment to a career in academia by providing debt relief to qualified applicants.			
	Applicant Types				
	Funding Limit	25,000.00 maximum			
	Limited Submission	No			
124908	Dr. Mark K. Setter Leadership in Periodontology and Dental Implantology Award	American Academy of Periodontology Foundation		01-Jun-2025	10,000 USD
	Contact Name	Ariel A. Medoff			
	Contact Telephone	312-573-3254			
	Contact Email	ariel@perio.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2025			
	Synopsis	The Dr. Mark K. Setter Leadership in Periodontology and Dental Implantology Award is presented annually in the amount of \$10,000 to recognize a periodontal resident who exemplifies the leadership qualities that Dr. Setter lived and encouraged throughout his lifetime.			
	Applicant Types				
	Funding Limit	10,000.00 maximum			
	Limited Submission	No			

Non Federal Funding Opportunities

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
130733	AACR Grant For Innovative Bladder Cancer Research	American Association for Cancer Research		05-Jun-2025	50,000 USD
	Contact Name				
	Contact Telephone	215-440-9300			
	Contact Email	grants@aacr.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2025			
	Synopsis	The AACR Grant for Innovative Bladder Cancer Research seeks to encourage the development of novel approaches to address bladder cancer. Applications are invited from researchers currently in the field as well as investigators with experience in other areas of cancer or biomedical research who have promising ideas and approaches that can be applied to bladder cancer research.			
	Applicant Types				
	Funding Limit	50,000.00 maximum			
	Limited Submission	No			
071222	General and Dedicated Research Grants	American Association of Nurse Anesthetists Foundation		30-Jun-2025	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	foundation@aana.com			
	Sponsor Website	Link to sponsor website			

Non Federal Funding Opportunities

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2025 , 30-Sep-2025 , 31-Dec-2025			
	Synopsis	The American Association of Nurse Anesthetists Foundation's mission is to advance the science of anesthesia through education and research. One of the goals of the AANA Foundation is to support new and seasoned investigators in nurse anesthesia through grants. Programs are designed to develop researchers in nurse anesthesia. Only AANA member CRNAs (clinical or research) are appropriate for application.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
106678	Clinician Scientist Development Grant (CSDG)	American Cancer Society, Inc.		01-Jun-2025	135,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	grants@cancer.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2025 , 01-Dec-2025			
	Synopsis	The Clinician Scientist Development Grant (CSDG) supports full-time faculty members in becoming independent investigators as clinician scientists. This grant is designed for people trained primarily as clinicians who want to maintain clinical practice and conduct cancer research.			
	Applicant Types				
	Funding Limit	135,000.00 maximum			

Non Federal Funding Opportunities

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
112975	Discovery Boost Grants (DBG)	American Cancer Society, Inc.		01-Jun-2025	270,000 USD
	Contact Name				
	Contact Telephone	404-329-7558			
	Contact Email	grants@cancer.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2025 , 01-Dec-2025			
	Synopsis	Discovery Boost Grants (DBG) support high-risk, high-reward exploratory cancer research across the research continuum. Investigators may focus on developing research methodologies, establishing feasibility, or leading pilot tests. It is expected that preliminary data generated from a completed DBG will have the potential to secure additional grant funding to further the research and open new and highly innovative areas for investigation. Discovery Boost Grants are funded up to \$135,000 per year for up to 2 years, plus 10% indirect costs. The maximum allowable budget is \$297,000 for a 2-year project period.			
	Applicant Types				
	Funding Limit	135,000.00 per year			
	Limited Submission	No			
014117	Edward A. Flinn III Award	American Geophysical Union		06-Jun-2025	Not Specified
	Contact Name				
	Contact Telephone	202-777-7322			

Non Federal Funding Opportunities

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email honors@agu.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 06-Jun-2025 Synopsis The Edward A. Flinn III Award is given annually to mid-career or senior scientists, either individually or in a small group, who personifies AGU's motto 'unselfish cooperation in research' through their facilitating, coordinating, and implementing activities. This award is for the unsung heroes who provide the ideas, motivation, and labors of love that build and maintain the infrastructure without which our science could not flourish. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
023802	Melvin Judkins Young Clinical Investigator Award	American Heart Association		01-Jun-2025	1,000 USD
	Contact Name Contact Telephone 214-570-5978 Contact Email council.awards@heart.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Jun-2025 , 05-Jun-2025 , 06-Jun-2025 Synopsis The Melvin Judkins Young Clinical Investigator Award recognizes meritorious research from early career investigators and promotes careers in cardiovascular radiology. Applicant Types				

Non Federal Funding Opportunities

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	1,000.00 see detail			
	Limited Submission	No			
023809	Vivien Thomas Young Investigator Award	American Heart Association		01-Jun-2025	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	council.awards@heart.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2025 , 05-Jun-2025 , 06-Jun-2025			
	Synopsis	The Vivien Thomas Early Career Investigator Award acknowledges the accomplishments of early career investigator members of the Council on Cardiovascular Surgery and Anesthesia (CVSA) who are focusing on fundamental and applied surgical research.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
067869	Wayne F. Placek Grants	American Psychological Foundation		12-Jun-2025	15,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	programs@ampsychfdn.org			
	Sponsor Website	Link to sponsor website			

Non Federal Funding Opportunities

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Jun-2025			
	Synopsis	The American Psychological Foundation's Wayne F. Placek Grant encourages research to increase the general public's understanding of homosexuality and sexual orientation, and to alleviate the stress that LGBTQIA+ individuals experience in this and future civilizations. Two grants of up to \$15,000 are available.			
	Applicant Types				
	Funding Limit	15,000.00 maximum			
	Limited Submission	No			
102829	Mitchell A. Baran Achievement Award for Clinical Excellence in Aerosol and Airway Clearance Therapies	American Respiratory Care Foundation		01-Jun-2025	2,500 USD
	Contact Name	Crystal Leighton			
	Contact Telephone				
	Contact Email	crystal.leighton@aarc.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2025			
	Synopsis	This award is given to recognize and honor those individuals demonstrating clinical excellence and leadership in advocating and promoting the use of evidence-based, clinically sound practices for the delivery of aerosolized medications and/or the application of non-pharmacologic airway clearance therapies.			
	Applicant Types				
	Funding Limit	2,500.00 see detail			

Non Federal Funding Opportunities

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Limited Submission No					
068798	Thomas L. Petty, MD Invacare Award for Excellence in Home Respiratory Care	American Respiratory Care Foundation		01-Jun-2025	500 USD
<div> <div>Contact Name</div> <div>Crystal Leighton, ARCF Executive Assistant</div> </div> <div> <div>Contact Telephone</div> <div>972-243-2272</div> </div> <div> <div>Contact Email</div> <div>crystal.leighton@aacrc.org</div> </div> <div> <div>Sponsor Website</div> <div>Link to sponsor website</div> </div> <div> <div>Program URL</div> <div>Link to program URL</div> </div> <div> <div>Deadline Dates (ALL)</div> <div>01-Jun-2025</div> </div> <div> <div>Synopsis</div> <div>The American Respiratory Care Foundation offers an award to recognize outstanding individual achievement in home respiratory care. This award consists of a plaque and \$500 cash, plus coach airfare, one night's lodging, and registration to AARC Congress.</div> </div> <div> <div>Applicant Types</div> <div></div> </div> <div> <div>Funding Limit</div> <div>500.00 see detail</div> </div> <div> <div>Limited Submission</div> <div>No</div> </div>					
068786	Forrest M. Bird, MD, PhD, ScD Lifetime Scientific Achievement Award	American Respiratory Care Foundation		01-Jun-2025	2,000 USD
<div> <div>Contact Name</div> <div>Crystal Leighton, ARCF Executive Assistant</div> </div> <div> <div>Contact Telephone</div> <div>972-243-2272</div> </div> <div> <div>Contact Email</div> <div>crystal.leighton@aacrc.org</div> </div> <div> <div>Sponsor Website</div> <div>Link to sponsor website</div> </div>					

Non Federal Funding Opportunities

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2025			
	Synopsis	The American Respiratory Care Foundation established an award to acknowledge outstanding individual scientific contributions in the area of respiratory care of cardiopulmonary disorders with a grant from Dr. Forrest M. Bird, MD, PhD, ScD. Dr. Bird is the founder of Bird Products Corporation, a manufacturer of respiratory care equipment. This award consists of a plaque and \$2000 cash, plus coach airfare, one night's lodging, and registration to AARC Congress.			
	Applicant Types				
	Funding Limit	2,000.00 see detail			
	Limited Submission	Yes			
130486	Pathology Interest Group Grants	American Society for Clinical Pathology		30-Jun-2025	250 USD
	Contact Name				
	Contact Telephone	312-541-4999			
	Contact Email	residentcouncil@ascp.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2025 , 30-Sep-2025 , 31-Dec-2025			
	Synopsis	ASCP Foundation Pathology Interest Group Grants provide support for medical students' Pathology Interest Groups.			
	Applicant Types				
	Funding Limit	250.00 maximum			
	Limited Submission	No			

Non Federal Funding Opportunities

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
035693	ASRM/NIH/Duke Clinical Research/Reproductive Scientist Training (CREST) Program	American Society for Reproductive Medicine (ASRM)		13-Jun-2025	Not Specified
	Contact Name				
	Contact Telephone	202-863-4985			
	Contact Email	Nicole.Goetz@CUAnschutz.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	13-Jun-2025			
	Synopsis	<p>The ASRM/NICHD/DUKE Clinical Research/ Reproductive Scientist Training (CREST) Scholars training program is offered by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the Clinical Research Training Program (CRTP) at Duke University, the American Society for Reproductive Medicine (ASRM), and the University of Colorado School of Medicine. CREST meets an existing need for formalized academic training in the quantitative and methodological principles of clinical research in reproductive medicine. Designed specifically for physicians in private or academic clinical practice in reproductive medicine, this innovative 2-year program engages the practicing physician in clinical research while allowing the individual to maintain an active role in clinical practice.</p>			
	Applicant Types				
	Funding Limit	0.00 not provided			
	Limited Submission	No			
032660	ASH-EHA Translational Research Training in Hematology	American Society of Hematology		26-Jun-2025 [LOI/Pre-App]	1,080 USD

Non Federal Funding Opportunities

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 202-776-0544</p> <p>Contact Email training@ehaweb.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Jun-2025 [LOI/Pre-App], 19-Sep-2025</p> <p>Synopsis Translational Research Training in Hematology (TRTH) is a year-long training and mentoring program focused on helping early stage researchers, including senior postdoctoral fellows and junior faculty, gain the tools necessary to build successful careers in blood-related translational research. Each year, 24 early-career scientists (12 from North America and 12 from Europe) are selected to participate in the prestigious and rigorous training program led by faculty who are international leaders in hematology. Topics covered include biostatistics and biomarkers, genetics and molecular biology, ethics, and phase I clinical study design.</p> <p>Applicant Types</p> <p>Funding Limit 1,000.00 see detail</p> <p>Limited Submission No</p>				
065121	Research Grants	American Society of PeriAnesthesia Nurses		15-Jun-2025	10,000 USD
	<p>Contact Name Amy Berardinelli, ASPAN Director for Clinical Inquiry</p> <p>Contact Telephone 877-737-9696</p> <p>Contact Email aberardinelli@aspan.org</p> <p>Sponsor Website Link to sponsor website</p>				

Non Federal Funding Opportunities

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL	Link to program URL
Deadline Dates (ALL)	15-Jun-2025
Synopsis	The Nursing Research Grants Program is designed to support active American Society of PeriAnesthesia Nurses (ASPAN) members seeking to conduct research that contributes to the advancement of perianesthesia nursing science and the improvement of patient care. This support may be in the form of peer review, thoughtful critique, and recommendations, as well as financial support. A beginning nurse researcher can expect between \$500-\$5,000. An experienced nurse researcher can expect between \$3,000-\$10,000.
Applicant Types	
Funding Limit	10,000.00 maximum
Limited Submission	No